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Abstract 
Banning the use of antibiotic growth promotors in animal feed has forced poultry breeding 
companies to select birds with improved disease resistance. One area of focus is the chicken innate 
immune system, which includes a family of avian β-defensins (AvBDs) that are synthesised by 
epithelia in response to microbial challenge. The aim of this thesis was to investigate the in vivo 
gene expression, antimicrobial activity (AMA) and mechanisms of action of AvBDs 6 and 9.  
Endpoint and qPCR were used to investigate AvBD6 and 9 gene expression in an array of epithelial 
tissues taken from day 7 and 35 broiler chickens reared in low and high hygiene conditions. The 
expression profiles of pro (interleukin-6: IL-6) and anti (Transforming Growth Factor β4:TGFβ4) 
inflammatory cytokine genes, and the chicken galectin-3 gene (CG3) were also examined. To 
explore AMA recombinant (r)AvBD peptides and their variants, including rAvBD9 3CA (lacking 
3 of the 6 conserved cysteine (C) amino acids), rAvBD9 6CAG (lacking all the conserved C amino 
acids) and rAvBD9 W38G were synthesised, and their AMAs against E. coli and E. faecalis tested 
in vitro using time-kill assays. The structural properties and membrane interactions of the rAvBDs 
and custom synthesized linear (s) AvBD6 and 9 peptides were also investigated using circular 
dichroism (CD), liposome entrapped calcein leakage assays and peptide modelling.  
The in vivo gene expression analyses revealed that AvBD6 and 9, IL-6, TGFβ4 and CG3 were 
expressed in all the broiler chicken tissues examined. However, the data were compromised by the 
small bird numbers, and the variability in the tissue expression data between individual birds within 
a group resulted in no statistically significant trends associated with rearing environment being 
detected.  
The AMA data showed that the rAvBD6 and 9 peptides were antimicrobial against both Gram 
negative and positive microbes with rAvBD6 > rAvBD9 (using 100 µg/ml peptide, 76.4% 
(23.6±2.3 % survival) of E. coli were killed by rAvBD6 compared to 64.3% (35.7±7.2% survival) 
for rAvBD9). These data were potentially related to the physical properties of the peptide with 
AvBD6 being more cationic (+6.8) and hydrophobic than AvBD9 (+3.8), although modelling data 
also suggested that AvBD6 contained a hook-like foramen structure.    
The AMAs of the rAvBD9 and AvBD9 3CA peptides were not significantly different. Using 50 
µg/ml peptide 49% (51±12% survival) and 60% (40±8% survival) of E. coli were killed compared 
to 53% (47±20% survival) and 69% (31±13% survival) killing for E. faecalis. Nu-PAGE data 
suggested the AMA potency of AvBD9 3CA was associated with dimer formation. At 50 µg/ml 
neither the rAvBD9 6CAG nor the synthetic linear AvBD9 peptides were active against the E.coli 
isolate. However, in the presence of proteinase inhibitor (Roche-1:1000 dilution), 45% E.coli BL21 
killing (55±1% survival) was observed, which strongly supported the roles of the di-sulphide bonds 
in protecting the AvBD peptides against proteolysis. Substituting the C-terminal tryptophan (W) of 
rAvBD9 for a glycine (G) also resulted in a loss of AMA against bacteria (at 50 µg/ml 0% killing 
of E. coli and 15% (85.5 ±20.5% survival) killing of E. faecalis was detected). These data indicated 
that the C terminal W amino acid is also important for AvBD9 AMA.  
In the presence of SDS micelles mimicking the bacterial membrane synthetic AvBD1, 6 and 9 
peptides showed increased α-helicity. Membrane leakage experiments using calcein-entrapped 
liposomes and synthetic peptides (1.5 µg/ml) showed sAvBD6 induced more leakage at 4 minutes 
than sAvBD9 (60.3±6.3% (n=4) versus 11.5% (n=1)). Although compromised by the lack of 
replicates these data suggested that AvBD9 may not function through membrane disruption 
suggesting other mechanisms including inhibition of nucleic acid synthesis and/or cell division.  
Membrane leakage experiments using sAvBD1 peptides modelling an AvBD1 SNP found in 
poultry showed NYH >SSY> NYY.  
Overall these data show AvBD6 and 9 are expressed in bird tissues and have AMA against gram 
negative and positive bacteria. The studies supported different mechanisms of action of the two 
defensins with AvBD6 causing membrane damage compared to AvBD9, which probably functions 
through disrupting intracellular systems. These data suggest that the AvBD peptides work in 
synergy in defending the epithelia and warn against poultry geneticists selecting individual AvBD 
genes for breeding purposes. 
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Chapter 1  
1. Introduction 
1.1. Background 
Poultry, particularly chicken, meat is a major source of protein worldwide and its 
commercial value has, for decades, underpinned research into maximising meat production 
per bird. However, more recent research has focussed on rearing  ‘robust’ birds that not 
only show optimal feed to gain ratios, but that can also resist infectious and/or zoonotic 
diseases (Lowenthal et al., 2013). In fact, breeding disease resistant birds is a major 
research objective of poultry breeders supplying birds for the poultry industry with the 
research driven, primarily, by EU legislation banning the use of antibiotics in poultry feeds 
(Huyghebaert et al., 2011). The research aims are directed, primarily, towards genetically 
selecting birds with ‘improved’ innate immunity and therefore enhanced resistance to 
disease.  
One particular focus of poultry breeders is the bird gut and the selection of commercial 
chicken lines with improved gut innate immunity. The challenge is to breed chicks that are 
especially resistant to infection during the first week after hatch, when they are particularly 
susceptible to disease. A particular area of interest is the expression and synthesis of avian 
antimicrobial peptides (AMPs), which are antimicrobial agents produced by epithelia and 
antigen presenting cells, and hence an important part of the bird innate immune defences.  
An understanding of the involvement and roles of the host innate defences, specifically 
Avian β-defensins (AvBDs) that exhibit potent antimicrobial properties, in protecting birds 
(young and growing) against disease is lacking. Commercially such information on the 
roles of AvBDs in bird gut health may be used to improve disease resistance in commercial 
lines and exploited through selective breeding programmes.  
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1.2. Host- microbial interactions 
The avian gut is particularly susceptible to infection as birds feed from the environment 
immediately from hatch. While transfer of maternal antibody via the egg yolk does help 
chick survival antibody titres suggest the antibodies have disappeared by day 10 and thus 
no longer afford the bird protection against disease (Gharaibeh and Mahmoud, 2013). 
Innate factors participating in the vertebrate gut host response that help protect against 
microbial damage include gastric acid and mucus production, the epithelial barrier and the 
presence of pathogen recognition receptors (PRRs) such as Toll-like receptors (TLRs) on 
the epithelium. The latter detect microbial components including lipopolysaccharides 
(LPS), peptidoglycan (PG) and flagellin leading to AMP and /or cytokine production 
resulting in microbial death directly and/or the attraction of phagocytes including 
heterophils and macrophages (Wigley, 2013) that precipitate microbial death. However, in 
contrast to their mammalian counterpart, avian heterophils depend on AMP synthesis rather 
than oxidative myeloperoxidase activity for bacterial killing (Cuperus et al., 2013). 
The gut however, is a unique organ in that it is colonised naturally by microbes. The gut 
commensal microbiota contains bacteria that survive naturally and colonize the host 
gastrointestinal tract without causing disease. Identification of microbiota colonizing the 
gut mucosal surfaces by molecular analysis of 16S rRNA sequences using pyrosequencing 
and/or metagenomics analysis of whole extracted microbial DNA, allows the type and 
composition of the microbes living mutually within the host intestine to be defined 
(Sergeant et al., 2014). In health this gut colonization is balanced, but it can change in 
response to nutrition, drug administration, disease and environment resulting in gut 
problems. Interestingly one of the most important factors affecting gut microbial 
colonization, although not normally negatively, is genetic variation between animal species 
and individuals within the same species (Bevins and Salzman, 2011).  
Many genera of bacteria have been identified in the chicken gut, including bacteria from 
the family Enterobacteriaceae in the small intestine, and Bacteroides, Bifidobacterium, 
Clostridium, Enterococcus, Escherichia, Fusobacterium, Lactobacillus, Streptococcus and 
Campylobacter within the cecum (Brisbin et al., 2008). Host-microbial interactions, 
particularly those of gut commensals, play significant roles in gut immunity that is 
indicated by vulnerability of germ free animals to infections and the impact of the 
microflora on T cell populations and cytokine profiles (Brisbin et al., 2008). Antibiotic 
usage as a growth promoter is probably linked to the reduction of gut microbial loads and 
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the increased absorption of nutrients by the intestinal epithelia (Brisbin et al., 2008). 
However, gut bacterial populations have been shown in poultry to be changed by antibiotic 
use (Brisbin et al., 2008), with low dose antibiotic added as a feed additive decreasing gut 
colonisation by some species of Lactobacillus, eg Lactobacillius salivarius. These data 
suggest that the long term use of antibiotics can have negative effects, for example by 
reducing Lactobacilli lactic acid production which is involved in inhibiting the growth of 
pathogens via a reduction of the gut niche pH (Brisbin et al., 2008). 
Colonisation of the gut with microbes is also proposed to play a role in the development 
and maturation of the gut immune system and vice versa, i.e., the microbiota and host 
immune system function to maintain a symbiosis. For example, bacteria are detected by 
PRRs located on the gut epithelia and their numbers are controlled by the secretion of 
cytokines and/or antimicrobial peptides, often referred to as physiological inflammation 
(Crhanova et al., 2011). The system breaks down due to gut pathogens, including 
Salmonella enterica, being able to avoid the gut innate immune defences, resulting in an 
increase in the pathogen and dysbiosis (Salzman et al., 2010). Moreover, this disruption of 
the microbiota and induction of pathological inflammation enhances pathogen colonisation, 
and persistence, resulting in poor gut health, and in extreme cases the potential death of the 
host. Thus potentially AMPs are important in controlling the natural gut microbiota and 
maintaining optimal gut health.   
1.3. Host defence proteins 
The term host defence proteins (HDPs) encompasses groups of gene encoded innate 
immune peptides and proteins including the AMPs as well as other molecules such as 
lactoferrin and lysozyme (Hancock and Scott, 2000). The focus of this thesis is primarily 
the AMPs which are 12-50 amino acids in size, cationic (net charge +2 to +11) and 
generally rich in histidine, lysine and arginine amino acids, with the presence of 
hydrophobic and hydrophilic amino acids providing their amphipathic characteristics 
(Sugiarto and Yu, 2004). The peptides show broad spectrum anti-microbial activity (AMA) 
against various microbes including bacteria, fungi, enveloped viruses and some protozoa, 
and in mammals immuno-modulatory activities including cytokine induction and immune 
cell recruitment to the site of infection (Wilmes et al., 2011).  
There are four classes of these host defence AMPs as defined by their amino acid 
composition, secondary structure and number of disulphide bonds (Figure 1.1). The first 
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group includes the linear α-helical peptides such as magainin 2 (synthesised by frog skin), 
the second contains cysteine free extended helical peptides with repeated amino acids such 
as the tryptophan rich indolicidin (synthesised by bovine neutrophils), the third, which 
includes Thanatin (an insect peptide), is defined by a loop structure and a disulphide bond 
while the final group is characterised by β-(β) sheet structures and three disulphide bonds. 
The latter group includes the defensins, which are secreted by vertebrates, invertebrates, 
fungi and plants (reviewed by Wilmes (2012)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.Defensins 
Depending on their cysteine disulphide bonding patterns, there are three groups of 
defensins found in vertebrates, invertebrates, fungi and/or plants (Figure 1.2) (reviewed by 
Wilmes (2012)). In vertebrates, three classes have been described including α-(α), β-(β) 
Figure 1.1 Structures of host defence peptides (Wilmes, 2012) 
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and theta (θ) defensins. The first two groups are present in humans while the latter group, 
the θ-defensins, has been found only in the Rhesus monkey (Semple et al., 2003). 
Furthermore, only β-defensins have been identified in birds (van Dijk et al., 2008). The 
observation that α- and θ-defensins have not been found in phylogenetically older 
vertebrates, such as birds and fish, suggests that all the defensin subfamilies evolved from 
an ancestral β-defensin gene, presumably by duplication and diversification (Zhao et al., 
2001; Semple et al., 2003; van Dijk et al., 2008). While β-defensins are expressed and 
synthesised by epithelia, α-defensins are localised to bone marrow cells, neutrophils (Linde 
et al., 2009) and in humans the gut Paneth cells (Salzman, 2010).  
Both α-and β-defensins differ according to the location and connection of their disulphide 
bridges (Selsted and Ouellette, 2005; van Dijk et al., 2008). These bridges are arranged as 
Cys1–Cys6, Cys2–Cys4, Cys3–Cys5 for α-defensins versus Cys1–Cys5, Cys2–Cys4, 
Cys3–Cys6 for β-defensins. 
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Figure 1.2 Sequences and 3D structures of selected defensins. Residues with a positive charge are marked in red, negatively charged residues are marked 
in blue (Wilmes, 2012) 
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Defensins are broad spectrum antimicrobials active against a wide variety of pathogens, 
including both Gram positive and negative bacteria, in addition to yeast, fungi and viruses 
(Sugiarto and Yu, 2004; Soman et al., 2009). The molecules serve as a first line of defence 
against invading pathogens (Soman et al., 2009) and show immuno-regulatory 
characteristics boosting the acquired immune defences through attraction of monocytes, T 
cells, juvenile dendritic cells and mast cells to areas of inflammation (van Dijk et al. 2008; 
Soman et al. 2009). In addition they can stimulate histamine liberation from mast cells as 
well as macrophage phagocytosis (Soman et al., 2009). Thus in mammals they serve as key 
factors in connecting the innate and adaptive immune responses (Soman et al., 2009).  
Bacterial killing is proposed to occur through mechanisms including membrane disruption 
and pore formation leading to cell lysis and irregular septum formation in dividing cells 
(Ganz 2003; van Dijk et al. 2008). It is proposed that the anti-microbial mechanisms of 
defensins involving pore formation depend on the two characteristics of antimicrobial 
peptides ie their cationic charge and amphipathicity. Basically, β-defensins bind to bacterial 
membranes as a result of interactions between the anionic (negatively charged) bacterial 
membrane and the exposed cationic (positively charged) amino acid side chains of the 
peptide. One killing mechanism suggests a peptide dimer forms that initiates a channel 
between the amino-end of the β-strands of the two β-defensin monomers; the channel is 
created such that the hydrophobic sites of the peptides are facing the inner bacterial 
membrane and the hydrophilic sites are facing each of the β-defensin monomers (Sugiarto 
and Yu, 2004). The dimer effects transmembrane potential, membrane permeability and 
resulting in cell death (Sugiarto and Yu 2004; Higgs, et al. 2005). Defensin antibacterial 
activity can also reflect the environmental availability of positively charged divalent 
cations. For example, magnesium cations (Mg2+), found free in serum, are able to compete 
with the positively charged defensins for binding to the negatively charged microbial 
membranes. Thus microorganisms are more susceptible to defensins in areas of low cation 
concentration, which include the vacuoles of phagocytes and on the surfaces of the skin, 
and epithelia (Sugiarto and Yu, 2007a).  
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1.5.Evolution of defensins 
AMPs are secreted by all organisms including prokaryotes and eukaryotes, and an 
evolutionary relationship between the two has recently been hypothesised, focused on the 
bacteriosin laterosporulin synthesised by Brevibacillus sp. strain GI-9. This bacterial 
molecule exhibits β-strands and its six cysteines form three disulphide bonds [Cys1-Cys5, 
Cys2-Cys4, and Cys3-Cys6] like that of β-defensins, lending support to it being a link 
between the bacterial bacteriocins and mammalian defensins (Singh et al., 2015). 
Additionally, the amino acid sequence homology of the fungal defensin, plectacin, to 
dragonfly and mussel defensins also indicates the fungal defensin being an ancestor to 
vertebrate defensins (Lehrer et al., 2012). However, the evolutionary links remain 
controversial as the C-terminal part of ‘big defensin’ (BD) from horseshoe crab has also 
been hypothesised to be the ancestor of vertebrate β-defensins, as argued through 
comparisons of amino acid sequences, conserved defensin motifs 
(CXXXXGXCRXXCFXXE), net charges, disulphide bond arrangements and functions of 
invertebrate and vertebrate defensins including the human β-defensin 125, chicken 
AvBD13, Anole (reptile) βD, Tetraodon (teleost) βD, Amphioxus (cephalo-chordate 
invertebrate) βD, Crassostrea (oyster) βD and Tachypleus (horseshoe crab) βD (Lehrer and 
Lu, 2012). Furthermore, bioinformatics analyses suggest that  exon reshuffling and 
intronisation has underpinned the emergence of the vertebrate β-defensins from its 
ancestral ‘big defensin’ origin (Zhu and Gao, 2013).  Further factors supporting  a common 
ancestry among the β-defensins are the conservation of cationic, hydrophobic and 
hydrophilic amino acid sequence patterns in the plant, insect and human defensins, the 
similar defensin mechanisms of action and the sharing of functional features in the different 
kingdoms eg treating mouse fungal infections with plant defensins (reviewed by Wilmes et 
al. (2011)). 
Evidence for the divergence of the β-defensins to both α- and θ-defensins is that α-defensins 
are synthesised only in mammals and marsupials with the θ-defensin synthesised only by 
some species of rhesus monkey (Lehrer and Lu, 2012). Interestingly, the θ-defensin gene 
is present in humans, but a premature stop codon in its signal peptide sequence inhibits its 
synthesis (Lehrer and Lu, 2012). It has been proposed that the θ-defensin gene evolved 
from the α-defensin gene with the causative mutations resulting in the synthesis of a 
heterodimeric θ-defensin composed of two monomers each containing nine residues and 
linked by three intra disulphide bonds forming a cyclic peptide (Lehrer et al., 2012; 
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Kudryashova et al., 2015). In addition, the θ-defensin genes reside within the α-defensin 
genes that in turn cluster within the β-defensin gene cluster suggesting that the β-defensins 
evolved to α-defensins, which further evolved to theta defensins (Cuperus et al., 2013). It 
has been suggested that in mammals, apart from New World Monkeys, the θ-defensins, 
known to have anti-viral and anti-toxic activities, were ‘lost’ due to the high production of 
α-defensins in neutrophils. Although the α-defensin peptides appear in vitro to show 
reduced antimicrobial potency compared to the θ-defensins their increased synthesis 
presumably provided far greater protection against microbial assault and supported their 
evolutionary selection (Lehrer et al., 2012). 
Comparison of defensin gene clusters among vertebrates including human, mouse and 
chicken suggest that gene duplications, fusions, diversifications and translocations also 
played significant roles in the evolution of the defensin genes (Xiao et al., 2004). Exon 
fusion is also another feature predicted to have occurred during defensin evolution as 
typified by the fusion of the last two exons of AvBD12, which has three exons, compared 
to the four of other AvBDs (Cuperus et al., 2013).  
1.6.AvBD sequence homology 
The Avian β-defensins (AvBDs) in particular show a close evolutionary relationship.  For 
example, AvBD6 and AvBD7 are located in the middle of the chicken defensin family gene 
cluster, and their DNA sequences suggest gene duplication (Meade et al., 2009a). This is 
further illustrated by AvBD3, AvBD4, AvBD5 and AvBD14, which share similar promotor 
elements. In fact, bioinformatic analyses of a number of bird genomes reveals the depth of 
AvBD conservation. For example Duck AvBD1 shares 78% and 68% amino acid homology 
with the turkey and chicken AvBD1 sequences, with geese AvBD1 having amino acid 
similarities of 88%, 71%, 68%, and 66% with duck, ostrich, turkey and chicken, 
respectively (Ma et al., 2013). Ostrich AvBD2 has 86%, 83%, 83% and 82% nucleotide 
sequence similarities with those of geese, chicken, duck and turkey respectively (Lu et al., 
2014). Duck AvBD3 and 6 peptides reveal 100% similarity to the comparable chicken 
sequences (Peng et al., 2013). AvBD4 and AvBD9 show identical amino acid sequences 
among the majority of passerine species (Cuperus et al., 2013). Duck AvBD5 displays 97% 
and 88% homology to the comparable chicken and geese peptide sequences (Ma et al., 
2012a). Moreover, ostrich AvBD7 shows 81% homology to AvBD7 of chicken and duck 
and 75% similarity with AvBD6 of chicken, duck and geese, which strongly supports the 
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suggestion that AvBD6 evolved from AvBD7 by gene duplication (Hellgren and Ekblom, 
2010; Lu et al., 2014).  
1.7.Avian β-defensin 
To date 40 AvBD genes have been identified in birds and these include the 14 chicken β-
defensin genes which are localised to a 129 kb single β-defensin cluster on chromosome 3 
(Lan et al., 2014) as well as those genes identified in other avian genomes including the 
duck, zebra finch and crested ibis (Figure 1.3). Gallins or ovodefensins are also viewed as 
AvBDs based on their disulphide bond arrangement and 3D β-sheet structures (Herve et 
al., 2014). Additionally,  the gallin gene cluster is located on chromosome 3 and close to 
the AvBDs gene cluster; the AvBD13 gene is positioned at 107,019.512K, gallin-3 is 
positioned at 106,750.937K, gallin-2 at 106,747.961K, and gallin-1 at 106,740.473 K 
(NCBI gene map viewer): 
(http://www.ncbi.nlm.nih.gov/gene?cmd=retrieve&dopt=full_report&list_uids=422030). 
Thus the gap between the AvBD and gallin clusters is 268.575K (Figure 1.4), which 
suggests and supports close genomic relations. 
As stated previously chicken β-defensin genes consist of four exons, with the exception 
being the AvBD12 gene where the last two exons have fused (Figure 1.5). The genes each 
encode a signal sequence that directs the peptide through the endoplasmic reticulum for 
secretion, a pro-region, although this is absent in AvBDs 3, 12, 14, and a mature 
antimicrobial peptide (Figure 1.6). 
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Figure 1.3 Organization of β-defensin gene clusters. Avian β-defensin clusters from (a) 
chicken, (b) duck, (c) zebra finch, and (d) crested ibis. Vertical bars: gene locations; lengths 
drawn to scale (upper right corner). Paralogous genes for AvBD1 (orange) and AvBD3 
(blue) and chicken-specific AvBD6 (green) are shown. Red: tRNA clusters. Small triangles: 
transcriptional orientations of defensin gens. Duplicated regions are bracketed by double-
sided arrows and dotted lines  (Lan et al., 2014). 
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Figure 1.4: Genomic organisation of gallin gene clusters in relation to the last cluster of AvBDs 
(AvBD 13) 
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The mature AvBD peptide sequences contain the six cysteines (C), which are essential for 
disulphide bond folding, cationic residues such as histidine (H), lysine (K) and arginine 
(R), which are important for electrostatic interaction between the peptide and microbial 
lipid membrane, and hydrophobic aromatic amino acids including tryptophan, tyrosine, and 
phenylalanine that are proposed to play a role in the insertion of the peptide into the 
microbial membrane (Figure 1.6). Interestingly ten of the AvBDs display a C-terminal 
tryptophan amino acid in their mature peptide sequence (Figure 1.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Genomic organization of avian and mammalian. Differential transcription 
and subsequent translation of exons (E1–4) into the 50 and 30 untranslated regions 
(UTR) and peptide encoding regions for: signal peptide (diagonal striped bars), 
propiece (dotted bars) and mature peptide (solid blue bars) (van Dijk et al., 2008).  
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1.7.1. AvBD expression 
Investigation of AvBD expression in response to microbial challenges helps to explain the 
roles of the peptides in the protection of the host against potential pathogens. Experiments 
have been performed in vitro and in vivo  and overall the results often appear confusing and 
contradictory, which probably reflects the different cell lines used, bird genetics, rearing 
environment, bird age and/or the microbes used in the challenges.  
The expression of several AvBDs have been identified in healthy gut tissues. AvBD1, 2, 4, 
6, 9, and 13 expression were detected in the small intestinal tissues of avian species 
(reviewed by van Dijk et al. (2008)). AvBD3 was detected in small intestine, large intestine 
and caecal tonsils of 15 day old geese (Ma et al., 2013). AvBD2, but not AvBD7, was 
expressed in gut tissues of 90 day old ostriches (Lu et al., 2014). Duck AvBD6 expression 
was reported in the intestinal tissues of 5 month old Chaohu ducks (Peng et al., 2013).  
Figure 1.6 AvBD amino acid sequences. 
Yellow: cysteine; red: anionic; blue: cationic; green: and aromatic hydrophobic 
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A study of AvBD expression in Cobb strain birds, performed by Meade et al., (2009), 
indicated that AvBD expression varied with bird age and tissue analysed. For example, all 
AvBDs, except AvBD11, were expressed in day 3 embryos with high expression reported 
for AvBD5, AvBD7, AvBD9 and AvBD10. At 6 days post hatch, the expression of all 
AvBDs, except AvBD8 and 13, were elevated compared to day 3, with the highest gene 
expression recorded for AvBD5, AvBD9 and AvBD10. Moreover, AvBD8, AvBD9 and 
AvBD10 gene expression were confined to the abdomen, while the other genes were 
expressed in both the head and abdomen (Meade et al., 2009a). In another study performed 
by Wang et al., (2010), quail AvBD9 expression was detected in most tissues analysed, 
including caecal tonsils, small intestine and caecum at day 14. However, in 80 day old 
birds, the expression levels were lower indicating lesser roles for the AvBDs in fighting 
infection in older birds (Wang et al., 2010a).  
AvBD mRNA expression is generally enhanced in response to bacterial challenges and this 
has been reported to occur either directly in response to bacterial components (reviewed by 
Cuperus et al. (2013)) or via the pro-inflammatory cytokines. For instance, using an ovarian 
theca cell culture AvBD12 expression was stimulated by recombinant IL-1β, which was 
induced by Salmonella lipopolysaccharide (Abdelsalam et al., 2012). These data suggested 
that LPS can trigger IL-1β-which in turn can regulate the AvBD12 expression. 
Furthermore, AvBD1, 7 and 12 expression were enhanced in thecal cells of hen ovarian 
follicles by injection of 1 mg of bacterial LPS/Kg body weight (Subedi et al., 2007). LPS 
also induced AvBD5, 9, 10 and 12 expression in sperm (Das et al., 2011). An in vitro study 
showed that AvBD1 and 3 were upregulated by CpG oligodeoxynucleotides and pro-
inflammatory cytokines in hen vaginal cells (Sonoda et al., 2013). A recent in vivo  study 
also showed that LPS injection in  1-day-old Taihe silky chicks enhanced the intestinal 
expression of AvBD6, 7 and 9 after 4, 24 and 48 hours (Lu et al., 2015). 
To help explain the variability in AvBD expression it has been suggested that expression 
is related to the breed/strain of bird being used. For example, AvBD1 and 2 were more 
highly expressed in a line of chickens (known as Line 6) resistant to Salmonella infection, 
than the comparable bird line (known as Line 151) showing increased susceptibility 
(Derache et al., 2009a). Interestingly challenge with live Salmonella enteritidis was shown 
to supress the expression of AvBD2 in 151 intestinal cells, while inactivated bacteria 
resulted in enhanced expression. The authors linked the suppression mechanism to the 
switching off or evasion of the host defences by bacterial mechanisms that were inactivated 
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or lost during the bacterial inactivation process (Derache et al., 2009a). Therefore, the 
authors suggested that AvBD expression supports protection of the gut epithelium against 
Salmonella infection (Derache et al., 2009a). Furthermore, Hong et al., (2012) reported that 
the AvBD expression patterns in two bird lines, Cobb and Ross, were different following 
infection with the same microbes (E. maxima and C. perfringens), with the Ross line 
showing increased levels of expression. These data probably reflect the genetics of the lines 
of birds employed in the different studies and presumably impacts on their susceptibilities 
to infection (Hong et al., 2012). 
The expression of AvBDs also varies according to the types of microbial challenges. For 
instance, using Ross 308 birds most of AvBDs were upregulated including AvBD3, 10 and 
12 mRNA expression following an in vivo  Salmonella infection, but AvBD gene, 
particularly AvBD3, 4, 8, 13 and 14, downregulation was observed in response to 
Campylobacter challenge (Meade et al., 2009b). Moreover, chickens infected with the 
respiratory associated microbe Haemophilus paragallinarum, showed increased tracheal 
AvBD3 expression compared to healthy control birds (Zhao et al., 2001). AvBDs are also 
upregulated in response to viral infections such as duck hepatitis virus, which were shown 
to induce liver mRNA expression of AvBDs1, 3, 5 and 6 (Ma et al., 2012a). 
Reports indicate that the AvBD expression levels varies in response to different kinds of 
infections. For example, AvBD1 and 2 were not significantly changed in response to a 
salmonella infection (Derache et al., 2009a), but AvBD1 and 7 were increased in birds 
suffering from with necrotic enteritis which is a disease caused by coccidian and clostridia.  
The mRNA expression of the AvBDs in response to the bacterial challenges also varies 
markedly between genes. For example, all AvBDs were expressed in normal gut tissues 
including duodenum, jejunum, ileum and caecum of 3 day old Punjabi broiler-1 chicks 
(Ramasamy et al., 2012). Twenty four hours post infection with Salmonella enterica 
pullorum, AvBD 3, 4, 5, 6 and 12 mRNA expression were upregulated while AvBD10, 11, 
13 and 14 were downregulated, with no significant differences in AvBD1, 2, 7, 8 and 9 
gene expression (Ramasamy et al., 2012). Moreover, Ma et al., (2013) have also explored 
the impact of in vivo bacterial challenging on AvBD1, 3 and 6 mRNA expression in 
different gut tissues of geese in response to Salmonella infection. The authors only reported 
upregulation of AvBD3 expression after Salmonella infection, indicating the variable 
responses of the genes to microbial challenge (Ma et al., 2013).  
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Despite the wide range of AvBD expression in various organs, Cuperus et al., (2013) 
argued that the variability in AvBD expression between different studies was due to the 
different environments, ages, breeds and technical issues eg design of PCR primers 
(Cuperus et al., 2013). Dietary factors also seem to have impact on AvBD expression. For 
instance, AvBD9 expression was enhanced in jejunal cells in response to short chain fatty 
acid-like butyrate molecules (Sunkara et al., 2014). Moreover, vitamin D3 treatment also 
increased the upregulation of AvBD4, 5 ,6 and 10 expression following LPS treatment (Lu 
et al., 2015). 
It has been proposed that single nucleotide polymorphisms (SNPs) impact on AvBD gene 
expression and resultant functions of the encoded proteins (Hasenstein and Lamont, 2007). 
Hasenstein and Lamont (2007), analysed genetic variations in the AvBD1-13 genomic 
cluster of two bird lines within eight generations, in relation to Salmonella loads. The 
authors identified 109 intronic SNPs and studied one SNP for each of the 13 AvBDs. They 
reported that an AvBD5 SNP was related to an increase in splenic colonisation by 
Salmonella while AvBD3, AvBD11, AvBD12 and AvBD13 SNPS were correlated with 
the Salmonella colonisation of the caeca of Leghorn birds. The authors argued that the 
intronic  AvBD SNP genetic variations, allowed the AvBDs to be used as genetic markers 
for monitoring bird susceptibility to bacterial infections (Hasenstein and Lamont, 2007). 
Similarly Yacoub et al., (2011), claimed that AvBD genes can be used as candidate gene 
markers for the genetic selection of disease resistant birds since all AvBDs are located on 
the same chromosome and assembled in one location (Yacoub et al., 2011). It is probable 
that SNPs, intronic and within non-coding regions, affect the expression of AvBDs, 
resulting in variability within individual birds especially in response to different 
environments and microbial loads.  
Twenty seven SNPs in the AvBD9 gene have been recorded on the NCBI website (on 
20.10.2014). However, no SNP has been found in the mature peptide coding sequence 
which would affect, potentially, the functionality of AvBD9. One of the SNPs is located at 
the C-terminus of AvBD9 pro-peptide, but the change GAC to GAT is synonymous as both 
encode an aspartic acid (D). Also 17 AvBD6 SNPs were recorded in NCBI (20.10.2014) 
with all located either in 5’ non-coding or intron sites. Several intronic AvBD6 and 9 SNPs 
have been reported in Aviagen birds (Butler, 2010).  
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1.7.2. Localisation of AvBD peptides in tissues  
Immuno-histochemistry can be considered a useful method to identify sites of protein and 
peptide synthesis. Mammalian defensin synthesis has been identified in gut tissues with α-
defensin peptides localised to Paneth cells (Ouellette et al., 1999; Salzman and Bevins, 
2013), but studies within the avian have been compromised by a lack of commercial 
antibodies. Previous immunohistochemical analyses were reported for AvBD 3, 11 and 12 
but focussed in the avian reproductive tract (Shimizu et al., 2008; Watanabe et al., 2011), 
and gallin in chicken egg (Gong et al., 2010). 
AvBD3 peptides have been identified as being secreted in the male reproductive organs, 
with the anatomical locations including the spermatids and seminiferous tubules, 
suggesting that the AvBDs are produced during the final phase of spermatogenesis and 
remain in the sperm until ejaculation. This observation supports the potential importance 
of AvBD3 in the protection of sperm against infection before and after ejaculation (Shimizu 
et al., 2008). Immunoreactive staining for AvBD11 and AvBD12 were also found in the 
epididymis and testis, suggesting that these AvBDs are synthesised in both organs and like 
AvBD3 probably function in innate protection of the reproductive tissues (Watanabe et al., 
2011).  
Staining for gallin, an egg defensin, was identified in the tubular glands and ciliated cells 
of magnum and shell glands of the hen oviduct. These data suggest that gallin functions in 
the egg white and shell to help protect the embryo against potential pathogens (Gong et al., 
2010). Proteomics has also been utilised to identify the presence of peptides in avian 
tissues. Using mass spectrometry, AvBD11 and AvBD10 (gallinacin-8) have also been 
identified in the chicken egg shell (Mann et al., 2006), and AvBD11 in both egg white  
(Mann, 2007) and vitelline membranes (Mann, 2008). 
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1.7.3. Structure of AvBDs 
Structural studies of the AvBDs supports understanding of the functionality of the peptides, 
particularly antibacterial activity. To date, the 3D structures of Penguin AvBD103 (Figure 
1.7), AvBD2 (Figure 1.8) and gallin have been solved and shown to contain β-sheets linked 
by three disulphide bonds (Landon et al., 2004; Derache et al., 2012; Herve et al., 2014). 
The AvBD103b backbone structure bears an N-terminal α-helix, which is proposed to 
facilitate bacterial membrane permeation, and the surface of the peptide shows a 
‘hydrophobic patch’, which is proposed to be responsible for antimicrobial action, and is 
preserved in avian species (Landon et al., 2004). In contrast to AvBD103b, AvBD2 does 
not appear to contain a N-terminal α-helix and three of the cysteine residues participating 
in disulphide bond formation are fully buried in the AvBD2 structure (Derache et al., 2012). 
Interestingly, the even distribution of cationic and hydrophobic residues on the surface of 
AvBD2 may reflect the peptide AMA characteristics via bacterial membrane interaction 
(Figure 1.8) (Derache et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 Figure 1.7 Global fold and lipophilic and electrostatic potentials of Sphe-2 
(AvBD103b). Two above pictures showed hydrophobic (brown) and hydrophilic 
(blue) potential areas. The two bottom pictures showed electrostatic positive (red) 
and negative (blue) areas. Intermediate areas are in green in both cases (Landon et 
al., 2004). 
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1.7.4. Anti-microbial activity of AvBDs 
The mammalian defensins are multi-functional and properties include anti-microbial 
activity (AMA) against microbes including bacteria, viruses, yeast and fungi; 
chemoattractant capacity for monocytes and immature dendritic cell; anti-oncogenic ability 
against cancer cells and wound healing (Taylor et al., 2008; Semple and Dorin, 2012). 
Classically however, anti-microbial activity (AMA) is considered the most important 
function of the defensin family.  
There are several reports exploring the AMAs of the AvBDs and while the majority of 
studies have used either synthetic (linear) or GST-tagged peptides all support AvBDs 
having AMA. For example synthetic linear and recombinant GST tagged geese AvBD1, 3 
and 6 peptides at 50 and 100 ug/mL peptide concentrations were highly antimicrobial 
against Pseudomonas aeruginosa, Pasturella multocida and Proteus mirablis but only 
moderately antimicrobial against E. coli and Salmonella species (Ma et al., 2013). In 
comparison quail AvBD9, both synthetic linear and GST tagged forms, displayed the same 
AMA against both Gram positive and negative bacteria (Wang et al., 2010b). Synthetic 
linear ostrich AvBD2 and AvBD7 were reported to be highly active against E. coli, P. 
multocida, Salmonella choleraesuis and Streptococcus agalactiae (Lu et al., 2014), while 
synthetic linear and GST-AvBD6 both similarly inhibited the growth of Gram positive and 
negative bacteria including E. coli and E. faecalis (Peng et al., 2013). Synthetic, but 
Figure 1.8 Global fold and lipophilic and electrostatic potentials of (AvBD2). Two above 
pictures showed hydrophobic (brown) and hydrophilic (blue) potential areas. The two 
bottom pictures showed electrostatic positive (red) and negative (blue) areas. 
Intermediate areas are in green in both cases (Derache, et al., 2012). 
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refolded Penguin spheniscin 2 also showed AMA against both Gram positive and negative 
bacteria (Thouzeau et al., 2003). 
Higgs et al. (2007), investigated the effects of amino acid substitution on AvBD8 killing 
activities against Escherichia coli, Listeria monocytogenes, Salmonella typhimurium, and 
Streptococcus pyogenes (Higgs et al., 2007). In this study the authors changed Valine (V), 
Isoleucine (I), or Threonine (T) amino acids to either Arginine (R), which bears a positive 
charge or to Aspartic acid (D), which carries a negative charge (Figure 1.9), and these 
changes increased or decreased the overall charge of AvBD8. The authors concluded that 
an increased charge enhanced the antibacterial activity of AvBD8. For example, using wild 
type AvBD8 a peptide concentration of 27 μM was needed to kill 50% of viable cells of E. 
coli, but modifying the peptide to include Arginine resulted in a concentration of only 2-3 
μM required to kill 50% of the E. coli cells. In contrast, modifying the peptide to include 
Aspartic acid required a concentration of 27 μM, comparable to the wild type, to kill the 
50% of the E.coli sample. 
 
 
The susceptibility of bacteria to the AvBDs is variable according to the actual strain. For 
example AvBD2 was reported to be less active against Salmonella enteric serovar 
Enteritidis LA5 strain which is a field isolate strain, than against Salmonella enterica 
serovar Enteritidis ATCC, a laboratory strain (Derache et al., 2009b). 
 
 
 
Figure 1.9 Sequences and charges of chicken AvBD8 and its modified versions. Substituted 
amino acids are underlined (Higgs et al. 2007) 
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1.8.Mechanism action of defensin 
Generally, AMPs kill bacteria either through microbial membrane permeabilisation or 
inhibition of intra-cellular molecular synthesis mechanisms. The former mechanism can be 
described by four models: aggregate, toroidal pore, barrel stave and carpet models. These 
models vary according to the size and structure of the peptides and are mostly based on 
pore forming α-helical peptides (Jenssen et al., 2006). In the aggregate model, shown here 
using the horseshoe crab peptide polyphemusin I, the peptides do not form organised 
structures, but through translocation, create informal channels in the membrane (Figure 
1.10 A). In the toroidal model, the peptides, for example the bee peptide Melittin, are 
perpendicularly embedded into the microbial membrane, forming distinct pores into which 
the phospholipid head groups are directed (Figure 1.10 B). In the barrel stave model the 
peptides form a membrane channel lined with perpendicularly organised peptides with their 
hydrophobic tails directed into the lumen of the pore (Figure 1.10 C). Finally in the carpet 
model, peptides such as sheep cathelicidin Smap29 cause a ‘membrane flip flop’ in which 
a piece of the membrane is detached from the whole lipid bilayer resulting in the formation 
of a large pore sealed by the aggregation of the peptides (Figure 1.10 D). Other models that 
do not rely on membrane disruption involve peptides that inhibit intracellular DNA, RNA, 
protein, enzyme and cell wall syntheses (Figure 1.10 E to I). These inhibitory activities are 
initiated by the peptides binding to the outer membrane of bacteria followed by peptide 
translocation and blocking of molecular synthetic pathways. This mechanism has been 
observed for both α-helical and disulphide bond containing peptides (Wilmes et al., 2011). 
It has been reported that fungal, invertebrate and human defensins can inhibit the molecules 
responsible for cell wall biosynthesis. For example, the fungal defensins plectasin, 
oryzeasin and eurocin, the invertebrate oyster defensins lucifensin and gallicin and the 
human defensins HNP1 (α) and HBD3 (β) can bind to lipid II and consequently interfere 
with peptidoglycan formation (Wilmes et al., 2011). The lipid II binding ability of defensin 
has been confirmed by crystallisation of both peptide and lipid together, and the finding 
that Isoleucine 20 and Leucine 25 residues of the HNP-1 monomer bind to Lysine 3 and D-
alanine 4 of lipid II pentapeptide while Isoleucine 20, Leucine 25 and Arginine 15 amino 
acids bind to γD-Glu-2 and the phosphate/N-acetyl muramic acid moiety of Lipid II 
(Varney et al., 2013). 
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Figure 1.10 Mechanisms of action of antibacterial peptides. The bacterial membrane= yellow 
lipid bilayer. Peptides= cylinders, the hydrophilic regions are colored red and the hydrophobic 
regions are blue. Cell wall-associated peptidoglycan molecules are depicted as purple cylinders. 
Models to explain mechanisms of membrane permeabilisation are indicated (A to D). The 
“aggregate” model (A), the “toroidal pore” model (B), the “barrel-stave” model (C) and the 
“carpet” model (D) causing formation of micelles and membrane pores. The mechanisms of 
action of peptides which do not act by permeabilising the bacterial membrane are depicted in 
E to I. Inhibition of DNA and RNA synthesis (E). Decrease in the rate of protein synthesis (F). 
Targeting an enzyme involved in chaperone-assisted protein folding (G). Inhibition of enzymes 
involved in the modification of aminoglycosides (H). Targeting the formation of the cell wall 
(I); such as the transglycosylation of lipid II, which is necessary for the synthesis of 
peptidoglycan (Jenssen et al., 2006). 
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Investigation of specific residues of antimicrobial peptides are important to reveal their 
potential roles in the antimicrobial mechanism of action. The cationic amino acids Arginine 
(R), Lysine (K), and Histidine (H) are important in membrane-defensin interactions. The 
mammalian α-defensin has more conserved arginines than lysine, but in contrast  β-
defensin has more selected lysines (Zou et al., 2007).  To explore the importance of R and 
K residues, research was performed by Zou et al (2007), in which all the lysine amino acids 
of human β-defensin 1 were mutagenised to arginine (RHBD1), and all the arginine 
residues of human neutrophil peptide 1 were modified to non-coded α-amino acids 
(aacHNP-1). The results, which supported increased AMA associated with charged amino 
acids and suggested key roles of the arginine  and lysine positive amino acids in the anti-
microbial specificities of each type of defensin (Zou et al., 2007). In HBD3 the positively 
charged amino acids are located in the C-terminal region of the peptide. This region of the 
peptide is proposed to interact with the anionic part of the bacterial membrane lipid bilayer 
thus facilitating the embedding of the hydrophobic residues into the membrane 
(Sudheendra et al., 2015).  
There are relatively few reports investigating the mechanisms by which the AvBDs interact 
with bacterial membranes. Ovotransferrin, a chicken cationic AMP, caused leakage of a 
NPN fluorescent dye and β-galactosidase from E. coli, and released K+ ions from liposomes 
created by E. coli phospholipids. These data suggested that the peptide can kill the bacteria 
through membrane permeabilisation and consequent leakage of the cytoplasmic content 
(Ibrahim et al., 2000).  
In a study performed by Sugiarto and Yu (2004), both ostrich AvBDs, ostracin 1 and 
ostracin 2 were able to bind E. coli lipopolysaccharide, and induce leakage of fluorescent 
dyes taken up by the model bacterial membranes. However, the binding and leakage 
abilities were remarkably weaker than that of a membrane lytic AMP, sheep myeloid 
antimicrobial peptide-29 (SMAP-29), suggesting a different mechanism of action 
associated potentially with DNA binding rather than membrane lysis (Sugiarto and Yu, 
2007b). Furthermore, a recent study has shown that the Penguin defensin, AvBD103b has 
both bacterial DNA binding capabilities and membrane lytic activities (Teng et al., 2014) . 
These authors found that the peptide attaches to the bacterial (Salmonella enteritidis) 
surface via increasing cell surface hydrophobicity. They also identified using NPN dye 
methodology, atomic absorption and electron microscopy that the peptide causes 
membrane leakage. The DNA binding capacity of the peptide was also investigated using 
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gel retardation assays and its cell cycle arrest properties identified using flow cytometry  
(Teng et al., 2014). 
Electron microscopy has also been employed as a tool to investigate the anti-microbial 
mechanism action of defensins. For example, AvBD9 peptides have been shown to cause 
morphological changes such as granulation of intracellular materials, irregular septum 
formation in a dividing cell, cytoplasmic retraction, lysis at the cell septa, cytoplasmic 
membrane degranulation and complete bacterial cell lysis (van Dijk et al., 2007). Electron 
microscopy showed that GST tagged AvBD6 cause lysis and shrinkage of Aeromonas 
veronii (Peng et al., 2013), while bovine neutrophil defensins killed E. coli and 
Staphylococcus aureus by inducing bacterial cell content release (Wu et al., 2011). 
1.9.Resistance of the microbes to AMPs 
Alongside the evolution of AMPs, microbes have also evolved to resist the activity of 
AMPs. There are several mechanisms through which microbes have acquired resistance 
against antimicrobial peptides including the secretion of proteolytic enzymes to destroy the 
peptides, active efflux of the peptides, down regulation of host AMP expression and 
modification of their bacterial cell membrane to reduce the negative charge (Nizet, 2006). 
For example, Salmonella typhimurium has replaced LPS with L-arabinose thus decreasing 
the net anionic charge of its outer membrane (Yeaman and Yount, 2003). Some gram 
negative strains of bacteria acquire resistance by the translocation of the AMP into the their 
membrane via acylation of the lipid A (Yeaman and Yount, 2003). Other examples include 
the Phop/PhoQ system of Salmonella typhimurium, the energy dependent efflux system of 
Neisseria gonorrhoea and the Dlt operon functioning in the Staphylococcus aureus cell 
wall (Ganz, 2003). 
Protease enzymes are used by bacteria as a defence mechanism for both survival and 
growth. Common examples of proteases in the field of antimicrobial research are the E. 
coli outer membrane protease (OmpT) and the Salmonella PgtE protease, which play 
important roles in the survival resistance mechanism against host AMPs (Yeaman and 
Yount, 2003). Their importance is shown by experiments using mutant strains with the 
OmpT mutant strain, showing increased sensitivity to AMPs. Interestingly the PgtE mutant 
Salmonella strain showed no resistance against protamine that is folded and contains 
disulphide bonds (Yeaman and Yount, 2003). These data suggest that folded peptides such 
as the defensins are more resistant to proteolysis. This characteristic has been explored by 
 25 
 
researchers using cysteine mutant AMPs, e.g., mouse α-defensin cryptidin-4 which is 
sensitive to proteolysis when lacking di-S bonds (Maemoto et al., 2004). Other proteases 
include the heat shock serine protease DegP, which increases the survival rate of E. coli 
against Lactoferricin B, and proteases secreted by pathogenic bacteria including 
Streptococcus, Staphylococcus, and Yersinia, are proposed to have a major role in 
pathogenesis of host diseases and antimicrobial resistance (Yeaman and Yount, 2003).  
In addition to proteolysis, ionic buffer strength plays a role in the inactivation of AMPs. 
For instance, folded AvBD9 AMA is inactive when tested in high salt (150 mM) against 
both Gram positive and Gram negative bacteria including E coli. However, this inactivity 
can be rescued by using sodium phosphate buffer (10 mM) or low salt concentrations (20 
mM) (van Dijk et al., 2007). Using 150 mM NaCl also reduced the AMA of duck AvBD1, 
3, 5, 6, and 16 against Micrococcus tetragenus and Pasturella multocida, and geese 
AvBD1, 3 and 6 against S. aureus and P. mirabilis (Ma et al., 2012a; Ma et al., 2013). 
Similarly the AMA of synthetic linear ostrich AvBD2 and 7 against both E. coli and S. 
aureus was decreased at 150 mM compared to 100mM, suggesting the ions prevent the 
binding of the peptide to the bacterial membrane (Lu et al., 2014). Moreover, the cysteine-
mutant HNP-1 was more active than wild type HNP-1 against E coli, S. aureus and 
Pseudomonas aeruginosa although the latter was highly resistant to the cysteine-mutant 
HNP-1 in high salt concentrations, indicating that ionic buffer strength also has a negative 
impact on the AMA of linear peptides (Varkey and Nagaraj, 2005) 
Furthermore, the increasing salt concentration of the airways of cystic fibrotic patients has 
been linked to the decreased AMA of HBD1 (Goldman et al., 1997). The synergetic effects 
of several AMPs were also reported to be reduced in the salt concentration of the airway 
fluid of cystic fibrotic patients (Singh et al., 2000). However, Ratussin, a five cysteine 
peptide expressed in rat gut, which has a potent AMA against both E. coli and S. aureus 
linked to homo-dimerisation, retains its AMA regardless of the salt concentration and 
presence of divalent ions (Patil et al., 2013). Interestingly the peptide folding state seems 
to play a role in the  stability of AMPs in marine organisms, for example, the presence of 
four disulphide bonds in oyster defensins is proposed to make the peptide more resistant to 
the high salt concentration of the sea water (Wilmes et al., 2011). 
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1.10. Chicken cytokines 
The avian β-defensins are antimicrobial agents and have been reported to kill bacteria and 
fungi (Milona et al., 2007; Ma et al., 2008; van Dijk et al., 2008). Although research has 
focussed mainly on the mammalian defensins the peptides have also been shown to interact 
with other innate immune defences, including cytokines (Soman et al. 2009).  
Cytokines are small (less than 30 kDa in size) soluble peptides that have either pro or anti-
inflammatory functions resulting in either stimulatory or inhibitory effects on cell 
immunity, development and inflammation. In this way, they help modulate the types of 
immune response to an infection (Davison et al., 2008). 
The cytokine structure is comparable to that of the defensins as it includes 4-6 cysteine 
residues, 2-3 disulphide bonds and hydrophobic residues, and is generally conserved 
between animal species. Many chicken cytokines have been identified including IL-3, IL-
4, IL-13, GM-CSF (Avery et al., 2004), IL-18 (Schneider et al., 2000), IL-17 (Min and 
Lillehoj, 2002), IL-16 (Min and Lillehoj, 2004), IL-10 (Rothwell et al., 2004). Kaiser et al. 
(2005), have in their review listed the genes encoding 23 ILs including IL-1β, IL-2, IL-6 
and TGFβ4 (Kaiser et al., 2005). Like the defensins, cytokines are activated early in 
infection (Kaiser et al., 2006), supporting potential relationships between the two groups 
of peptides. 
1.10.1. Interleukin-2  
The chicken IL-2 gene, located on chromosome 4, consists of 4 exons and 3 introns and is 
similar to that identified in mammals although exon 2, and introns 2 and 3, are shorter 
(Kaiser and Mariani, 1999). It encodes a signal peptide of 22 amino acids and a mature 
protein of 143 amino acids (Wigley and Kaiser, 2003) and is known to activate both T-cells 
and heterophils (Kaiser et al., 2006) although the mechanism by which avian IL-2 functions 
is not well-understood. In mammals, IL-2 is known to bind to a cytokine receptor on 
immune cells, including T cells, leading to receptor phosphorylation, signal transduction 
and transcriptional activation of signal transducer and activator of transcription (STAT) 
proteins involved in the further functioning of the immune system (Wigley and Kaiser, 
2003). 
Limited studies have been performed investigating IL-2 gene expression in gut tissues. 
Choi and Lillehoj (2000), showed that following Eimeria (parasite) infection of poultry gut 
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IL-2 gene expression was increased and associated with an increase in gamma delta cells 
in the gut mucosa. Gamma delta cells are proposed to function as a link between the innate 
and adaptive immune systems and these data suggest that IL-2 may function to activate that 
link (Choi and Lillehoj, 2000). Interestingly, the gut expression of IL-2 appears to vary 
according to the infectious agents. For example, in chickens IL-2 mRNA expression 
increased during a primary infection of Emeria acervulina, but decreased in response to E. 
tunella. However, expression remained unchanged in response to secondary infections of 
both Eimeria strains (Hong et al., 2006). 
1.10.2. Interleukin-6  
Interleukin-6 (IL-6) is a pro-inflammatory cytokine that can modulate the innate response 
by activating a number of immune cells including macrophages and lymphocytes (Wigley 
and Kaiser, 2003). The chicken IL-6 gene is located on chromosome 2 (2p21–p13), 
identified by fluorescent and in situ hybridization, and is comprised of 4 exons and 3 
introns. Interestingly the mammalian IL-6 gene has 5 exons and 4 introns and in the chicken 
it appears that the first two exons are fused together, forming one exon. The chicken IL-6 
promoter region resembles that of the human gene in the regulatory sequences identified 
(Kaiser et al., 2004) The mechanism by which avian IL-6 functions is not well understood, 
but in mammals, it is known to bind to cytokine receptors which like IL-2 activates the 
transcription of STAT proteins (Wigley and Kaiser, 2003). 
1.10.3. Transforming growth factor β4 (TGFβ4)  
Originally TGFβ4 was thought to have a role in tumour development, but it is now accepted 
that TGFβ4 has anti-inflammatory characteristics (Burt and Jakowlew, 1992; Wigley and 
Kaiser, 2003; Kaiser et al., 2006) and is important for T-lymphocyte activation (Wigley 
and Kaiser, 2003). TGFβ4 gene expression has been shown to be increased in the chicken 
cecal, spleen and duodenal lymphocytes following E. acervulina infection (Choi et al., 
1999). The expression of TGFβs was investigated in lymphoid tissues, including 
thymocytes, thymic stromal cells, and splenocytes of chicken as well as embryonic chicken 
fibroblasts, and the data suggested that TGFβs help modulate the development of the 
immature cells, particularly thymocytes (Mukamoto and Kodama, 2000).  
Jakowlew et al. (1997) compared TGFβs 2, 3 and 4 mRNA expression in chicken embryos 
and adults, and showed that TGFβ2 and 3 spleen expression was increased in embryos, but 
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decreased in adults. Using immunohistochemistry, the authors showed that TGFβs stained 
weakly in the intestinal epithelia of young birds (1-2 weeks of age), with staining localised 
to the tips of intestinal microvilli. These results suggested that TGFβs 2 and 3 isoforms are 
important for cell growth and development. In contrast TGFβ4 expression increased in the 
intestine of one month old birds, suggesting that it has additional roles in the defence of the 
gut against infection (Jakowlew et al., 1997). 
To date there is significant interest in exploring potential links between gut cytokine 
profiles and gut microbial populations, particularly in humans with inflammatory diseases 
(Sydora et al., 2010). Similarly in birds the effects of age, rearing conditions and microbial 
challenge on gut development, microbiota and cytokine profiles are of significant interest 
to commercial breeders selecting for birds with improved innate immunity and good gut 
health. 
1.11. Chicken galectin-3 
Galectin, previously known as animal lectin, has been identified in lower and higher 
vertebrates suggesting a pivotal role in vertebrate physiology and/or immunology. 
Galectins can be categorised into three groups according to their protein structures: proto, 
chimera, and tandem-repeat types. While their biological functions are not completely 
understood they are known to have roles in cell differentiation, morphogenesis and 
metastasis (Kasai and Hirabayashi, 1996). 
In mammals, four types of galectins (Galectin-1, -2, -3, and -4) and their structures have 
been described (Barondes et al., 1994). As shown in Figure 1.11, Galectin-3 is composed 
of one carbohydrate binding domain of 130 amino acid residues, an N-terminal domain 
(which is not present in other galectins) and a link peptide (Barondes et al., 1994). 
 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chicken galectins (CG) have been reported and include CG1A (liver) CG1B (lung), CG2 
(gut), CG3 (gut) and CG8 (jejunum and caecum) (Kaltner et al., 2009). The Chicken 
Galectin-3 (CG3) gene consists of 6 exons and 5 introns, and is located on chromosome 5 
(Kaltner et al., 2011). Chicken galectin-3 is expressed in a number of tissues including 
thymus, lung, heart, spleen, liver, esophagus, proventriculus, gizzard, jejunum, cecum, 
kidney, ovary, shell egg, bursa, skin and fibroblasts (Kaltner et al., 2011). 
An immunological function of chicken Galectin-3 is not obvious. Galectins can however 
interact with glycoproteins and glycolipids of the host cell-surface and extracellular matrix, 
through lectin-carbohydrate bindings (Liu, 2005). They can also enhance cell growth, affect 
cell survival, regulate cell adhesions and induce cell migration (Liu, 2005). Galectin-3 may 
also act as an opsonin, forming a link between the carbohydrate components of bacteria 
cell membranes and the surface glycoproteins of phagocytes (Almkvist and Karlsson, 
2004). Moreover, in mammals at high concentrations (1μM) it acts as a chemo-attractant 
to macrophages and stimulates monocyte migration (Sano et al., 2000). In fact in the studies 
by Sano et al, (2000), using an in vivo mouse model, Galectin-3 was shown to increase the 
Figure 1.11 Schematic of the overall structures of galectin-1, -2, -3, and 4. The proteins 
are shown schematically as linear diagrams corresponding to single peptide chains (top) 
and as assembled proteins (bottom). The carbohydrate-binding domains of about 130 
amino acid residues are blue, the proline-, glycine-, and tyrosine-rich repeating domain 
of galectin-3 (about100 residues) and link peptide of galectin-4 (about 30 residues) are 
orange, and the N-terminal domain of galectin-3 (about 30 residues) is green. (Barondes 
et al. 1994).  
 30 
 
number of moncytes in mouse air pouches (Sano et al., 2000). Thus, it is feasible that 
chicken Galectin-3 expression and synthesis at the avian gut epithelium functions in 
attracting monocytes and macrophages to a site of inflammation during bacterial infection 
and helps to increase phagocytosis of the bacteria. 
Aims and objectives  
In depth knowledge of the involvement and roles of the host innate defences, specifically 
avian β-defensins (AvBDs) in protecting birds (young and growing) against disease, 
particularly in commercial environments is lacking. Scientifically and commercially such 
information is of value as it may be used to improve disease resistance in commercial lines 
and exploited through selective breeding programmes. This research presented in this thesis 
aimed to explore the expression and functions of the AvBDs with the objectives of defining 
their roles in bird health.  
 
1. The first study using qPCR and immunocytochemistry aimed to explore potential 
relationships between the expression and synthesis of AvBDs and other immuno-regulatory 
molecules. The focus was on AvBD6 and 9, IL-6, TGFβ4 and CG3 in gut, kidney, liver and 
lung tissues of birds. 
2. The second study using recombinant and synthetic peptides aimed to explore the 
antimicrobial activity (AMA) of the AvBDs 6 and 9, against bacterial strains isolated from 
commercially reared birds.  
3. The third area of study using synthetic peptides, bacterial membranes, and structure 
modelling aimed to explore the killing mode of actions of the AvBDs 6 and 9 peptides.  
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Chapter 2 
2. Materials and Methods 
2.1.Chemicals and consumables 
All chemicals were purchased from Sigma Aldrich (Poole, U.K.) unless otherwise stated. 
All plastics were purchased from Starlab (Milton Keynes, U.K.).  
2.2.Bacterial culture: 
2.2.1. Growth medium broth  
Luria-Bertani (LB) growth media including Bacto-Tryptone and Bacto-Yeast were 
purchased from BD Biosciences (Oxford, UK). LB broth was prepared by dissolving 10 g 
Tryptone, 5 g yeast and 10 g sodium chloride in 1L double-distilled (ddH2O) water. The 
pH was adjusted to 7.4 using 1 M sodium hydroxide solution (NaOH) and the broth was 
autoclaved for 20 minutes at 121 °C and 15 PSI pressure.  
Tryptic soy broth (TSB) was prepared by dissolving 15 g of Tryptone soya broth (TSB) 
powder in 500 ml ddH20 and sterilised as described previously by autoclaving.  
NZY broth  was prepared by dissolving 10 g NZ amine, 5 g Yeast and 5 g NaCl in 1L H2O, 
adjusted to pH 7.5, and sterilised by autoclaving. This broth required the addition of 12.5 
ml 1 M MgCl2, 12.5 ml 1 M MgSO4, and 10 ml 2 M Glucose before use.  
2.2.2. LB agar plates 
Plates were prepared by dissolving 15 g of agar (BD Biosciences, Oxford, UK) in 1L of the 
LB broth. After sterilisation, approximately 20 ml of LB agar was poured into each petri 
dish and left to solidify. The plates were dried at 37 °C before use. Antibiotics including 
Ampicillin (50 μg/ ml dissolved in ddH2O) and Chloramphenicol (30 μg/ ml dissolved in 
ethanol) were added to the cooled agar medium as required.   
2.2.3. Blood agar based plates  
Forty grams of blood agar base (Sigma) was dissolved in 1L ddH2O. Following 
autoclaving, the agar (~ 20 ml) was poured into each petri dish, allowed to set and the plates 
dried at 37 °C.  
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2.3.Bacterial strains 
The bacteria used in the anti-microbial assays included Escherichia coli and Enterococcus 
faecalis, which were clinical isolates purified from two birds resident on Aviagen farms 
and described previously by V. Butler (2010).  
The competent cells exploited for cloning and hyperexpression were E coli DH5 α-and E 
coli BL21 (DE3) pLysS strains (Table 2.1), purchased from Promega, Southampton, U.K.  
 
Strains Genotype 
DH5α F- Φ80lacZΔM15 Δ (lacZYA-argF) U169 recA1 endA1 
hsdR17 (rk-, mk+) phoA supE44 λ-thi-1 gyrA96 relA1 
BL21 (DE3) 
pLysS 
F –, ompT, hsdSB (r B 
–, m B 
–), dcm, gal, λ (DE3), pLysS, 
Cmr. 
Table 2.1 Genotypes of competent cells used for cloning and hyperexpression 
2.4.Buffers 
2.4.1. Phosphate buffered saline (PBS) 
Phosphate buffered saline (PBS) tablets were purchased from Sigma. To prepare 1 x PBS 
(8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, 0.24 g of KH2PO4, per 1L of distilled H2O, 
pH 7.2), one tablet was dissolved in 200 ml distilled water. All PBS solutions were 
sterilised by autoclaving.  
2.4.2. Sodium phosphate buffer 
Monobasic phosphate buffer (200mM), was prepared by dissolving 13.8 g of 
NaH2PO4∙H2O (MW= 137.99) in 500 ml ddH2O. Dibasic phosphate buffer (200 mM), was 
prepared by dissolving 17.8 g of Na2HPO4∙2 H2O (MW = 177.99) in 500 ml ddH20. Sodium 
Phosphate buffer (100 mM) was prepared by mixing 47.5 ml of monobasic phosphate 
buffer with 202.5 ml dibasic phosphate buffer. The pH was adjusted to 7.4 if required and 
the final solution sterilised by autoclaving.  
2.4.3. GST ‘cleaving’ buffer 
GST ‘cleaving’ buffer used to facilitate removal of the GST tag from recombinant peptides 
was prepared by dissolving 0.88 g NaCl, 0.029 g Na-EDTA and 0.015 g DDT in 100 ml 
Tris- HCL (50 mM). The pH was adjusted to 7.4 and the solution sterilised by autoclaving.  
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2.4.4. Sample loading buffers 
Protein: SDS sample loading buffer was prepared as follows: 1 g SDS, 5 ml 0.25M Tris pH 
6.8, 2.5 ml of 50% Glycerol, 2.5 ml 2-β-Mercaptoethanol and 4 ml 0.1% Bromophenol blue 
dye.  
DNA: DNA loading buffer was prepared by mixing 3 ml glycerol (30%), 25 mg 
bromophenol blue (0.25%), and sterile distilled water to 10 ml. 
2.4.5. Gel running buffers 
Protein: SDS PAGE running buffer was prepared by mixing 3% w/v Tris, 14% w/v Glycine 
and 1% w/v SDS. The pH was adjusted to 8.3 using 1 M NaOH. DNA: The buffer used for 
DNA agarose gel electrophoresis was 1 X Tris borate EDTA (TBE), which was prepared 
by dissolving 10.8 g of Tris base, 5.5 g of boric acid and 0.74 g of EDTA in 1L of distilled 
water, pH 8.3.  
2.4.6. Tris glutathione elution buffer (TGE) 
TGE buffer was prepared by dissolving 0.06 g reduced L- Glutathione (20 mM), and 0.06 
g Tris pH 8 (50 mM) in 10 ml sterile ddH2O, in a sterile 20ml universal.  
2.4.7. Neutral buffered formalin 
Neutral buffer formalin (10%) was prepared by mixing 100 ml 37% Formaldehyde, 900 ml 
deionised water, 4 g Sodium phosphate monobasic buffer and 6.5 g sodium phosphate 
dibasic buffer, pH 7.  
2.5.Tissue sample collection 
For the tissue panel expression analyses tissue samples collected previously by V Butler 
from Day 7 and Day 35 Aviagen Line X birds reared in low and high hygiene conditions, 
preserved in RNA later solution (Ambion, Applied Biosystems, UK) and stored at -80 °C 
were utilised.  
The tissue samples for immunohistochemistry were fixed in 10% neutral buffered formalin 
for 48 hours. The fixed samples were transferred to 70% ethanol and stored at room 
temperature. 
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2.6.RNA extraction 
Endpoint PCR: RNA extractions were performed by homogenising 10-20 mg tissue 
samples in 1 ml of Trizol (Invitrogen, Paisley, UK), with a rotor-stator style homogenizer 
(Tissue Rupter, Qiagen, Crawley, UK). Isopropanol 200 µl/ ml was added to each sample, 
the solutions mixed for 3 minutes at room temperature and centrifuged at 12000 x g, 4 ˚C 
for 15 minutes. The clear supernatant layer was removed and mixed with an equal volume 
of 70 % ethanol. This mixture was loaded onto a purification column (PureLink™RNA 
mini kit, Invitrogen, Paisley, UK), washed three times with wash buffers and eluted using 
30 μl molecular grade water. To aid RNA preservation, 1 μl of RNAse inhibitor (RNAsin, 
Promega, Southampton, UK), was added to all samples before storage at -80 °C.  
Real time PCR: RNA extractions of tissues from small intestine, caecum, caecal tonsils, 
kidney, liver and lung were performed using a SV Total RNA Isolation System (Promega, 
Southampton, U.K.). Tissue samples stored at -80 °C were cut into small pieces (10-20 mg) 
using a sterile scalpel, and cells lysed by the addition of 300 μl lysis buffer (5 ml β-
mecaptoethanol+ 500 ml RNA lysis buffer). The tissues, in liquid nitrogen, were ground 
using pestle and mortar, homogenised for one minute and kept at -20 °C overnight. The 
thawed mixtures were further diluted by adding 350 μl RNA dilution buffer and mixed well 
by inverting the tubes at least 5 times. This was followed by incubation at 70 °C for 3 
minutes and centrifugation twice at 4 °C, 13,000 x g for 10 minutes and the supernatants 
collected and stored in clean sterile microfuge tubes. The samples were washed by adding 
200 μl 95% ethanol, mixed by pipetting, transferred onto the columns and centrifuged at 
4 °C, 13,000 X g for 1 minute. The samples were further washed using 600 μl RNA wash 
solution (350 μl 95% ethanol+206 μl RNA wash solution) and centrifuged at 4 °C, 13,000 
x g for 1 minute. The columns were treated with 50 μl DNAse I (5 μl MnCl2+5 μl 
DNAse+40 μl yellow core buffer) and incubated at room temperature for 15 minutes. The 
DNAse treatment was stopped by adding 200 μl DNAse stop solution to each column and 
centrifuging at 4 °C, 13,000 x g for 1 minute. After washing twice with 600 and 250 μl of 
RNA washing solution, each time centrifuging at 4 °C, 13,000 for 1 minute, the samples 
were eluted with 100 μl pure molecular grade water, again centrifuging at 4 °C, 13,000 x g 
for 1 minute,  and collected in clean sterilised microfuge tubes. The eluted samples were 
kept at -80 °C.  
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2.7.RNA quantification 
The RNA concentration of each sample was determined using a NanoDrop 
(NanoDrop®,ND-1000). The RNA concentration was measured and the purity checked by 
measuring ODs at (A260/A280) and (A260/A230). Values between (1.8-2.2) were 
considered as a pure RNA.  
2.8.DNAse treatment 
Endpoint PCR: Prior to RNA expression analyses DNAase treatment of each RNA sample 
was performed to remove any potential contaminating genomic DNA (Promega kit, USA). 
Essentially 4.5 μg RNA was mixed in a microfuge tube with 4.5 μl DNAse enzyme (1 unit/ 
µl), 2 μl 10 X DNAse buffer and sterile molecular grade water (to final volume of 20 μl). 
The tube contents were mixed and incubated at 37 ˚C for 30 minutes. The reaction was 
stopped by adding 4 μl DNA Stop solution for 10 Minutes at 65 ˚C.  
Real time PCR: The DNAse treatment was performed as described in section 2.6. 
2.9.Reverse transcription 
Endpoint PCR: Reverse transcription of the RNA to cDNA was performed in a microfuge 
tube using reagents from a cDNA Reverse Transcription kit (Applied BioSystem, UK).  
Briefly, 10 μl DNAsed treated RNA sample was mixed with 1.0 μl Mulv Reverse 
transcriptase enzyme (50 units/ µl), 3.2 μl MgCl2 25 mM, 2.0 μl HEX (Hexamer solution), 
4 μl of 10 X reverse transcriptase buffer, 16 μl dNTPs 10 mM, and 3.8 μl sterile molecular 
grade water. The solutions were incubated for 60 minutes at 42 ˚C, 5 minutes at 95 ˚C, and 
finally 5 minutes at 5 ˚C. Samples were either used in subsequent PCR reactions or stored 
at -80 ˚C.   
Real time (q) PCR: The RNA was reverse transcribed as for end point PCR but in this case 
250 ng RNA was used for each tissue sample. The master mix was prepared by mixing 5 
μl Mulv RT buffer, 6.25 μl dNTPs 2 mM, 0.25 μl RNAsin, and 0.5 μl Mulv RT enzyme. 
The reaction was set up by adding 1 μl of Hexamer 0.5 mg/ ml to 250 ng RNA/10 μl H2O 
and the PCR tubes incubated in the light cycler at 60 °C for 5 minutes. Twelve (12 μl) of 
the master mix was added to each sample, the samples incubated at 42 °C for 2 hours and 
kept at -20 °C.  Each RT was diluted 1:4 before qPCR.   
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2.10. Endpoint PCR primers 
Endpoint PCR primers are shown in Table 2.2. BamH1 and EcoR1 restriction sites were 
incorporated into the Avian β-defensin 6 and 9 primers to allow cloning into the expression 
vector pGEX6p-1 (GE Healthcare Life Sciences, Buckinghamshire, U.K.). Primers 
encoding chicken cytokines IL-2, IL-6, TGFβ4 and Galectin-3 were designed, to cross at 
least two exons. All primers were purchased from Integrated DNA Technologies (UK) in 
a lyophilized form and diluted with sterilised molecular grade water to give a stock solution 
of 100 mM. This stock solution was further diluted to a PCR working solution of 10 mM.  
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Gene Gene bank 
accession No. 
Forward primer Reverse primer Size 
(bp) 
Tm  
AvBD6 
M 
NM_001001193.1 CGCGGATCCAGCCCTATTCATGCTTG CGAGAATTCTCAGGCCCACCTGTTCCTC
AC 
126 61 
AvBD6 
P+M 
NM_001001193.1 CGCGGATCCGGTCAGCCCTACTTTTC CGAGAATTCTCAGGCCCACCTGTTCCTC
AC 
144 61 
AvBD9 
M 
NM_001001611.2 CGCGGATCCGCTGACACCTTAGCATG CGAGAATTCTCAGGAGCTGGGTGCCCA
TTTG 
126 63 
AvBD9 
P+M 
NM_001001611.2 CGCGGATCCGCTTACAGCCAAGAAGAC CGAGAATTCTCAGGAGCTGGGTGCCCA
TTTG 
144 63 
IL-2 AJ224516.1 GATAACTGGGACACTGCCATGATG GTCTCAGTTGGTGTGTAGAGCTCG 305 56 
IL-6 AJ250838.2 GTCCGGAGAGGTTGGGCTGG GCCGTCCTCCTCCGTCACCTTG 280 60 
TGFβ4 M31160.1 GACCTCGACACCGACTACTG GCAGGCACGGACCACCATATTG 332 58 
CG3 EF429082.1 GCCATATCCTGGAGGACCAACTG GAAGTTGAACTGCAGCAGGTGAG 385 56 
Table 2.2 Primers designed for AvBDs, cytokines, and Chicken Galectin-3 genes.  
AvBD6 M= Avian β-defensin 6 primer encoded mature peptide, AvBD6 P+M= Avian β-defensin 6 primer encoded promature peptide, AvBD9 M= Avian β-
defensin 9 primer encoded mature peptide, AvBD9 P+M= Avian β-defensin 9 primer encoded promature peptide. Underlined nucleotides represent the 
restriction sites of BamH1 (forward primers) and EcoR1 (reverse primers). IL-2= Interleukin-2 primer, IL-6= Interleukin-6 primer, TGFβ4= Transforming 
growth factor β4 primer, CG3= Chicken galectin-3 primer. Tm= Melting temperature. Size= product size (bp) amplified by the PCR primers.  
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2.11. End point polymerase chain reaction (PCR) 
PCR was performed in a microfuge tube using reagents from a Bioline kit (Bioline London, 
UK). RT samples (10.0 μl) were mixed with 10X PCR buffer (4.0 μl), MgCl2 50 mM (0.8 
μl), sterile molecular grade water (20.7 μl), BioTaq Polymerase (0.5 μl), forward primer 
10mM (2.0 μl) and reverse primer 10mM (2.0 μl). Following mixing the tube contents were 
incubated at 95 ˚C for 3 minutes; 35 cycles of (94 ˚C / 1 minute, Tm/ 1 minute, 72 ˚C/ 1 
minute) using a thermal cycler (Techne, Bibby Scientific Limited, UK); 72 ˚C / 12 minutes 
and a hold cycle of 4 ˚C. 
2.12. Real time (Quantitative- Q) PCR 
AvBD6, AvBD9, IL-6, TGFβ4 and chicken Galectin-3 QPCR were performed using the 
Sybr green system, and a Roche Lightcycler 480 (Roche, Basel, Switzerland). 
2.12.1. Real time PCR primers: 
Primers for the real time PCR analyses are shown in Table 2.3. TGFβ4 and chicken 
Galectin-3 primers were designed for this project while AvBD6, AvBD9 and IL-6 primers 
were designed previously by Dr Catherine Mowbray (Newcastle University). 
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Gene Gene Bank No. Forward primers Reverse primers 
Size 
(bp) Tm 
AvBD6 NM_001001193 TCTTGCTGTGTGAGGAACAGG TTAGAGTGCCAGAGAGGCCA 95 61 
AvBD9 NM_001001611.2 GCAAAGGCTATTCCACAGCAGA CTTCTTGGCTGTAAGCTGGAGCA 103 62 
IL-6 NM_204628.1 CTTCGACGAGGAGAAATGCCT ACTCGACGTTCTGCTTTTCG 110 58 
TGFB4 M31160.1 GTACAACCAACACAACCCG GCAGGCACGGACCACCATATTG 136 57 
CG3 EF429082.1 GCCGCTCCACTGAAAGTC GTGGAAGGCAATGTCTTGC 143 56 
Table 2.3 Real-time PCR primers. AvBD6, AvBD9 and IL-6 primers were designed by Dr.Catherine Mowbray, Newcastle University 
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2.12.2. Standard curves: 
Real time PCR standard curves for TGFβ4 and Chicken Galectin-3 were prepared by serial 
dilution of the cloned plasmids (pGEM-T® easy vector, Promega, Southampton, U.K.). 
Standard curves for AvBD6, AvBD9 and IL-6 were prepared by Dr Catherine Mowbray 
(Newcastle University).  
Ten (10) microlitres of plasmid standard diluted 10-4, 10-5, and 10-6 were added to 90 μl of 
pure molecular grade water to make 10-5, 10-6 and 10-7 dilutions respectively for each gene. 
Pure molecular grade water was used as a negative control. 
2.12.3. Real time PCR reaction 
A master mix was prepared as follow: 5 μl Sybrgreen, 0.5 μl mixed primers 10 μM and 2.5 
μl pure molecular grade water. Eight (8) μl of the master mix was added into each well of 
a 96 qPCR plate (Roche, Basel, Switzerland), followed by either 2 μl reverse transcribed 
cDNA (1:4 diluted), water [negative control] or plasmid standard [positive control]. Each 
sample was loaded into the wells in duplicate. The plates were sealed by nylon sheets and 
mixed by spinning (Labnet MPS 1000 mini plate spinner) for one minute. Expression was 
calculated by normalisation of the crossing point (CP) values with the plasmid standards to 
acquire arbitrary units (A.U.) of the expressed mRNA. The relative quantification of the 
expression was performed by dividing the AU value of each sample by the geometric mean 
of two housekeeping genes, SDHA (Succinate dehydrogenase complex, subunit A, 
flavoprotein variant) and SF3A1 (Splicing factor 3 subunit 1) (GeNorm kit, Primerdesign 
Ltd, Southampton, U.K.).  The housekeeping genes were cloned into the same plasmid by 
Dr. Catherine Mowbray (PhD, Newcastle University).  
2.13. Production of recombinant plasmids  
2.13.1. cDNA PCR product purifications 
PCR products were purified using a Qiagen purification kit as recommended by the 
manufacturer instructions. Essentially 5 volumes (600 μl) of PB buffer was added to one 
volume of PCR product (120 μl). This was pipetted onto a Qiagen column and centrifuged 
for 1 minute at 4 °C 13,000 g with the flow through being discarded. The column was 
washed twice, using centrifugation, each time with 750 μl PE buffer and the flow through 
discarded.  The DNA was eluted from the column using 50 μl molecular grade water. 
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2.13.2. pGEX-6p-1 vector system and cDNA cloning 
AvBD cDNAs were cloned into pGEX-6P-1 (Figure 2.1) via BamH1 (GGATCC) and 
EcoR1 (GAATTC) restriction sites.  
The purified PCR products and pGEX-6P-1 were restricted with BamH1 and EcoR1, and 
the enzymes removed using the Qiagen PCR purification kit. Ligations were set up and 
each ligation included 1 μl of vector DNA (100 ng), 5 μl of the PCR product, 1 μl T4 DNA 
Ligase (Promega, Southampton, U.K.), 1 μl of ligase buffer, and 2 μl of water. Ligations 
were incubated for 2 hours at room temperature.  
 
2.13.3. pGEM T Easy vector system and cDNA cloning 
TGFβ4 and chicken galectin-3 cDNAs were cloned into pGEM T Easy vector (Promega, 
Southampton, U.K.). The ligation reaction was as follows: 1 μl of the vector (50 ng), up to 
2 μl of the cDNA, 1 μl of T4 DNA ligase, 2 μl of the ligation buffer and 4 μl of molecular 
grade water. Ligations were incubated at 4 ˚C overnight.  
 
Figure 2.1 pGEX-6P-1 plasmid map. 
It contains multiple cloning sites such as BamH1 and EcoR1.It also bears Ampicillin resistant 
gene (Amp), GST tag and PreScission protease sites (GE Healthcare Bio-Sciences AB). 
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2.13.4. Competent cell preparation 
Bacterial strains of E. coli, DH5α-and BL21 (DE3) pLysS, stored at -80oC were thawed on 
ice, streaked out on LB agar plates and incubated overnight at 37 ˚C. A single colony was 
picked and cultured in 10 ml LB overnight at 37 ˚C, with gentle shaking (Gallenkamp 
orbital shaker, Sanyo Gallenkamp Plc, Leicester, UK). For competent cells, 1 ml of 
overnight culture was added to 100 ml LB broth and shaken vigorously at 37 ˚C, for 
approximately 80 minutes or until an optical density [OD600nm] of 0.3-0.4 was reached. 
The culture was decanted into two Falcon tubes (50 ml for each), the bacterial cells pelleted 
by 5 minutes centrifugation at 4000 x g and 4 ˚C (Heraeus Biofuge Stratos centrifuge) and 
the supernatant decanted off. Four ml of 0.1 M MgCl2 was added to each pellet, mixed well 
by vortexing, the solutions transferred to one tube and the cells re-centrifuged. After the 
supernatant was discarded, 4 ml of 0.1 M CaCl2 was added to the pellet, the solution 
vortexed and the cells left on ice for 2 hours before being used in the transformation 
process.  
To prepare glycerol stocks, 0.5 ml of competent cells plus 0.5 ml of 50% glycerol were 
mixed in a microfuge tube and stored at -80 ˚C.  
2.13.5. Bacterial cell transformation  
The ligated vector was transformed into the competent cells by heat shock. To achieve this 
100 μl of competent bacterial cells were added to 5 μl of the ligation mix in a microfuge, 
incubated on ice for 10 minutes, incubated at 42 ˚C for 2 minutes and returned to ice for 3 
minutes. Finally, 200 μl of LB broth was added to the transformation mix and this was 
gently shaken at 37 ˚C for at least 1 hour. Increasing amounts of the transformation mix 
(50 μl, 100 μl, and 150 μl) were spread on LB-Ampicillin or LB-Ampicillin-
Chloramphenicol plates for either DH5α or BL21 competent cells respectively, and the 
plates incubated at 37 ˚C overnight.  
2.13.6. Blue-white colony screening method 
To screen for  recombinant pGEM T Easy colonies, LB-Ampicillin agar plates were 
prepared and spread with 100 μl of 10 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) 
followed by 100 μl of 50 mM 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, (X-gal). 
As described in section 2.13.5, increasing volumes of the appropriate transformation mix 
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(25 μl, 50 μl, 75 μl, and 150 μl) were spread on the LB- Ampicillin- IPTG- X gal plates, 
and the plates incubated at 37 ˚C overnight.   
2.13.7. PCR screening for gene inserts 
Using a sterile toothpick single white colonies were picked, spotted onto a LB-Ampicillin 
agar plate and also mixed into 5 μl of molecular grade water contained in a PCR microfuge 
tube. To each colony solution, 11.5 μl of molecular grade water, 0.6 μl MgCl2, 2.0 μl 10X 
PCR buffer, 0.6 μl forward primer, 0.6 μl of forward and reverse primer (10 mM), 0.5 μl 
dNTPs, 0.2 μl BioTaq polymerase was added and the contents subjected to PCR at 94 ˚C 
for 1 min, 25 cycles of (94 ˚C for 30 sec, Tm ˚C for 30 sec, 72 ˚C for 1 min) 72 ˚C for 12 
minutes and 4 ˚C hold.  Agarose gel electrophoresis was used to identify which colonies 
contained recombinant plasmid. Positive colonies that contained the required plasmid were 
cultured overnight in 5 ml LB- broth containing the appropriate antibiotic, subjected to 
plasmid preparation by QIAprep Spin Miniprep Kit (Qiagen, Crawley, UK) and DNA 
sequenced.    
2.13.8. Recombinant plasmid extraction from the competent cells 
Each five ml of overnight culture was pelleted by centrifugation at 8000 g, for 3 minutes at 
4 °C (Microcentrifuge Peqlab) and the plasmid prepared using the QIAprep Spin Miniprep 
Kit protocol. The plasmid DNA was eluted with 30 μl molecular grade water in a sterilized 
microfuge tube and stored at -20 ˚C. The purified extracted plasmid were confirmed by 
PCR using cDNA primers and 1.5 % agarose gel electrophoresis.  
2.14. DNA gel electrophoresis 
PCR products were analysed using either 1.5 or 2 % agarose gels.  To prepare the gels 0.75 
(1.5%) or 1 (2%) g agarose was dissolved in 50 ml 1x TBE, the gel was allowed to cool to 
approximately 60 ˚C, 5 μl ethidium bromide solution (5 µg/ ml) was added, and the gel 
poured into electrophoresis apparatus. The gel was allowed to set for 15-30 minutes and 
then submerged in 1X TBE buffer.  Each sample (8 μl) was mixed with 2 μl DNA loading 
buffer and the samples loaded into the wells; the gel electrophoresed at 50V for 1 hour or 
as required. DNA markers (Bioline, London, UK) included hyperladder IV (4 μl/well) (10 
bands from 100 bp – 1013 bp) and Hyperladder I (14 bands from 200 bp – 10,037 bp).  
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2.15. DNA sequencing 
The cDNA products and recombinant plasmids were sequenced using forward/reverse 
primers of either the plasmid or gene insert (GeneVision, Newcastle, UK). The sequences 
were read by chromatograph (Chromas lite, Version 2.0, Technelysium Pty Ltd), 
(http://chromas-lite.software.informer.com/2.0/) and where appropriate blasted against the 
chicken genome (Gallus gallus) (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
2.16. AvBD9 site directed mutagenesis 
Site directed mutagenesis (Quick-change Lightning Multi Site-Directed Mutagenesis Kit, 
Agilent Technologies) was used to change the DNA sequence of the AvBD genes. The 
method is shown in Figure 2.2. This is a PCR-based mutagenesis using double stranded 
plasmid as template. To mutagenise the targeted sequence, three steps were required. In the 
first step (A), using thermal cycling, the DNA template was denatured so that the mutagenic 
primers could be annealed and extended, and the new template ligated using Pfu Fusion-
based polymerase enzyme blend. The second step (B) involved Dpn 1 (endonuclease, target 
sequence: 5´-Gm6ATC-3´) digestion of the template to remove the parental non-mutated 
methylated and hemimethylated DNA. Finally, the newly mutagenised single stranded 
DNA (C) was transformed into the Gold ultra-competent cells. 
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2.16.1. Mutagenesis primers 
Mutagenesis primers are shown in Table 2.4, and designed using a quick change primer 
design programme on the Agilent Technologies website: 
(https://www.genomics.agilent.com/primerDesignProgram.jsp:) 
A 
B 
C 
Figure 2.2 Basic steps of PCR based site directed mutagenesis.  
A: DNA template denatured, primers with desired mutation annealed and extended through PCR 
using Pfu DNA polymerase. B: Dpn 1 digestion of the parental DNA (Me groups of parental DNA 
recognised) resulting in the stable mutagenised SS DNA (C), which is transformed into competent 
cells.  
Parental DNA is methylated (Me) and shown as light blue (outer circle) and brown (inner circle). 
The mutagenised SS DNA is non-methylated and shown as dark blue. Agilent technologies, UK. 
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Primer Forward Reverse Mutagenised 
AvBD9 C1/A GCTGACACCTTAGCAGCCAGGCAGAGCCACGG CCGTGGCTCTGCCTGGCTGCTAAGGTGTCAGC TGC to GCC 
AvBD9 C2/A CAGAGCCACGGCTCCGCCTCTTTTGTTGCATGC GCATGCAACAAAAGAGGCGGAGCCGTGGCTCTG TGC to GCC 
AvBD9 C6/A TGGGAAGCTGAAATGCGCCAAATGGGCACCCAGC GCTGGGTGCCCATTTGGCGCATTTCAGCTTCCCA TGC to GCC 
AvBD9 C4/G TTGACATTGGGACCGGCCGTGGTGGGAAG CTTCCCACCACGGCCGGTCCCAATGTCAA TGC to GGC 
AvBD9 C3/G CTCCGCCTCTTTTGTTGCAGGCCGTGCTCC GGAGCACGGCCTGCAACAAAAGAGGCGGAG TGC to GGC 
AvBD9 C5/G CCGTGGTGGGAAGCTGAAAGGCGCCAAATG CATTTGGCGCCTTTCAGCTTCCCACCACGG TGC to GGC 
AvBD9 W38/G GGGAAGCTGAAATGCTGCAAAGGGGCACCCAGC GCTGGGTGCCCCTTTGCAGCATTTCAGCTTCCC TGG to GGG 
Table 2.4 Primers (forward and reverse) designed for site directed mutagenesis.  
The underlined sequences are codons of the mutagenised amino acids. AvBD9 C1, 2 and 6 /A represent primers designed to mutagenise cysteines (C1, C2 
and C6) to Alanine. AvBD9 C3-5 /G means the primers to replace C3-5 by glycine. AvBD9 W38/G is the substitution of tryptophan (W38) with glycine. 
TGC (cysteine codon), mutagenised to GCC (Alanine codon) or GGC (Glycine codon). TGG (tryptophan codon), mutagenised to GGG (Glycine codon). 
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2.16.2. Mutagenesis reaction 
The mutagenesis reactions were set up as follows: 2.5 μl of 10 x QuickChange Lightning 
Multi reaction buffer, 13.5 μl pure molecular grade water, 0.75 μl QuickSolution,  2 μl of 
recombinant plasmid (50 ng/ μl), 2 μl of each primers, 1 μl dNTPs and 1 μl of QuickChange 
Lightning Multi enzyme blend. The reactions were incubated in one cycle of (95 °C for 2 
minutes); 30 cycles of (95 °C for 20 seconds, 55 °C for 30 seconds and 65 °C for 2.5 
minutes); 3 cycles of (65 °C for 5 minutes); and incubated on ice for 2 minutes. The parental 
DNA (non-mutated, methylated and hemimethylated double stranded DNA) was digested 
by incubating the reaction with 1 μl of Dpn I restriction enzyme at 37 °C for 5 minutes 
prior to the transformation step. 
2.16.3. Transformation of mutagenised plasmids  
The transformation of the mutagenised plasmids was performed by thawing 45 μl of the 
XL10-Gold ultra-competent cells in a 14-ml Falcon tube on ice, mixing with 2 μl of β-
Mercaptothanol and swirling the tube every 2 minutes for 10 minutes.  Dpn I-treated 
mutagenised plasmids (1.5 μl) were mixed with the thawed cells and incubated on ice for 
30 minutes. The mixture was incubated in a 42 °Cwater bath for 30 seconds, incubated on 
ice for 2 minutes, followed by the addition of 0.5 ml of preheated NZY broth. The 
competent cells plus DNA were incubated at 37 °C for 1 hour with shaking on an orbital 
shaker at 225 rpm. An appropriate volume (1 μl, 10 μl and 100 μl) of the transformed 
competent cells were plated on the LB-Amp (50 µg/ ml) agar plates and incubated 
overnight at 37 °C. The mutagenised plasmids were extracted as described in section 2.13.8, 
and DNA sequenced by Genevision (Section 2.15). 
2.17.  Hyper expression of AvBD6 and AvBD9  
For hyper-expression work recombinant plasmids, pGEX-6P-1+AvBD6 and pGEX-6P-
1+AvBD9, were transformed into BL21 (DE3) pLysS and colonies selected on the LB agar 
plates containing ampicillin (50 µg/ ml) and chloramphenicol (30 µg/ ml). Single colonies 
were picked and cultured overnight in 10 ml LB containing antibiotics with gentle shaking. 
The overnight culture (10 ml) was added to 1L of LB containing Ampicillin and 
Chloramphenicol, shaken at 37 ˚C for 3.5 hours or until an optical density of 0.8- 1 nm. 
Peptide production was induced with IPTG (1M) for 2-3 hours. The culture was centrifuged 
at 5000 rpm at 4 ˚C for 10 minutes (Beckman Coulter Centrifuge, JA10 rotor). The pellets 
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were collected and re-suspended in 20 ml sterile 1x PBS and frozen overnight at -80 °C. 
After thawing, the pellets were sonicated for 2 minutes using a Braun Labsonic U sonicator, 
set at low intensity ~42 watts and 0.5 second cycling, followed by centrifugation at 15,000 
x g, 4 ˚C for 30 minutes (Beckman Coulter Centrifuge, JA2.5 rotor). Each supernatant was 
collected, the pellets resuspended in 10 ml PBS and all fractions stored at 4 ˚C.  
2.18. Purification of AvBD peptides 
2.18.1. Column chromatography using glutathione sepharose resin  
CellThru 10-ml Disposable Columns (Clontech Laboratories, Inc.), were rinsed with 70 % 
ethanol and prepared by adding 3 ml of Glutathione Sepharose resin (Expedeon Ltd UK). 
The resin was washed using 10 ml of sterile 1 x PBS; this was followed by 20 ml cell free 
extract (CFE), 10 ml 1xPBS wash buffer and 5 ml of Tris glutathione elution buffer to 
obtain GST tagged AvBDs. All eluants were collected in 20 ml tubes for analyses by SDS 
PAGE.  
2.18.2. Desalting by gel infiltration 
The PD10 desalting columns (GE Healthcare life Sciences) were prepared by removing the 
column tips and discarding the storage solution. Three ml of 1 x PBS were passed through 
the column as an equilibrium agent. The samples (previously eluted using Tris- 
Glutathione) were put through the columns, followed by 1 x PBS to elute the GST tagged-
AvBDs. All eluents were collected separately in 20 ml tubes and analysed by NUPAGE. 
2.18.3.  Hyperexpression and purification of GST-tagged 3C PreScission protease 
enzyme  
The PreScission protease site is located between the GST gene and BamH1 of the pGEX-
6-P-1 vector (Figure 2.1). The enzyme cleaves the recombinant peptides from the GST at 
Gln and Gly residues position and was produced in house using a recombinant pGEX-6P-
1 -3C PreScission protease plasmid (GST-tagged HRV 3C PreScission protease, a kind gift 
of Professor Harry Gilbert, Newcastle University). After transformation into BL21 (DE3) 
pLysS was hyper expressed and purified as described previously. This GST tagged enzyme 
was used to cleave the GST tag from the AvBDs. 
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2.18.4. Cleaving the peptide from GST by PreScission protease enzyme (cutting off the 
columns) 
To cleave the GST tag from the AvBD peptides, 250 µl of PreScission protease (~0.5 mg), 
2 ml of desalted GST tagged AvBD (~50 mg) and 1 ml of cleaving buffer was mixed and 
incubated overnight at 4 oC. The peptides were eluted with 5 ml cleaving buffer. 
2.18.5. Cleaving the peptide from GST by PreScission protease enzyme (Cutting on the 
columns) 
In this procedure the GST was cleaved from the AvBD peptides while the latter were 
attached to the column. CellThru 10-ml Disposable Columns (Clontech), were rinsed with 
alcohol and prepared by adding 3 ml of Glutathione Sepharose resin (Expedeon) previously 
washed using 10 ml of 1 x BPS. This was followed by 20 ml cell free extract (CFE) and 10 
ml 1xPBS wash buffer. The GST tags were removed from the AvBD peptides by adding 3 
ml of cleaving buffer containing 300 μl of PreScission protease enzyme (~0.5 mg). The 
columns were left overnight at 4 oC. The peptides were eluted with 7 elutions of either 1 
ml cleaving buffer [AvBD9 peptides] or 1x PBS [AvBD6 peptides].  
2.18.6.  Protein separation by concentrator columns 
The cleaved AvBD9 peptides were passed through Vivaspin 20 columns [10 kDa MWCO 
(Polyethersulfone) membrane] (GE Healthcare Life Sciences, UK) and centrifuged at 3000 
x g at 4 °C for 20 minutes (Heraeus Biofuge Stratos centrifuge). This trapped the GST tag 
and protease enzyme at the top part of the column while the pure AvBD9 passed through 
and was collected. The pure peptide was desalted as described in section 2.18.2. The 
cleaved AvBD6 was not put through this column due to solubility issues (discussed in 
Chapter four). 
2.18.7. Freeze drying of the peptide 
The desalted purified samples were transferred to microfuge tubes with pinholes in the lid 
and stored at -80 C˚ for at least one hour before drying in a freeze dryer (Christ Alpha 1-2, 
Shropshire, UK) for 2-3 days. The samples were stored lyophilised at 4 °C. 
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2.19. Synthetic peptides 
The synthetic peptides including AvBD6, AvBD9 and AvBD9 W38G were synthesised 
and supplied by Peptide Synthetics, Peptide Protein Research Ltd (Hampshire, UK), with 
purities (>95%) as determined by RP-HPLC and electrospray mass spectrometry. The 
peptides were supplied lyophilized and reconstituted in sterilised grade molecular water to 
1 mg/mL. The samples were stored at -20 °C. 
2.20. Peptide quantification 
Protein/ peptide concentrations were measured using a qBCA kit (Sigma), using bovine 
serum albumen standards (BSA) ranging from 0 to 30 μg/ml. The freeze dried peptides 
were reconstituted in molecular grade water, diluted 1:100, 1:200 and 1:400. The qBCA 
working solution was prepared as per manufacturer instructions by mixing 1 ml solution 
A, 1 ml solution B and 40 μl solution C. The wells of a 96 well plate were loaded with 150 
μl of either diluted peptide or standard and 150 μl of the qBCA working solution. The plate 
was shaken gently for 5 minutes, incubated either at 37 °C for 2 hours or  60 °C for an hour, 
and OD562 nm measured using a microplate plate reader (POLARstar Omega, BMG LAB 
TECH LTD). Peptide concentrations were calculated in relation to the BSA standards. 
2.21. Identification of the peptide   
2.21.1. SDS PAGE 
Two volumes of the protein samples (~50 μg cell lysate) were mixed with one volume of 
SDS loading buffer, and boiled for 10 minutes. SDS PAGE gels (15%) consisted of a 
Resolving gel (4.7 ml 0.75 M Tris/SDS pH 6.8, 3.5 ml 40% (v/v) acrylamide, 1.13 ml sterile 
water, 90 µl 10% (w/v) Ammonium persulphate and 30 µl of N,N,N’,N,-
Tetramethylethylene diamine (TEMED) and stacking gel (1.9 ml 0.25 M Tris/SDS pH 6.8, 
0.4 ml 40% (v/v) acrylamide, 1.5 ml sterile water, 60 µl 10% (w/v) Ammonium persulphate 
and 20 µl TEMED). The resolving gel was poured into the glass plates until one quarter of 
the space was left and this was topped up using water. When the gel was set the water was 
poured off, the gel edge dried using filter paper, the stacking gel added and the comb 
inserted carefully. After setting, the plates were put into a vertical gel tank and the tank 
filled with 1 X SDS running buffer. The comb was removed from the stacking gel, the 
samples loaded and gel electrophoresis performed at 100 V for 2 hours. Gels were stained 
with Instant Blue dye (Expedeon, Cambridge, U.K.) for up to 45 minutes.  
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2.21.2. NUPAGE 
The purified proteins were observed using NUPAGE gel electrophoresis. The NUPAGE 
materials was purchased from Life Technologies (A Thermo Fischer Scientific brand), 
which included NUPAGE tank (XCell SureLock™ Mini-Cell Electrophoresis System), 
precast gels ( NuPAGE® 4-12% Bis-Tris Gel 1.0 mm, 12 or 15 wells, Novex®), LDS 
(Lithium dodecyl sulfate) sample loading buffer (SDS analogue), reducing agents, Novex 
prestained protein markers, antioxidants and 20 X Mes SDS running buffer. 
The protein samples were prepared by mixing 4 μl LDS sample buffer, 1.6 μl reducing 
agents and 10 μl peptide (5-10 μg) and incubated at 70 °C for 10 minutes. The 1 X NuPAGE 
running buffer was prepared by mixing 42.5 ml of 20X Mes SDS running and 807.5 ml 
deionised water and mixed well. NUPAGE gels were washed with distilled water, and the 
tape and comb carefully removed, followed by rinsing the wells with the 1 X NUPAGE 
running buffer. The electrophoresis tank was set up with the upper chamber containing 200 
ml 1 x NUPAGE running buffer and 0.5 ml antioxidant, and the rest of 1 x NUAPGE buffer 
poured into the lower chamber. The Novex pre stained protein marker and protein samples 
were loaded into the wells, the electrophoresis performed at 200 v, 125 mA for 45 minutes 
and the gels stained with Instant Blue (Expedeon, UK). 
2.21.3. MALDI TOF mass spectrometry 
Peptides were sent for amino acid sequencing by MALDI TOF Mass spectrometry 
(Proteomics Laboratory, York University, UK). Peptides were transferred by C18 ziptip 
into 50 % (v:v) aqueous acetonitrile containing 0.1 % (v:v) trifluoroacetic acid before 
spotting out (1:1) with 4-hydroxy- -cyano-cinnamic acid (CHCA) matrix, 2,5-
dihydroxybenzoic acid (DHB) matrix, or 1,5-diaminonapthalene (DAN) matrix. The 
samples were analysed by MALDI-MS and In-Source Decay (ISD) using a Bruker 
ultraflex-III mass spectrometer. 
2.22. Anti-microbial activity assays 
Antimicrobial activity (AMA) was analysed using both Radial Immuno-Diffusion (RIDA) 
and Time-Kill Colony Counting assays (CCA). AvBD peptides tested for antimicrobial 
activity were solubilized in PBS. To test the proteolytic activity of E. coli a protease 
inhibitor cocktail tablet (Roche Diagnostics Ltd. UK) was dissolved in 10 ml 1X PBS 
solution and serially diluted (1:10, 1:100, 1:1000, 10000 and 1:100000) in PBS. 
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2.22.1. Radial immuno-diffusion Assay 
Bacterial cultures were grown to mid-log phase [OD600 0.3-0.4], diluted to OD600 0.2 then 
further diluted 1:50 using 10mM Na phosphate buffer. An underlay gel was prepared by 
mixing 1% agarose and 0.3mg/ml Tryptone soya broth (TSB) with 100 mM Na phosphate 
buffer. Following cooling to ~50 °C, the gel (4.5 ml) was mixed with 0.5 ml of the diluted 
bacterial culture (OD600 0.2) and poured into a petri dish. After setting, holes were carefully 
punched into the agarose gel layer and loaded with 2μl of peptide of known concentration 
(0.5, 1 and 3 μg/μl). The plates were incubated for three hours at 37 °C and then overlaid 
with 5 ml of an overlay gel [100 mM Na phosphate buffer, 1% agarose and 6% TSB]. The 
plates were incubated for a further 16 hours at 37 °C. AMA was defined by the presence of 
halos around each well.  
2.22.2. Time-kill colony counting Assay 
Colony counting assays were performed as reported by Townes et al 2004. Initially the 
bacteria were cultured over-night at 37 °C in 5 ml of Luria broth (LB). Of the overnight 
culture, 100 μl was added into 10 ml of LB and incubated for approximately 1.5 h at 37 °C 
to obtain mid log phase (0.3-0.4) at OD600. Ten (10 μl) of the culture was added to 10 ml 
PBS, and 10 μl of each peptide or PBS was added to 90 μl of the diluted bacterial culture, 
vortexed and incubated for 3 h at 37 °C. The suspensions were serially diluted to 10−4 in 
PBS, and each dilution was spread onto a blood agar plate. All plates were incubated 
overnight at 37 °C, and the colonies counted. The number of surviving colonies for each 
dilution plated (10-2, 10-3, 10-4) were determined by multiplying the colony number counted 
by the dilution factor. The effects of the PBS and peptide treatments were calculated by 
subtracting the mean bacterial colony number following a 3h incubation with PBS or 
peptide from the colony number determined at 0 hours of incubation. The % survival was 
deduced by dividing the (loss/gain) value for the peptide by the (loss/gain) value for PBS. 
Triplicate plates were used for each test sample and each time-kill experiment was repeated 
at least twice. 
2.23. Calcein leakage assay 
A lipid stock solution (50 mg/ml) was prepared by mixing 0.345 g soya bean, type II S 
Phospholipid powder, L-α- Phosphatidylcholine (Sigma, P-5638, kindly gifted by 
Professor Jeremy Lakey, Newcastle)  with 7 ml hexane (BHD, VWR, UK) and a few drops 
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(up to 0.5 ml) of ethanol, and kept at -20 °C. 100 mg (2 ml of 50 mg/ml) of the lipid were 
dried in a round bottom flask using compressed air until the lipid film had attached to the 
wall of the flask. The lipid film was further dried using a vacuum pump for 2 hours at room 
temperature to remove any residues of the organic solvent. All drying processes were 
performed in a fume cabinet. 
Calcein solution (20 mM) was prepared by dissolving 62.25 mg of Calcein (Sigma) in 5 ml 
of 100 mM sodium phosphate buffer and filtered through 0.2 µm membrane. To create 
Calcein-trapped multilamelar (MLV) vesicles, 2 ml of the Calcein solution was added into 
the lipid film and shaken with clean glass beds (2.5-3.5 mm) for 20 minutes at room 
temperature. Unilamellar vesicles (ULV) were prepared by passing the MLV through a 
miniextruder (Avanti) with 100 nm polycarbonated membrane at least 11 times. Untrapped 
(free) calcein molecules were removed using a PD-10 desalting column (GE Healthcare), 
(Hyldgaard et al., 2012), and the column was eluted with 3 x 1 ml of 100 mM sodium 
phosphate buffer. Calcein leakage from the ULV liposomes was monitored by mixing 5-
10 µl of the liposomes with 3 ml Sodium phosphate buffer (100 mM) in a quartz cuvette 
(1mm thick) containing magnet. The leakage was measured using a fluorescent 
spectrophotometer (Varian) and Cary Eclipse software, Excitation (493 nm) and emission 
(505-600nm). TritonX-100 (1% final concentration) was used a 100% leakage positive 
control.  Leakage was calculated using the equation: 
Leakage %= (Fp-F0)/ (Ft-F0) *100% 
Where Fp is the measurement of fluorescent leakage by the peptides, Ft is the complete leakage by 
TritonX and F0 is intact vesicles before adding peptide or TritonX 
2.24. Circular dichroism (CD)  
Eighty (80 µl) of either peptide (250 µg/ml) or Sodium Phosphate buffer 50 mM or 1% 
SDS (30 mM) were added to a 0.2 cm Hellma cuvette. Far-UV measurements  (250- 185) 
nm were recorded by Jasco-810 CD spectropolarimeter with interval band width 0.2 nm, 
data pitch 0.5 nm, scanning speed 100 nm/min, response 10 sec and accumulation 10 at 
room temperature (Park et al., 2002). Signals detected below 190 nm were removed due to 
high tension (HT) voltage measurements increasing to >600 V (all HT measurements were 
required to be <600 V).  
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After subtraction from the buffer baseline, the data were extracted in millidegree (theta 
machine unit) using Jascow software, converted to text files and then calculated to Δε 
(M−1cm−1) which is a per residue molar absorption units of circular dichroism. The quantity 
of secondary structure types such as α-helix, β-sheet, β-turns and disordered structure were 
predicted using Dichroweb ( http://dichroweb.cryst.bbk.ac.uk/html/home.shtml). The CD 
spectra data were inputted and outputted as text files and delta epsilon units from 190-240 
nm using SELCON3 and Set4 or K2D. This software quantifies the secondary structures 
of proteins based on an algorithm (Sreerama and Woody, 2000).  
2.25. Immuno-histochemistry (IHC) 
2.25.1. Antibodies for IHC 
Polyclonal antibody to AvBD9 was prepared by Cambridge Research Biochemicals, 
through immunising a rabbit with AvBD9 antigen (LASRQSHGS-Ahx-C-amide). The 
antisera was purified by the Company using affinity chromatography and thiopropyl 
sepharose 6B coupled to the antigen.  
The Rabbit polyclonal anti-body to IL-6, which recognises chicken IL-6 was purchased 
from Abcam (ab24769, Cambridge, UK).  
2.25.2. Tissue processing 
Following fixation the avian tissues the samples were processed into paraffin blocks. Tissue 
was sectioned to a thickness of 4 µm onto SuperFrost Plus slides (Thermo Scientific) and 
allowed to dry for 24 to 48 hours before staining.  
2.25.3. IHC staining and antibody procedure 
For immunohistochemistry, slides were dewaxed in xylene, rehydrated through graded 
alcohols to water and subjected to a hydrogen peroxide block (1.5% in water) for 10 
minutes. All antibodies were assessed independently to determine the appropriate antigen 
retrieval method for use with each stain. Methods assessed were pressure cooking with 
citrate buffer (pH6.0), pressure cooking with EDTA (pH8.0), enzymatic digest with trypsin 
(pH7.8 at 38 oC) and no antigen retrieval. For the AvBD9 and IL-6 detecting antibodies, 
pressure cooking with EDTA worked most effectively (Performed by Dr C Mowbray, 
Newcastle University). After antigen retrieval, staining was carried out using the Vectastain 
Elite ABC peroxidase kit (rabbit) (Vector Laboratories) as per manufacturer’s instructions. 
AvBD9 and IL-6 antibodies (0.5 mg/ml) were used at a dilution of 1/70 and 1/120 in TBS 
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(pH7.6) for 1 hour at room temperature, respectively. The reaction was developed using 
the peroxidase chromogen DAB (3, 3 diaminobenzedine tetrahydrochloride) (Sigma) as per 
manufacturer’s instructions, and the nuclei counterstained using Mayer’s Haematoxylin 
and Scot’s tap water substitute. Sections were dehydrated through graded alcohols and 
cleared in xylene before mounting using DPX (Sigma). 
2.26. Statistical analysis  
The real time expression data were analysed using Graph Pad Prism software and one way 
ANOVA followed by Tukey’s multiple comparison tests. The AMA and leakage assay data 
were managed in Excel and analysed by Minitab 17 statistical software (MINITAB®, 
Minitab Inc) using one way ANOVA followed by Dunnett’s multiple comparison tests. The 
AMA raw data were statistically analysed for the number of colonies survived. 
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Chapter 3 
3. In vivo expression analyses of chicken genes associated with gut 
innate immunity 
3.1.Introduction  
In 2008 a bird trial was performed that focussed on a commercial Aviagen broiler chicken 
line, designated Line X, characterised by its increased susceptibility to gut inflammation. 
The aim of the trial was to explore the effects of rearing environment on the innate immune 
responses of Line X birds, particularly the tissue expression of genes encoding avian β-
defensin (AvBD) antimicrobial peptides (AMPs).  
The Line X birds were reared for 35 days in two contrasting environments pedigree (high 
hygiene, HH), or sib-test (low hygiene, LH). To achieve the HH environment the rearing 
barn was subjected to a complete disinfection process between flocks and a tight bio-
security control system was enforced. In contrast, the LH environment modelled the 
conditions of an UK commercial broiler unit. 
Previous analyses reported the expression of the AvBD 1, 4 and 10 genes in ten tissues 
removed from birds reared either in the LH or HH conditions (V. Butler 2010, PhD Thesis). 
The bird AvBD expression levels were very variable, even between birds within a specific 
group, but the data supported a distinct trend in that mean duodenal AvBD gene expression 
values were elevated in birds of line X raised in the LH compared to the HH environment. 
Thus despite the susceptibility of the birds to gut inflammation these data suggested a 
robust AvBD1, 4 and 10 gene response.   
This Chapter extended the analyses and explored the gene expression of AvBDs 6 and 9, 
IL-2, IL-6, TFGβ4 and chicken galectin-3 (CG3). AvBDs 6 and 9 were targeted due to the 
identification of SNPS (Table 3.1), including two SNPs relating to the AvBD6 gene and 
three SNPs relating to the AvBD9 gene (V. Butler, 2010D Thesis).   
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The expression of cytokines IL-2 and IL-6 were studied as the genes encode pro-
inflammatory agents, while TFGβ4 gene expression was analysed as the encoded protein 
functions as an anti-inflammatory agent. Chicken galectin-3 (CG3) gene expression was 
also explored as an earlier proteome analysis of the bird gut mucosae using LC-MS 
specifically identified the chicken galectin-3 peptide, a carbohydrate binding lectin, in the 
gut extracts of Line X samples thereby suggesting a role in the innate defences of the birds 
(V. Butler 2010, PhD thesis).  
The aim of this chapter was to use Endpoint (RT-PCR) and Real-time (qPCR) to compare 
the gene expression of AvBD6 and 9, IL-2, IL-6, TFGβ4 and CG3 in tissue samples, 
excised from young Day 7 (D7) and older Day 35 (D35) Line X Aviagen broiler chickens 
raised in LH and HH environments. Additionally immunohistochemistry was performed to 
identify and compare the synthesis and localisation of both AvBD9 and IL-6 in the gut, 
specifically the duodenal tissues.  
3.2.Endpoint PCR analyses of AvBDs 6 and 9, chicken galectin-3, IL-2, IL-6 and 
TGFβ-4 gene expression 
Endpoint PCR provided a method to screen samples and establish gene expression before 
developing methods to quantify the actual levels of tissue expression.  
3.2.1. Tissue panels investigating AvBD6 and 9 gene expression in birds raised in Low 
and High hygiene conditions 
AvBD6, 9 and 18S gene expression were studied using end-point PCR and initially an array 
of Day 7 bird tissues, including thymus, liver, kidney, small intestine, caecum, caecal 
tonsils, lung, spleen, bursa and testis were analysed. The AvBD6 and AvBD9 primers were 
Frequency is for the presence of the T base in allele designated A. (V. Butler 2010, PhD 
Thesis).  
Table 3.1 List of 5 SNPs in an Illumina study that were identified in Aviagen Line X 
birds. 
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each designed to amplify cDNAs of 126 bp (section 2.10) and the size of the 18S 
housekeeping cDNA was 500 bp.  
The results, shown as panels, are presented in Figures 3.1 and 3.2. The data (Figure 3.1), 
indicated that the AvBD6 and 9 genes were expressed in all the bird tissues analysed and 
regardless of the rearing conditions. It was not possible, however, using these data to 
identify whether gene expression was affected by the different rearing conditions. 
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Figure 3.1 AvBD6/ 9 and 18S cDNA expression panels using tissues from a single bird, D7, Line X 
birds raised in low (A) and high (B) hygiene conditions. Lanes comprise: M=DNA marker 100-1000 
bp, Th=thymus, Lv=liver, Kd=kidney, SI=small intestine, Ca= caecum, CT=caecal tonsils, Lu=lung, 
Sp=spleen, Bu=bursa, Te=testis. 
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In relation to AvBD6 (Av6) expression (Figure 3.1C), three cDNA bands of approximately 
100 bp, 126 bp and 200 bp were amplified. The strong band was of the correct size (126bp) 
and confirmed as AvBD6 by DNA sequencing. Bands of less than 100bp were due to 
primer dimers. The negative controls represented the PCR reactions of each set of gene 
primers, in which cDNA was replaced by molecular grade water. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.2. Sequencing results for AvBD6 and 9 cDNA: 
To verify that the cDNA bands were AvBD6 and 9, the 126 bp cDNA PCR products were 
cloned into pGEX-6p-1 and the plasmids sequenced by Genevision, Newcastle, UK using 
primers shown in Table 2.2. 
Figure 3.3 shows the DNA sequences of AvBD6 (panel A) and AvBD9 (panel B) taken 
from the NCBI (National Centre for Biotechnology) database 
(http://www.ncbi.nlm.nih.gov/) and the sequences of the amplified PCR products. 
Authenticity of the cDNA products was proven by the 100 % sequence match.   
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Figure 3.1 C Agarose gel electrophoresis of AvBD6, AvBD9 and 18S PCR products amplified from 
small intestinal and caecal tissues excised from a single bird, D 7, Line X, HH bird alongside 
negative controls. AvBD6 (Av6), AvBD9 (Av9), 18S. M= DNA Marker (100-1000bp).  
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3.2.3. Tissue panels investigating IL-2, IL-6, TGFβ4 and chicken galectin-3 gene 
expression  
Due to the lack of sensitivity of the endpoint PCR analyses and to help conserve the sample 
RNA material, IL-2, IL-6, TGFβ4 and CG3 gene expression were performed using only 
selected tissues from birds raised in the LH environment. Figure 3.3 shows the expression 
of Interleukin-2 (IL-2), Interleukin-6 (IL-6), Transforming growth factor β-4 (TGFβ-4) and 
Chicken Galectin-3 (CG3) in the selected tissues, which included gut tissues, the thymus 
and bursa (two primary lymphatic organs) and the spleen (a secondary lymphatic organ). 
Copy (c) DNA bands of 305 bp (IL-2), 280 bp (IL-6), 332 bp (TGFβ4) and 385 bp (CG3) 
A 
B 
Figure 3.2 Sequencing results for AvBD6 (A) and AvBD9 (B) DNA products. ‘Query’ represents 
the amplified cDNA products. ‘Sbjct’ is the NCBI database gene sequence. 
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were identified in all tissues indicating the expression of the genes of interest. However, 
two bands of approximately 200 and 305 bp were observed in relation to IL-2 gene 
expression (Figure 3.3A), and similarly for IL-6 gene expression, two bands of 
approximately 200 and 280 bp in size were recorded (Figure 3.3B). Thus DNA sequencing 
of the cDNA bands was performed in each case to confirm the cDNA amplified actually 
reflected the targeted gene.  
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Figure 3.3 IL-2 (A), IL-6 (B), TGFβ4 (C), CG3 (D) and 18S (E) expression panels. Tissues 
were excised from D7, Line X birds raised in LH conditions. Lanes are M= DNA Marker 
(100-1000bp), SI=small intestine, Ca=Caecum, CT=Caecal tonsils, Bu=Bursa, Th=Thymus, 
Sp=Spleen. bp= base pairs. 
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3.2.4. Sequence results of IL-2, IL-6, TGFB4 and CG 3 cDNAs 
cDNAs obtained using the IL-2, IL-6, TGFβ4 and CG3 primers were cloned into the pGEM 
T Easy vector and sequenced using the appropriate gene primers shown in Table 2.2.  
Figures 3.4 to 3.6 show the results of the DNA sequence analyses. These data indicated 
95%, 99%, and 98 % identity to NCBI sequences for IL-2 (305bp band), TGFβ4 and CG3 
cDNAs respectively. Putative nucleotide changes highlighted in the sequences reflected 
either poor quality sequence or potential nucleotide base changes. 
Figure 3.4B shows the DNA chromatograph of an IL-2 cDNA sequence. The circles 
represent nucleotides missed by the software due to poor quality sequencing. However, 
manual reading of the peaks allowed the gaps to be identified; for example, A10 (Green) 
was recorded as absent, but the peak was present in the chromatograph albeit hidden under 
the G9 and T11 peaks. The boxes represent potential nucleotide changes and include A70, 
T75, A81, T131, A157, C174, T175 and T177. However,   the DNA was sequenced in one 
direction only, thus SNPs cannot be confirmed.
Figure 3.4 A: Sequencing and BLAST results of an IL-2 PCR product amplified from D7 caecum 
Line X bird. ‘Query’ is the sequence analysed;’Sbjct’ is the NCBI database gene sequence. The 
boxes represent either poor quality sequence or potential nucleotide changes.  
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Figure 3.4 B: Sequenced PCR product from a D7 caecum Line X bird showing the poor quality sequence (circles) and the potential nucleotide changes 
(Boxes) in IL-2. The different bases are colour-coded, A-green, T-red, G-black and C-blue. 
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Similar observations for TGFβ4 (Figure 3.5 A-B) and CG3 (Figure 3.6 A-B) gene 
sequences were noted with nucleotides either missing or different due to poor quality 
sequence and/or potential nucleotide changes. 
For example, Figure 3.5 B shows that a peak for C26, recorded as T26 in the TGFβ4 
sequence, was present in the chromatograph but hidden under the A25 and T27 peaks. The 
boxes represent potential nucleotide changes and include G47 and C165.  
 
 
 
 
 
 
 
 
Figure 3.5 A: Sequencing and BLAST results of a TGFβ4 PCR product amplified from D7 
Line X bird (caecum). ‘Query’ is the sequence analysed;’Sbjct’ is the NCBI database gene 
sequence. The boxes represent either poor quality sequence or potential nucleotide 
changes. 
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Figure 3.5 B: Sequenced PCR product from a D7, Line X bird (caecum) showing the poor quality sequence (circles) and the potential nucleotide changes (Boxes) 
in TGFβ4.  The different bases are colour-coded, A-green, T-red, G-black and C-blue. 
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Figure 3.6B shows the poor quality DNA sequence and potential nucleotide changes of a 
CG3 cDNA product amplified from caecum of a Line X bird. For example, G32 was 
recorded absent in the CG3 gene sequence but its peak was present in the chromatograph. 
Potential nucleotide changes include C93, A115 and C231. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.6 A: Sequencing and BLAST results of a CG3 PCR product amplified from caecal tissue. 
‘Query’ is the sequence analysed;’Sbjct’ is the NCBI database gene sequence. The boxes represent 
either poor quality sequence or potential nucleotide changes. 
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Figure 3.6 B: Sequenced PCR product from a D7, Line X bird (caecum) showing the poor quality sequence (circles) and the potential nucleotide 
changes (Boxes) in CG3.  The different bases are colour-coded, A-green, T-red, G-black and C-blue. 
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Unlike the data relating to IL-2, TGFβ4 and CG3 the cloned cDNA amplified using the IL-
6 primers did not match the NCBI chicken IL-6 gene sequence. The amplified sequence 
was identified as a hypothetical protein (Figure 3.7).  
This non-specific amplification was attributed to the high GC content in the mRNA 
sequence of the IL-6 gene; in fact the GC content was identified as 79.7 %, 60.5 %, and 
53.7% in exons 1-3 respectively. It was predicted that the high GC content in exons 1 and 
2 to which the IL-6 primers were designed (Table 2.2) resulted in secondary structure 
formations that inhibited polymerase activity and encouraged the amplification of non-
specific cDNA sequences. To explore this further the RT-PCR analyses were repeated, but 
using the Qiagen Q solution kit designed to amplify GC rich sequences. However, this did 
not result in amplification of IL-6 specific cDNA bands suggesting an IL-6 primer design 
problem.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Sequencing and BLAST results of a putative IL-6 PCR product D7 Line X bird (caecum). 
‘Query’ is the sequence analysed;’Sbjct’ is the NCBI database gene sequence.  
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To address this a new set of IL-6 primers (Table 2.3) were designed to cross the second and 
third exons, and used for the endpoint analyses. The expression of IL-6, using the new 
primers, in the Day 7 tissues including kidney, spleen, liver, bursa, thymus, duodenum, 
jejunum, ileum, caecum and caecal tonsil tissues is shown in Figure 3.8A. DNA sequencing 
indicated the authenticity of the amplified cDNA sequence (Figure 3.8B).   
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Figure 3.8 Panel (A): End point PCR for IL-6. kidney (Kd), Spleen (Sp), Liver (Lv), Bursa (Bu), 
Thymus (T) Duodenum (Du), Jejunum (Je), Ileum (Il), Caecum (Ca), and Caecal tonsils (CT) of LH, 
Day 7 birds. Marker is a 100 bp-1000 bp.  
Panel (B): Sequencing and BLAST result for IL-6. Query represents the amplified and sequenced 
product. Sbjct is the NCBI database gene sequence. (PCR and BLAST Analyses performed by Dr. 
Catherine Mowbray, Newcastle University). 
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3.3.Real time PCR analyses of AvBD6, AvBD9, chicken galectin-3, IL-6 and TGFβ4 
expression in line X bird tissues 
The end-point PCR data supported expression of all the genes investigated in the Line X 
bird tissues.  To allow direct comparisons between gene expression in the different tissues 
of D7 and D35 birds reared in the different environments ie (LH and HH) quantitative real-
time assays were used.   
3.3.1. qPCR assay development  
Quantitative assays were developed for AvBD6, AvBD9 and IL-6 gene expression by Dr. 
Catherine Mowbray (Newcastle University). The housekeeping or reference genes SDHA 
and SF3A1 (chicken GEnorm kit, PrimerDesign, UK) were selected following GEnorm 
analysis of chicken RNA material and utilised throughout the study to normalise the 
expression data. The GEnorm analysis data is shown in Figure 3.9, and indicated that of 
the six housekeeping genes analysed in relation to gene expression in chicken tissues ie 
(GAPDH, YWHAZ, ACTB, UBC, SDHA & SF3A1). SDHA and SF3A1 had the lowest 
GEnorm M values, which reflected the stability of their expression. Normalization of all 
qPCR expression data was performed using the two stably expressed reference genes 
SDHA and SF3A1. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 GeNorm analysis showing the most appropriate genes for real-time qPCR in 
avian tissues (Kevin Cadwell, 2014, PhD Thesis). 
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Quantitative assays for chicken galectin-3 and TGFβ4 were not available and were 
developed as follows. The amplification, melting and standard curves for chicken galectin-
3 and TGFβ4 were constructed using 1:10 serial dilutions of the recombinant plasmids 
containing each of the targeted genes and a Roche Lightcycler 480 (Figures 3.10-3.15). To 
minimise errors, two curves were prepared for each dilution of the plasmid. The 
amplification curve relating to the highest concentration of plasmid relates to the lowest 
number of cycles while the curve relating to the lowest concentration of plasmid relates to 
the highest number of cycles (Figures 3.10 and 3.13). Melting curves represented by a 
single peak indicated the specificity of the primers (Figures 3.11 and 3.14). These data were 
supported by robust standard curves with the efficiency of the CG3 standard curve being 
1.97 with error 0.02 (Figure 3.12) and the efficiency of that for TGFβ4 being 1.89 and error 
0.02 (Figure 3.15). 
 
Figure 3.10 Amplification curves of diluted chicken galectin-3 plasmids. The dilutions of each 
plasmid relate to arbitrary units ie one gene cannot be directly compared to another.  
Figure 3.11 Melting curves for diluted chicken galectin-3 plasmids. The dilutions of each plasmid 
relate to arbitrary units ie one gene cannot be directly compared to another. 
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Figure 3.12 Standard curve of diluted chicken galectin-3 plasmids. Each green point represents a 
dilution of the plasmid. The dilutions of each plasmid relate to arbitrary units ie one gene cannot be 
directly compared to another 
Figure 3.15 Standard curve of diluted TGFβ4 plasmids. Each green point represents a dilution. The 
dilutions of each plasmid relate to arbitrary units ie one gene cannot be directly compared to another. 
 
Figure 3.13 Amplification curves of diluted TGFβ4 plasmids. The dilutions of each plasmid relate to 
arbitrary units ie one gene cannot be directly compared to another 
Figure 3.14 Melting curves of diluted TGFβ4 plasmids. The dilutions of each plasmid relate to 
arbitrary units ie one gene cannot be directly compared to another. 
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3.3.2. Real time PCR 
Using the standard curves and reference genes described real time PCR analyses were 
performed to quantify the tissue expression of AvBD6, AvBD9, IL-6, TGFβ4 and chicken 
galectin-3 gene (CG3). Gene expression was determined in Day 7 (D7) gut, liver, kidney 
and lung tissues, and Day35 (D35) liver, kidney and lung tissues excised from birds raised 
in either LH or HH conditions. Gut and lung tissues were chosen as these are exposed, 
directly, to microbes in the environment, while the liver and kidneys are exposed to 
microbial pathogen associated molecular patterns, or PAMPs, which include 
lipopolysaccharide and peptidoglycan. 
3.3.2.1.AvBD6 mRNA expression by real time PCR 
Figure 3.16 shows the AvBD6 expression data in relation to the gut, kidney, liver and lung 
tissues. In D7 birds raised in LH conditions, five samples relating to small intestine, caecal 
tonsils, kidney and liver were analysed, but only four samples relating to lung and three 
relating to caecum were available. In D7 birds raised in HH conditions five samples relating 
to liver were analysed but only four samples relating to kidney, lung and caecal tonsils and 
two tissues relating to small intestine and caecum were available. For D35 birds raised in 
both LH and HH, three samples relating to kidney, liver and lung were analysed.  
The data sets were compromised by the small number of bird samples analysed and no 
statistically significant differences were found between AvBD6 expression in gut, kidney 
and lung tissues analysed from D7 and D35 birds raised in LH and HH conditions. 
However, liver AvBD6 expression (Figure 3.16C), was significantly suppressed (p<0.001) 
in D7 compared to D35 birds raised in the HH environments. Additionally, liver AvBD6 
expression was significantly reduced (p<0.01) in D35 birds raised in LH compared to HH 
conditions.  
The expression values were marked by their variability. For example in the small intestine 
and caecal samples, AvBD6 values ranged from 1 to 25 arbitrary units (AU), although one 
caecum value of 777 AU was recorded. Interestingly regardless of rearing environment the 
D7 gut data supported increased AvBD6 expression in the caecal tonsils compared to the 
small intestinal tissues (p<0.05), which suggested a key role for the secondary lymphoid 
organ in the innate responses of the gut. In D7, AvBD6 expression values ranged from 6- 
125AU in kidney, 4- 28AU in liver and 48- 958AU in lung, with the two highest recorded  
values in kidney and lung respectively linked to the same bird. These individual variations 
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probably reflected the immune responses of individual birds to their different rearing 
environments. In D35, AvBD6 expression values ranged from 2-34 AU in kidney, 6-546 
AU in liver and 47-307 AU in the lung. 
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Figure 3.16 Dot plots showing AvBD6 expression in chicken tissues as measured by qPCR. Gut (A), kidney (B), Liver (C) and Lung (D). LH= low hygiene, HH=high hygiene. 
D7, D35= ages of the birds in days.SI=small intestine, Ca=caecum, CT= caecal tonsils, each black point represents an individual expression value. Solid lines show mean values. 
* P < 0.05, ** P < 0.01, *** P < 0.001. Data analysed by one way ANOVA, followed by Tukey’s multiple comparison test. 
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3.3.2.2.AvBD9 mRNA expression by real time PCR 
Figure 3.17 shows the AvBD9 mRNA expression data relating to bird gut, kidney, liver 
and lung tissues. As with AvBD6, the AvBD9 expression values recorded were marked by 
their variability. Unlike AvBD6 no patterns relating to AvBD9 expression were observed 
along the gut. Moreover, no statistically significant differences reflecting either bird age 
and/or rearing environment were identified apart from in the kidney where the expression 
values increased significantly (p<0.05), with age and regardless of environment. What was 
interesting was the AvBD9 values recorded in the different tissues:  in D7 bird tissues 
expression values ranged between 2- 30 AU in small intestine, 1-90AU in caecum, 1-32AU 
in caecal tonsils, but 20-841AU in lung, 85-802 AU in kidney and 34,511- 236,391AU in 
liver. In fact, the values in the liver were 105 times greater than those of the gut. Increased 
expression values were also seen in older birds. For example, in D35 birds, the expression 
levels ranged from 451-8,501 AU in kidney; 3,143-223,385 AU in liver and 74-263 AU in 
lung tissues. 
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Figure 3.17 Dot plots showing AvBD9 expression in chicken tissues as measured by qPCR. Gut (A), kidney (B), Liver (C) and Lung (D). LH= low hygiene, HH=high hygiene. D7, 
D35= ages of the birds in days.SI=small intestine, Ca=caecum, CT= caecal tonsils, each black point represents an individual expression value. Solid lines show mean values. * P < 0.05. 
Data analysed by one way ANOVA, followed by Tukey’s multiple comparison test. 
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3.3.2.3.Chicken galectin-3 mRNA expression by real time PCR 
The chicken galectin-3 (CG3) gene expression data are shown in Figure 3.18 A-D. In the 
D7 birds studied CG3 small intestinal expression values ranged from 148-507 AU 
compared to 52-1242 AU in the caecal tissues and 127-2216AU in the caecal tonsils. The 
values were less variable in the other tissues ranging from 25-42 AU in the kidney, 12-58 
AU in the liver and 23-76 AU in the lung. In tissues analysed from D35 birds, the 
expression values ranged from 34-424 AU in the kidney, 33-351 AU in the liver and 75-
484 AU in the lung.  
Although compromised by small sample numbers no distinctive patterns relating to CG3 
expression were observed along the horizontal axes of the bird guts. However, the mean 
CG3 values recorded in both kidney and liver tissues were significantly increased (P<0.01) 
in D35 birds compared to D7 birds reared in high hygiene conditions (Figure 3.18 B and 
C). Additionally, the mean CG3 expression values of both the kidney and liver tissues were 
significantly reduced (P<0.05) in LH D35 reared birds compared to those reared in HH 
conditions. In contrast no significant differences were detected in the lung CG3 expression 
values (Panel D).   
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Figure 3.18 Dot plots showing CG3 expression in chicken tissues as measured by qPCR. Gut (A), kidney (B), Liver (C) and Lung (D). LH= low hygiene, HH=high hygiene. D7, 
D35= ages of the birds in days.SI=small intestine, Ca=caecum, CT= caecal tonsils, each black point represents an individual expression value. Solid lines show mean values. * P < 
0.05, ** P < 0.01. Data analysed by one way ANOVA, followed by Tukey’s multiple comparison test. 
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3.3.2.4.IL-6 mRNA expression by Real time PCR 
Expression of the gene encoding the pro-inflammatory molecule IL-6 was also assessed 
and the data are shown in Figure 3.19. Again sample numbers meant that statistical analyses 
of the gut data was limited, although the mean value of IL-6 expression was significantly 
higher (P < 0.05) in the caecal tonsil samples of LH raised birds compared to the LH small 
intestinal samples (Panel A). There was also the suggestion of IL-6 expression being 
suppressed in the caecal tonsils of the HH raised birds although the LH data was skewed 
by one outlier value of 126 AU.   
The panels B to D show IL-6 mRNA expression in the kidney, liver and lung tissues. No 
significant differences in expression were found between age equivalent LH and HH raised 
birds. However, in the kidney samples (Figure 3.19B), IL-6 was significantly increased in 
D35 birds compared to D7 birds reared in LH conditions (P< 0.01) and HH conditions (P 
< 0.05). Although not statistically significant similar patterns were identified for the liver 
and lung tissues.  
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Figure 3.19 Dot plots showing IL-6 expression in chicken tissues as measured by qPCR. Gut (A), kidney (B), Liver (C) and Lung (D). LH= low hygiene, HH=high hygiene. D7, 
D35= ages of the birds in days.SI=small intestine, Ca=caecum, CT= caecal tonsils, each black point represents an individual expression value. Solid lines show mean values. * P < 
0.05, ** P < 0.01. Data analysed by one way ANOVA, followed by Tukey’s multiple comparison test. 
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3.3.2.5.TGFB4 mRNA expression by real time PCR 
Figure 3.20 shows the data relating to the expression of the TGFβ4 gene, which encodes 
an anti-inflammatory molecule. In the kidney a significant (P<0.01) age related response 
was detected with TGFβ4 mRNA expression being increased in D35 birds although this 
was limited to the HH raised birds. A similar, but non-significant trend (p=0.057) was 
suggested in the LH raised birds. There was also a significant increase (P<0.01) in TGFβ4 
expression in the D35 HH raised birds compared to those raised in LH conditions.  
Similar data were observed for the liver tissues, although the D35 LH versus HH data was 
skewed by a D35 LH value of 3431 compared to the other values of 156 and 189. In the 
lung (Figure 3.20 D), TGFβ4 mRNA was significantly increased (P<0.01) in D35 
compared to D7 birds regardless of the rearing environment indicating an age effect.  
The D7 TGFβ4 mRNA expression levels in the gut (Figure 3.20A) were comparable to 
those recorded in the liver, lung and kidney. Although compromised by the sample numbers 
there was a suggestion of increased TGFβ4 expression in the caeca (P<0.01) and caecal 
tonsils (P<0.001) of LH raised birds compared to the small intestinal tissue. Additionally, 
expression levels were reduced (P<0.01) in the caecal tonsils of HH compared to LH raised 
birds.
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Figure 3.20 Dot plots showing TGFβ4 expression in chicken tissues as measured by qPCR. Gut (A), kidney (B), Liver (C) and Lung (D). LH= low hygiene, HH=high hygiene. D7, 
D35= ages of the birds in days.SI=small intestine, Ca=caecum, CT= caecal tonsils, each black point represents an individual expression value. Solid lines show mean values. * P < 0.05, 
** P < 0.01, *** P < 0.001. Data analysed by one way ANOVA, followed by Tukey’s multiple comparison test. 
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3.4.Immuno-histochemical examination of gut tissues: 
The data presented indicated the expression of AvBD6 and 9 in the gut, kidney, liver and 
lung tissues. The major interest of this project was the gut tissues and to further explore the 
synthesis and localisation of the AvBD, and cytokines in the gut tissues, 
immunohistochemistry was performed. These analyses described in section 2.25 were 
performed in collaboration with Dr. Catherine Mowbray (PhD, Newcastle University). 
AvBD9 and IL-6 were selected for immunohistochemistry as examples of an antimicrobial 
peptide and pro-inflammatory cytokine. 
3.4.1. Localisation of AvBD9 by immunohistochemistry 
Fixed duodenal tissue sections from Line X D7 birds were stained with a custom 
synthesised AvBD9 antibody (Cambridge Research Biochemicals). The control and 
AvBD9 staining results are shown in Figure 3.21 A-D. AvBD9 immunoreactivity was 
localised to the enterocytic cells and the staining was intense on the brush border (Figure 
3.21 B & C) and the luminal surfaces of the intestinal crypts (Figure 3.21 B & D) suggesting 
AvBD9 is synthesised by and involved in the defence of the gut epithelium.  
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3.4.2. Immuno-localisation of chicken IL-6 in gut tissues 
The duodenal tissues were also stained with rabbit poly clonal Anti-IL-6 antibody (Abcam) 
and the control and IL-6 staining results are shown in Figure 3.22 A-C.   
Staining was comparable to AvBD9 with a more intense signal observed in the apical 
surfaces ie brush border and intestinal crypts of the epithelium. These data suggested that 
AvBD9 and IL-6 were synthesised and secreted from similar cells of the gut epithelium.  
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Figure 3.21 Immuno-localisation of AvBD9 in duodenal tissues from D7, Line X birds. 
Antibody was at 1:70 dilution in EDTA).  
Negative control with no primary antibody (x40) (A); AvBD9 antibody (1:70 dilution in EDTA) 
immuno-staining in duodenum (x100) (B); mucosal epithelium longitudinal section (x400) (C) 
and mucosal crypts with cross sections (x400)(D).  
Mucosal villus (1), mucosal crypts (2), muscular layer (3), brush borders (4), goblet cells (5), 
lamina propria (6). (Dr. Catherine Mowbray, Newcastle University).      
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Figure 3.22 Immuno-localisation of IL-6 (dilution 1:120 in EDTA) in duodenal tissues from D7, 
Line X birds. Negative control with no primary antibody (X 40) (A); IL-6 immunostaining (x40 & 
x100) (B & C). Mucosal villi epithelium with brush borders (1), intestinal crypts (2), muscular layer 
(3) and serosa (4). (Dr. Catherine Mowbray, Newcastle University). 
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3.5. Discussion 
The tissue samples analysed in this study were isolated from a line of genetically related 
chicken broilers with increased susceptibility to gut inflammation. The birds were 
originally raised in LH and HH environments with the premise that the environmental 
conditions would challenge the birds’ immune systems and hence provide clues as to their 
susceptibility to inflammation.  
The AvBDs are part of the innate immune response and therefore a first line defence 
mechanism in protecting epithelia from microbial assault. Previous studies had analysed 
the Line X bird tissues for AvBD1, 4 and 10 gene expression. It was found that expression 
of the AvBD1 and 4 genes was elevated in LH compared to HH conditions (Butler 2010, 
PhD thesis), although AvBD10 expression was not affected by the rearing environment.  It 
was therefore decided to analyse these bird samples for AvBD6 and 9, IL-6, CG3 and 
TGFβ4 gene expression to explore whether there were specific patterns in the responses of 
the birds to their rearing environments. The hypothesis was that the gut epithelia of these 
birds would not be able to respond efficiently to the LH rearing conditions resulting in their 
increased susceptibility to inflammation.  
There are 14 AvBD genes; the original choice to study AvBD 1 expression was directed by 
the presence of SNPs in Exon 1 of the gene coding sequence. These SNPs were not 
expected to affect expression per se, but it was hypothesised that they could affect the 
functionality of the encoded peptides and this is discussed further in Chapter 5 II. The 
choice of AvBD4 was directed by presence of a SNP in the 3’UTR of the gene, which it 
was hypothesised could impact on its expression. In this study the choice of the AvBD6 
and 9 genes was again directed by the presence of SNPs although these were intronic for 
AvBD6 and intronic/3’UTR located for AvBD9 (Table 3.1). Thus the aim of this study was 
to extend the AvBD expression profile at Day 7 (D7) when the innate immune response of 
the young birds is key to their survival and at Day 35 (D35), when the adaptive immune 
system dominates to investigate if AvBD6 and 9 expression were compromised.   
Initially endpoint PCR analyses of mRNA isolated from D7 bird tissues were performed 
and the results indicated that AvBD6 and AvBD9 were expressed in all tissues (thymus, 
liver, kidney, small intestine, caecum, caecal tonsils, lung, spleen, bursa and testis) of the 
D7 Line X birds. These results were comparable to data reported by others, but using 
different bird genetic lines and ages. For example, AvBD6 (Gal4) was expressed in the 
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small intestine, large intestine, bursa, lung, kidney and testis of Day 21 Cobb 500 broilers 
(Lynn et al., 2004), in caecal tonsils of Day 1 ‘local hatchery’ chicks (Akbari et al., 2008), 
and in lung tissues of Day 5 Goldline chicks (Milona et al., 2007). Similarly AvBD9 
expression was identified in the small intestine, caecum, caecal tonsils, bursa, testis, kidney, 
liver, thymus, lung, and spleen of 6 week old Ross 308 broilers (van Dijk et al., 2007), and 
the lung, kidney, spleen, testis,  large intestine, but not small intestine of 21 day old Cobb 
500 broilers (Lynn et al., 2004). Furthermore, AvBD9 was expressed in Day 14 Chinese 
painted quail lung, small intestine, caecum, caecal tonsil, spleen and thymus tissues, but 
neither in liver nor kidney tissues (Wang et al., 2010b). It is interesting that the intestinal 
expression of the genes appeared variable; eg AvBD9 was not identified in Cobb broilers 
(Lynn et al., 2004), which may reflect the redundancy of the encoded peptide in the defence 
of the bird gut.  
The end point PCR analyses were not quantitative so it was not possible to identify any 
differences or trends in expression between the LH and HH rearing conditions. To address 
this, quantitative PCR assays were developed with normalisation of the targeted gene data 
using the two housekeeping genes SDHA and SF3A1, which were the most appropriate of 
a panel tested for chicken tissue analyses (Figure 3.9). This contrasts to other studies where 
β-actin (Ma et al., 2012a) or GAPDH (Sunkara et al., 2014) were used for normalisations. 
However, analyses performed in this study indicated that the β-actin and GAPDH 
housekeeping genes showed significant variability and therefore was not used. Also the end 
point PCR analyses indicated 18S variability, which precluded the use of this gene in the 
qPCR analyses.   
The quantitative PCR analyses were compromised by the small number of samples, but the 
data confirmed AvBDs 6 and 9 expression and suggested variability with outliers evident 
amongst the data (Figures 3.16 and 3.17). However, overall no significant effects of 
environment were observed on the gut (SI, caecal and CT) expression of the genes. It is 
possible that the individual variations in expression, particularly the outlier values, might 
be correlated to presence of the SNPs, including intronic SNPs affecting expression. This 
has been reported for human β-defensin1 with individuals carrying a 5’UTR homozygous 
polymorphism showing increased salivary peptide concentrations (Polesello et al., 2015). 
However, there were no correlations that connected the samples eg in relation to AvBD6 
the outlier related to a LH caecal sample, but no other gut samples relating to this bird were 
elevated. Additionally, the outliers observed in relation to lung and kidney expression (LH 
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environment) were also linked to different bird samples. This hinted at environmental rather 
than genomic effects although further investigation of all the genomic sequences of the 
birds is required to confirm this. In relation to AvBD9 gut expression there was one outlier 
that related to a HH caecal sample. Other ‘high’ expression values were recorded for the 
kidney, liver and lung tissues, but again there were no consistent patterns relating 
specifically to individual birds. The AvBD9 gene contains a SNP in the 3’UTR which 
potentially may affect expression through mRNA stability, as shown in sheep β-defensin 1 
(Monteleone et al., 2011). However, the majority of ‘high’ values were detected in the LH 
environment, and without any supporting genomic data it is impossible to state whether 
these values were due an environmental, genomic or an environmental/genomic effect. 
Thus the AvBD6 and 9 data contrasted to that of AvBD1 and 4 that showed elevated 
expression in D7 birds raised in LH compared to HH conditions.  
AvBD6 and 9 expression values varied according to the actual tissue studied. For example 
in HH D7 kidney samples AvBD6 baseline expression was <50 AU compared to >250 AU 
in the lung. Similarly the AvBD9 baseline expression values were increased in the kidney 
and liver tissues compared to those of the lung and gut.  Previous studies have also reported 
AvBD expression variability in different tissues (Meade et al., 2009a; Wang et al., 2010a; 
Ma et al., 2012b; Ma et al., 2013; Peng et al., 2013; Lu et al., 2014). In the lung the elevated 
AvBD6 baseline expression could have been linked to microbial exposure although the gut 
(apart from caecal tonsil) expression values, <50AU, do not support this. Similarly it is 
difficult to explain the higher baseline expression of AvBD9 in kidney and liver compared 
to the lung or gut using this argument. Multiple roles for mammalian defensins have been 
reported, including in wound healing and immunomodulation (Steinstraesser et al., 2011; 
Semple and Dorin, 2012), but apart from the duck Apl_AvBD2 defensin, which has been 
shown to have chemotactic functions other immunomodulatory properties have not been 
described for avian peptides. 
The data shown in Figure 3.16A showed that AvBD6 expression was particularly variable 
in the caecal tonsils compared to the caecum. The caecal tonsils are a pair of lymphoid 
nodules rich in both T and B lymphocytes, and suggested to play a role in the adaptive 
response through the production of antigen-specific antibodies (Casteleyn et al., 2010). 
Data, shown in this study, indicate a potential role for this secondary lymphoid tissue in the 
innate defences of the chicken gut. In support it has been reported that infection of one-
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day-old chicks with Salmonella serovar Typhimurium also increased AvBD6 as well as 
AvBD1, 2 and 4 expression in the caecal tonsils (Akbari et al., 2008).  
The AvBD expression data were compromised by the small number of samples, but 
generally no age related effects were observed. A significant increase in AvBD6 gene 
expression was observed in the D35 livers of the HH raised birds compared to D7, but an 
environmental effect was also observed in that increased liver expression was associated 
with the HH conditions. Why HH conditions should favour increased AvBD6 expression 
is difficult to explain, but it may indicate potential roles for the peptide in the physiology 
of liver cells. It has been reported that chicken liver expressed peptide 2 (cLEAP-2) mRNA 
expression is upregulated in liver and small intestine in response to salmonella infection 
indicating direct and systemic exposure (Townes et al., 2004). The immunological 
properties of human LEAP-2 was also explored using in vitro cell lines modelling the liver 
and gut epithelia, and immunohistochemistry showed that the peptide has a role in innate 
immunity in response to lipopolysaccharides, and the peptide was localised in the epithelial 
cytoplasm (Howard et al., 2010) . A significant increase in AvBD9 expression was detected 
in the kidneys of the D35 LH raised birds compared to D7, but this was not observed in the 
HH raised birds. This is challenging to explain as the kidneys are not directly exposed to 
microbes although it may have reflected systemic exposure to microbial PAMPs including 
lipopolysaccharides that stimulate defensin expression pathway (Sadeyen et al., 2004; 
Derache et al., 2009a). Dietary factors including butyrate can also impact on AvBD9 
expression (Sunkara et al., 2014), but it is unlikely that these gut metabolites would be in 
sufficient concentration systemically to have caused a localised kidney effect.  
As AvBD6 and 9 gut expression appeared unaffected in the birds despite the different 
rearing conditions the expression of genes encoding pro-inflammatory (IL-6) and anti-
inflammatory (TGFβ4) molecules was explored. The gut microbiota interact naturally with 
the host epithelia resulting in physiological inflammation (Crhanova 2011), which involves 
the controlled synthesis of pro and anti-inflammatory cytokines. When this homeostasis 
becomes imbalanced pathological conditions, including chronic inflammation, result. The 
molecular data showed that IL-6 was expressed in the gut epithelia of the Line X birds and 
synthesis was supported by IHC. No significant differences in D7 gut IL-6 expression were 
observed that could explain the susceptibility of the birds to inflammation, although these 
data were again compromised by small numbers. Also the lack of D35 gut samples meant 
the long term effects could not be reported. Trends were observed in the D35 kidney, liver 
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and lung samples that supported increased IL-6 levels regardless of rearing environment 
but these increases were matched by TGFβ4 expression patterns, which overall supported 
a controlled and hence physiological inflammatory response.    
The gut TGFβ4 expression patterns measured in the LH caecal and caecal tonsil tissues 
were interesting as these were reduced in the birds raised in HH conditions supportive of 
reduced inflammation. Although the sample numbers were small TGFβ4 gene expression 
was elevated in the caecal tissues of birds raised in LH compared to small intestinal tissues. 
Although not mirrored by the IL-6 data these TGFβ4 results may link to the increased 
microbial numbers residing naturally in the bird caecum.     
In this study the LH reared birds were challenged by higher bacterial and coccidian loads 
than the HH birds (Butler, 2010). Interestingly in response to coccidiosis (Eimeria maxima) 
infection, IL-6 upregulation in chicken intestinal intraepithelial lymphocytes was reported 
while TGFβ4 expression was not changed (Hong et al., 2006). Although these data relate 
to lymphocytes they do conflict with the results of this study. However, another report in 
which chickens were challenged with coccidian parasites, detected increased IL-6 
expression only in older, 3 week old birds, suggesting age related effects (Zhang et al., 
2012).  
Galectin-3 functions as an opsonin facilitating microbial destruction through attachment to 
the lipopolysaccharide (LPS) of the bacteria cell membrane and phagocyte surface 
glycoproteins (Almkvist and Karlsson, 2004). It also has chemo-attractive properties, 
attracting macrophages and stimulating monocyte migration (Sano et al., 2000). In mice 
galectin-3 participates in the inflammatory process via degranulation of mast cell contents 
(Dhirapong et al., 2009). Little is known of galectin’s role in the avian gut although it has 
been reported to activate dendritic cells via glycan binding and toll-like receptors (de Geus 
and Vervelde, 2013; Van Crombruggen et al., 2013). In the guts of D7 birds no significant 
differences in CG3 expression were observed despite the different rearing environments. It 
was noted that the baseline CG3 expression levels were elevated compared to other tissues 
supporting a link between gene expression and microbial presence.  
AvBD9 synthesis was localised by IHC to gut enterocytes.  There are few IHC studies 
showing AvBD localisation probably due to the lack of commercial antibodies and those 
published have focused on the reproductive tract. For example, the importance of AvBD3 
in the protection of sperm presumably against infection before and after ejaculation has 
been reported (Shimizu et al., 2008). Furthermore, positive staining for AvBD11 and 
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AvBD12 in the chicken epididymis and testis, suggests the production of these AvBDs in 
both organs (Watanabe et al., 2011), although their functions require further clarification. 
Research has shown that mammalian host defense peptides synthesised in epididymis play 
roles in maturation of sperm and protection against infection (Dorin and Barratt, 2014). 
Immunostaining for gallin, an egg defensin, in the tubular glands and ciliated cells of 
magnum, and shell glands of the oviduct also supports the activity of this AMP in the egg 
white and shell to help protect the embryo against potential pathogens (Gong et al., 2010). 
The chicken gut lacks Paneth cells (Nile et al., 2004) and in the current study, synthesis 
and secretion of AvBD9 was detected in the intestinal crypts and brush borders (Figure 
3.21). This supported the concept that enterocytes in the basal part of the crypts secrete the 
peptide to limit the invasion of the gut mucosa by both commensals and pathogens. In 
addition, the comparable localisation of IL-6 and AvBD9 in the gut suggest the peptides 
function collectively to control commensal numbers and help protect the gut epithelium 
from damage from potential pathogens.    
3.6.Conclusions 
Although the data were compromised by small sample numbers and variable expression 
real time PCR assay data showed the IL-6, TGFβ4, and CG3 genes were expressed in all 
bird tissues including the gut tissues. Overall no marked trends were detected and where 
elevated IL-6 tissue expression was detected this was matched by TGFβ4 suggesting 
physiological as opposed to pathological inflammation. Although only D7 data were 
available for the gut samples, AvBD6 and AvBD9 gene expression were detected in all 
samples examined with rearing environment having no significant effects on expression. 
These data, which suggested almost constitutive expression, contrasted to the AvBD1 and 
4 data, and suggested the reduced importance of AvBD6 and 9 in the AvBD hierarchy in 
the protection of the gut.  The original hypothesis was that the gut epithelia of these birds 
would not be able to respond efficiently to the LH rearing conditions resulting in their 
increased susceptibility to inflammation. The data reported did not support this hypothesis 
suggesting factors as yet unknown play a role in the pathology.  
To date it is assumed that the AvBD6 and AvBD9 gene encoded products have 
antimicrobial activity. To explore this further the peptides were synthesised in vitro and 
their activity against Gram positive and negative bacteria examined.  
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Chapter 4 
4. In vitro synthesis and analyses of the anti-microbial properties of 
AvBD6 and AvBD9 peptides 
4.1.Introduction 
Although the sample numbers were small the data presented in Chapter 3 confirmed the 
gene expression of AvBD6 and AvBD9, and AvBD9 peptide synthesis in Aviagen broiler 
chicken tissues including those of the gastrointestinal tract. Mammalian defensins are 
known, classically as host defence peptides due to their immunomodulatory as well as anti-
microbial activities (Bowdish et al., 2006). Compared to the mammalian defensins little is 
known about the properties of the AvBDs. However, AvBD expression and synthesis in 
the chicken gut tissues, populated naturally by microbes including commensals and 
potential pathogens, does suggest a key role for the AvBDs in the protection of the avian 
gut epithelium from potential microbial damage.  Central to such a role is that the AvBDs 
exhibit bacterial killing or antimicrobial properties.  
Mammalian α-defensins such as Human Neutrophil Peptide-1 (HNP-1) are synthesised 
containing a N-terminal pro-piece composed of 40 to 45 amino acids. This hydrophilic 
anionic peptide is proposed to function in subcellular sorting and peptide folding, and 
reduces the toxicity of the peptide during cell storage; proteolytic removal is essential for 
peptide activation (Wu et al., 2003). AvBDs, like mammalian β-defensins, contain no or 
short pro-pieces and the functions of any of these small peptides remain unknown (Ganz, 
2004; Cuperus et al., 2013). The AvBD6 and AvBD9 primary amino acid sequences predict 
short pro-sequences comprising the amino acids GQPYFS and AYSQED respectively 
(Figure 4.1).  
 
 
 
 
Figure 4.1 Amino acid composition of AvBD6 and 9 including pro and mature sequences. The 
pro- pieces are bold and underlined. Cysteines (Yellow); C-terminal tryptophan (Green). 
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This Chapter focussed on exploring the potential antimicrobial properties of AvBD6 and 
9. To address this an in vitro approach was used in which recombinant AvBD peptides were 
produced and their antimicrobial properties studied using Gram negative and positive 
bacterial strains isolated from commercially reared broiler chickens. Recombinant AvBD6 
and AvBD9 peptides were prepared that included and excluded the hexapeptide N-terminal 
pro-piece sequences. Defensin molecules are characterised by 6 C amino acids (Figure 4.1), 
which form three intramolecular disulphide bonds. To investigate the potential importance 
of the cysteine amino acids, variants of recombinant AvBD9 with either three or no 
cysteines were synthesised and used in the antimicrobial assays (AMAs). The family of 
AvBDs, apart from 8, 10, 12 and 13, all contain a C-terminally located tryptophan (Figure 
4.1). Thus to determine the significance of this amino acid in the antimicrobial activity of 
the AvBD9 peptide a recombinant variant was synthesised lacking the C-terminal 
tryptophan and its AMA tested.  
4.2. Recombinant AvBD synthesis 
Initially the AvBD6 and 9 peptides were prepared as recombinant peptides using a GST 
hyper-expression system.   
4.2.1. AvBD6 and AvBD9 cloning 
Avian (Av) BD 6 and 9 cDNAs encoding both pro and mature peptides amplified from 
RNA isolated from D7 Line X birds and the expression vector pGEX-6P-1 were each 
digested with BamH1 and EcoR1 restriction enzymes (Figure 4.2A). After ligation of the 
cDNAs into the vector and transformation into E. coli DH5α, recombinant colonies were 
selected and plasmid DNA prepared (Figure 4.2B). The cDNA inserts were confirmed by 
PCR (Figure 4.2C) and DNA sequencing (Figure 4.3). 
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Figure 4.2[A]: BamH1 and EcoR1 restricted cDNAs encoding: AvBD6 mature (1), 
AvBD6 promature (2), AvBD9 mature (3), AvBD9 promature (4), restricted pGEX-6P-
1 plasmid (5), uncut pGEX-6P-1 plasmid (6).  
DNA markers, 10 Kbp (M1) and 1k bp (M2); [B]: Uncut recombinant pGEX-6P-1 with 
AvBD6 mature (1), AvBD6 promature (2), AvBD9 mature (3), AvBD9 promature (4), 
Markers 10 Kbp (M); [C]: PCR of recombinant pGEX-6P-1 containing inserts of 
AvBD6 mature (1), AvBD6 promature (2), AvBD9 mature (3), AvBD9 promature (4), 
Markers, 1 Kbp (M)  
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C 
Figure 4.3 Sequencing results of recombinant pGEX-6P-1 plasmid. It contains inserts of AvBD6 mature peptide (A), AvBD6 promature peptide (B), AvBD9 mature peptide (C), 
and AvBD9 promature peptide (D). ‘Query’ represents the amplified and sequenced products. ‘Sbjct’ relates to the NCBI database gene sequences. The black box shows the pro-
peptide sequences (18 bp). Blue boxes indicate the partial sequence (s) of the restriction site, BamH1 (GGATCC). 
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4.2.2. Hyper expression of AvBD6 and AvBD9 peptide variants 
The four AvBD6/9 recombinant plasmids were each transformed into E. coli  BL21 (DE3) 
pLysS, grown to an OD600 of 0.8 at 37 
oC and expression induced for up to 3h by the 
addition of 1 M IPTG. Cell free extract (CFE) and pellet fractions were prepared as 
described in Section 2.17.  
Figure 4.4A shows the synthesis of the AvBD6 peptides at 37 oC with the tagged GST 
peptides migrating at 31 kDa. All gels (a typical example is shown in [A]) showed more 
protein to be located in the pellet (lanes 2 and 4) than the CFEs (lanes 1 and 3), which 
suggested that at 37 oC the peptides were less soluble in the CFE. To try and address the 
AvBD6 solubility issues the bacteria were grown more slowly at 16 oC and 25 oC 
respectively (panel B), and induced using 0.1M IPTG, as opposed to 1M. These 
adjustments helped to improve the solubility of the recombinant peptides with the 
suggestion of increased protein identified in the CFE (Figure 4.4B lanes 5 and 7) compared 
to the pellet (lanes 6 and 8) fractions. A protein band of ~26 kDa was observed below the 
GST tagged AvBD6, which from its size was predicted to be GST protein due to proteolysis 
of the recombinant proteins. 
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Figure 4.4 SDS PAGE (A) and NUPAGE (B) gels of recombinant pGEX-6P-1/AvBD6 induced by 
IPTG with 1M at 37 °C (A) and 0.1M at 16 and 25 °C (B), and stained with Instant blue. AvBD6 
mature CFE (1, 5, and 7), AvBD6 mature pellet fraction (2, 6, and 8), AvBD6 promature CFE (3), 
and AvBD6 promature pellet fraction (4). ClearPAGE protein marker (M1) and Novex sharp 
prestained protein marker (M2).     
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AvBD9 peptide was also hyperexpressed. As shown in Figure 4.5 the 37 oC/1M IPTG 
conditions supported the synthesis of a 30.5 kDa soluble AvBD9 GST tagged protein. In 
fact the GST tagged AvBD9 peptide proved soluble using growth temperatures of either 37 
oC or 25 oC (Panels A and B), with the suggestion of increased protein in the CFEs (lanes 
1, 3 and 5) compared to the pellet fractions (lanes 2, 4 and 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M 1 2 5 3 4 6 
7.6 
12 
22 
28 
33 
48 
71 
96 
142 
195 
30.5 kDa 
25 oC   0.1M 37 
oC  1M  
A B 
  
Figure 4.5 SDS PAGE gels of hyperexpressed pGEX-6P-1 BL21/AvBD9 induced by IPTG 
with 1M 37 °C (A) and 0.1M 25 °C (B), and stained with Instant blue.  
AvBD9 mature CFEs (1 and 5), AvBD9 mature pellet fractions (2 and 6), AvBD6 promature 
CFE (3), AvBD6 promature pellet fraction (4). ClearPAGE protein marker (M1).  
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4.2.3. Purification of AvBD6 and AvBD9 peptides 
Purification of the AvBD6 and 9 peptides was performed as described in Section 2.18. Two 
procedures were used: in the first the GST proteins were cleaved from the GST tagged 
AvBD peptides following elution of the tagged AvBD peptides from the CellThru 10-ml 
Disposable Columns (Clontech Laboratories, Inc.). This is termed ‘cleaving off the 
column’.  In the second procedure the GST tags were cleaved while the peptides were still 
attached to the column resin. This is known as ‘cleaving on the column’. 
4.2.3.1.Purification: cleaving off the column 
Purification focussed initially on the AvBD9 peptide due to its increased solubility. The 
AvBD9 cell free extracts (CFE) (Figure 4.6, lanes 1 and 5) were applied to a glutathione 
resin packed CellThru column and the GST tagged AvBD9 peptides (30.5 kDa) eluted 
using Tris glutathione buffer (20 mM reduced L- Glutathione and 50 mM Tris base pH 8) 
(Figure 4.6, lanes 2 and 6). The GST tags were removed by incubating the tagged fusion 
protein (50 mg) with 0.5 mg of 3C protease enzyme (GST-tagged HRV 3C PreScission 
protease) in cleaving buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM DTT 
pH 7.5) overnight at 4 °C (lanes 3 and 7). Pure peptide was separated and collected using 
a 10 kDa Vivaspin column (Vivaspin 20 columns, GE Healthcare Life Sciences, UK), 
(lanes 4 (4.5 kDa) and 8 (5 kDa)). The purified peptides were desalted using PD-10 
desalting columns (GE Healthcare life Sciences) to remove Tris glutathione buffer and 
concentrated by freeze-drying. Lyophilised AvBD9 peptide was reconstituted in sterilised 
molecular grade water when required. Removal of the cleaving buffer by desalting was 
necessary as the buffer chemicals interfered with the protein concentration measurements, 
which were performed using a QuantiPro™ BCA Assay Kit (Sigma Aldrich).    
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The purification procedures were repeated for AvBD6. However, using the ‘cutting off the 
column’ procedure, the yield of AvBD6 peptide was consistently poor as evidenced by the 
absence of pure peptide in Figure 4.7, lane 4. Therefore, to try and overcome the problem 
of poor yields a ‘cutting on the column’ procedure was used. 
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Figure 4.6 NUPAGE gel stained with Instant Blue showing AvBD9 purification (cleaving off 
the column). CFEs (1 and 5). GST tagged AvBD9 (2 and 6). GST cleaved by 3C protease (3 
and 7).  Pure AvBD9 (4 and 8). AvBD9 mature (1-4) and AvBD9 promature (5-8). Novex sharp 
prestained protein marker (M).  
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Figure 4.7 NUPAGE gel stained with Instant Blue showing AvBD6 purification (cleaving off 
the column). CFE (1). GST tagged AvBD6 (2). GST cleaved by 3C protease (3). Pure AvBD6 
(4). Novex sharp prestained protein marker (M).  
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4.2.3.2.Purification: cleaving on the column 
In this procedure, the CFEs containing GST tagged peptides on the glutathione resin packed 
CellThru were left overnight with 3C protease enzyme at 4 °C to allow cleavage on the 
column and then eluted with cleaving buffer. The eluent was applied to a 10 kDa Vivaspin 
column to facilitate separation of the GST, 3C protease and other bacterial proteins. The 
cleaving on the column procedure increased the yield and purity of the mature and 
promature AvBD9 peptides as shown in the NUPAGE gel, Figure 4.8. The data showed 
that the impure proteins were trapped at the top of the 10 kDa Vivaspin columns (Lanes 1 
and 4). The pure AvBD9 peptides were desalted (section 2.18.2) to remove the Tris and 
EDTA of the cleaving buffer (Lanes 3 and 6), lyophilised and reconstituted with sterilised 
molecular grade water.    
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Figure 4.8 NUPAGE gel stained with Instant Blue showing AvBD9 purification 
(cleavage on the column).  
The impure peptides removed by Vivaspin column (1 and 4). Pure AvBD9 in cleavage 
buffer (2 and 5). Desalted pure AvBD9 (3 and 6). AvBD9 mature (1, 2 and 3) and AvBD9 
promature (4, 5 and 6). Novex sharp prestained protein marker (M).  
 
 
102 
 
The procedure was repeated using GST tagged AvBD6 promature and mature CFEs (Figure 
4.9, lanes 1, and 5). As previously, the peptides and 3C protease were applied to the 
glutathione resin packed CellThru column, incubated overnight at 4 °C with 3C protease 
and the peptides eluted with cleaving buffer. Lanes 2 and 6 show the cleaved GST tagged 
peptides. The peptides were passed through 10kDa Vivaspin columns to separate the GST 
and 3C protease, but these procedures were unsuccessful with no pure peptide collected in 
the bottom of the 10kDa columns (lanes 4 and 8). These results suggested that most of the 
AvBD6 peptide was trapped on the Vivaspin column (Lanes 3 and 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To address this problem the cleaved AvBD6 peptides were eluted from the resin packed 
CellThru column using 1x PBS, instead of the cleavage buffer. The idea was that both GST 
and 3C proteases remained attached to the resin and the cleaved AvBD peptides were eluted 
with PBS, removing the need for the 10 kDa Vivaspin and desalting steps. While the elution 
with 1x PBS increased the yield of peptides (Figure 4.10, lanes 3-7), the final purity of the 
peptides was reduced due to contamination with GST and 3C protease residues. However, 
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Figure 4.9 NUPAGE gel stained with Instant Blue showing AvBD6 purification (cleaving 
on the column).  
AvBD6 mature (Lane 1-4) and AvBD6 pro (Lane 5-8). CFE (1 and 5). Cleaved GST 
tagged AvBD6 (2 and 6), GST, 3C protease and AvBD6 peptides trapped on the Vivaspin 
columns (3 and 7). Pure AvBD6 (5 and 8). Novex sharp prestained protein marker (M).  
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recognising the GST/protease contamination, the eluents from lanes 5, 6 and 7 were 
collected, freeze dried and when required reconstituted in sterilised molecular grade water. 
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The yield of pure lyophilised AvBD6 and AvBD9 variants was in the range 0.1 to 0.6 mg/L 
bacterial growth media. 
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Figure 4.10 NUPAGE gel stained with Instant Blue showing AvBD6 purification 
(cleaving on the column eluting with PBS).  
CFE (1). Cleaved GST tag from AvBD6 by 3C protease (2). Eluents with PBS (3-
7). Novex sharp prestained protein marker (M).  
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4.2.4. MALDI TOF mass spectrometry 
To ensure authenticity of the peptides the amino acid sequence of one purified peptide - 
AvBD9 (promature) - was analysed by peptide mass-spectrometry (York University) using 
CHCA, DHB and DAN matrices and these data are shown in Figures 4.11 A, B and C, 
respectively. The analyses resulted in a N terminal amino acid sequence of 
GPLGSAYSQEDADTLACRQSHGSCSFVACR with the pentamer GPLGS sequence 
representing the remaining residues of the GST tag (26 kDa) following cleavage, and the 
underlined hexamer the pro region. DHB matrix was used to reduce the number of salt and 
peptide adducts, and the data showed the derived sequence GPLGSAYSQEDADTLA at 
1594.6 m/z (Figure 4.11 B). Other sequences (including QSHGSCSFVACR) were detected 
using DAN matrix and MALDI-In Source Decay (ISD) spectrum (Figure 4.11 C). 
From the MALDI-MS/MS analyses (Figure 4.11 A) the single peak with the greatest 
deflection indicated a peptide with a mass of 5456.2 m/z, which supported the predicted 
mass of 5325.2 Da for the AvBD9 promature peptide. The multiple peaks shown in panel 
A were thought to be adducts of sodium ions or peptide components remaining in the 
sample during the purification processes.  
Overall these data authenticated the AvBD9 promature peptide produced in vitro and it was 
inferred from these data that the primary amino acid sequences of all the other peptides 
produced in vitro were authentic.  
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A 
B 
C 
Figure 4.11 A sample of purified AvBD9 promature 
peptide analysed by MALDI-MS/MS using CHCA (A), 
DHB (B) and DAN matrices (C). 
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4.3.AvBD9 site directed mutagenesis 
Once the purified peptides had been produced in vitro, the aim was to explore their 
antimicrobial activities (AMA). The amino acid sequences of the AvBDs, like all vertebrate 
defensins, are characterised by six cysteines. The AvBDs 1 -7, 9, 11, and 14 are also 
characterised by a distinctive C-terminal tryptophan (Figure 4.12).  
Studies on the cysteines in the AMAs of the defensins have generated conflicting findings. 
Kluver et al. (2005), reported that mutating the cysteines in human (H) BD3 had no 
significant effects on its AMA (Kluver et al., 2005).  In contrast, more recent reports have 
indicated that mutagenesis of the HBD3 cysteines reduces the peptide’s AMA properties 
presumably through conformational changes (Chandrababu et al., 2009; Wanniarachchi et 
al., 2011). Additionally, Maemoto et al. (2004) reported that mutagenizing cysteines of 
Crp4 (mouse α-defensin) increased its AMA, although they also reported that the peptide 
was more susceptible to proteolytic degradation (Maemoto et al., 2004).  
The literature is less confusing in relation to the roles of hydrophobic amino acids in 
defensin antimicrobial function. AvBD amino acid structures contain a number of aromatic 
hydrophobic amino acids (2-7 residues per mature peptide), and in silico and molecular site 
directed mutagenesis of the duck defensin Apl-AvBD2 has confirmed their importance in 
bacterial killing (Soman et al., 2010). Tryptophan 26, located at the C-terminus of HNP-1, 
a mammalian α-defensin,  has also been reported to be crucial for its activity, essentially 
directing interactions of the peptide with target molecules (Wei et al., 2010). Thus it was 
hypothesised that the C-terminal tryptophan functions in the bacterial killing mechanisms 
of those AvBDs in which it is found. 
To investigate the potential roles of the cysteine and tryptophan amino acids in AvBD9 
antimicrobial activity, the cysteines and C-terminal tryptophan of the molecule were 
mutated using site directed (SD) mutagenesis to either glycines or alanines and the bacterial 
killing properties of the mutated peptides analysed. AvBD6 was not investigated because 
of the potential problems linked to peptide purification.  
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Figure 4.12 AvBDs 1 – 14 primary amino acid sequences. Cysteines are highlighted (yellow), aromatic hydrophobic residues (green). Cationic (blue) and anionic 
(red). Underlined (propiece) which separate the signal sequence from mature sequence. Modified from xiao et al., 2004 and NCBI website. 
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4.3.1. Mutagenesis of cysteine residues  
The three cysteines (C1, C2 and C6) of AvBD9, shown in Figure 4.13, were proposed to 
be involved in disulphide bond formation, and to explore this further were each 
mutagenized to an alanine. This variant was named AvBD9 3CA and it was predicted that 
the alterations in sequence would cause disruption of the three di-sulphide bonds in the 
encoded peptide. The DNA sequencing results confirmed the SD mutagenesis had been 
successful (Figure 4.14 B-D). For the second construct (AvBD9 C6A/G) the remaining 
three cysteines (C3, C4 and C5) of AvBD9 3CA, were mutagenised to glycines (Figure 
4.14 E-G).  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.2. Site directed mutagenesis of C- terminal tryptophan residue 
To explore the role(s) of the C-terminal tryptophan in the AvBDs, Tryptophan number 38 
[W38] of the AvBD9 mature amino acid sequence was mutagenised to glycine (Figure 4.14 
panel H).   
 
 
 
 
 
 
 
Figure 4.13: Suggested disulphide bond arrangement of AvBD9 
between each three pairs of cysteines (C1-C5), (C2-C4) and (C3-C6) 
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AvBD9 mature 
GAGGCCGTTTGGTGGTGGCGACATCCTCCAAATCGGATCTGGAAGTTCTGTTCCAGGGGCCCCTGG 
             A    D    T    L    A   C     R     Q    S    H    G    S    C   S    F    V   A   C      R    A 
GATCCGCTGACACCTTAGCATGCAGGCAGAGCCACGGCTCCTGCTCTTTTGTTGCATGCCGTGCT 
  P   S    V    D    I     G    T   C     R    G    G     K    L   K      C    C    K   W   A    P    S 
CCTTCAGTTGACATTGGGACCTGCCGTGGTGGGAAGCTGAAATGCTGCAAATGGGCACCCAGC 
  S   * 
TCCTGAGAATTCCCGGGTCGACTCGAGCGGCCGCATCGTGACTGACTGACGATCTGCCTCGCGCGTT 
 
AvBD 9 C1A Cysteine number 1 to Alanine 
ACCAAAGTGTTTGGTGGTGGCGACATCCTCCAAATCGGATCTGGAAGTTCTGTTCCAGGGGCCCCTG 
                A     D    T    L    A   A     R     Q    S    H    G    S    C   S    F    V   A   C     R    A 
GGATCCGCTGACACCTTAGCAGCCAGGCAGAGCCACGGCTCCTGCTCTTTTGTTGCATGCCGTGCT 
   P    S    V    D    I     G    T   C     R    G    G     K    L   K     C    C     K   W   A    P    S 
CCTTCAGTTGACATTGGGACCTGCCGTGGTGGGAAGCTGAAATGCTGCAAATGGGCACCCAGC 
  S    * 
TCCTGAGAATTCCCGGGTCGACTCGA 
 
AvBD 9 C1A_C2A Cysteine number 1 and 2 to Alanines 
TGGGCAGTTTTGGTGGGTGGGCGACATCCTCCAAATCGGATCTGGAAGTTCTGTTCCAGGGGCCCCT 
                  A     D    T    L    A   A     R     Q    S    H    G    S    A   S   F    V   A     C     R     
GGGATCCGCTGACACCTTAGCAGCCAGGCAGAGCCACGGCTCCGCCTCTTTTGTTGCATGCCGT 
  A    P   S    V    D    I     G     T   C     R    G    G     K    L   K      C    C     K  W    A    P    
GCTCCTTCAGTTGACATTGGGACCTGCCGTGGTGGGAAGCTGAAATGCTGCAAATGGGCACCC 
   S    S  * 
AGCTCCTGAGAATTCCCGGGTCGACTCG 
 
AvBD 9 C1A-C2A C6A Three Cysteines to Alanines (AvBD9 3C A) 
TGCCCAAGTTTGTGTGGGTGGCGAACATCCTCCAAATCGGATCTGGAAGTTCTGTTCCAGGGGCCCC 
                    A     D    T    L    A   A     R     Q    S    H    G    S    A   S   F    V   A     C     R     
TGGGATCCGCTGACACCTTAGCAGCCAGGCAGAGCCACGGCTCCGCCTCTTTTGTTGCATGCCGT 
  A    P   S    V    D    I     G    T    C     R    G    G     K    L     K    C    A      K  W    A    P     
GCTCCTTCAGTTGACATTGGGACCTGCCGTGGTGGGAAGCTGAAATGCGCCAAATGGGCACCC 
   S    S  * 
AGCTCCTGAGAATTCCCGGGTCGACTCG 
A 
B 
D 
C 
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AvBD9 3CA variant (panel D) was performed by replacement of AvBD9 mature (Panel 
A) cysteines C1 (panel B), C2 (panel C) and C6 (panel D) to Alanine. AvBD9 6CA/G 
variant (panel G) was acquired by substitution of the rest cysteines of AvBD9 3CA variant, 
C4 (panel E), C3 (panel F) and C5 (panel G) to glycines. AvBD9 W38G variant was 
constructed by changing tryptophan 38 of AvBD9 mature peptide to glycine (panel H). The 
highlighted colours: BamH1 and EcoR1 restriction sites (Grey). The mutagenised codon 
sequences, Alanine (red) and Glycine (pink). Turquoise highlights are the name of the 
variants produced. Non-mutagenised residues, cysteines (yellow) and tryptophan (green).  
AvBD 9 C1A-C2A-C6A C4G Three Cysteines to Alanines. Cysteine 4 to glycine 
GGAGTCTTTTTGGTGGTGGCGACATCCTCCAAATCGGATCTGGAAGTTCTGTTCCAGGGGCCCCTGG 
             A    D   T     L    A    A     R     Q    S    H    G    S    A   S   F    V   A     C     R    A 
GATCCGCTGACACCTTAGCAGCCAGGCAGAGCCACGGCTCCGCCTCTTTTGTTGCATGCCGTGCT 
  P   S    V    D    I     G    T    G     R    G    G     K    L     K    C    A      K     W   A     P        
CCTTCAGTTGACATTGGGACCGGCCGTGGTGGGAAGCTGAAATGCGCCAAATGGGCACCC 
   S   S   * 
AGCTCCTGAGAATTCCCGGGTCGACTCGA  
 
AvBD 9 C1A-C2A-C6A-C4G -C3G Three Cysteines to Alanines. Cysteines 3 and 
4 to Glycines 
AGGACCTTTTTTGGTGGTGGCGACATCCTCCAAATCGGATCTGGAAGTTCTGTTCCAGGGGCCCCTG 
                A    D   T     L    A    A     R     Q    S    H    G    S    A     S   F    V    A     G     R     
GGATCCGCTGACACCTTAGCAGCCAGGCAGAGCCACGGCTCCGCCTCTTTTGTTGCAGGCCGT 
 A     P   S    V    D     I     G    T    G     R    G    G     K    L     K    C     A      K   W    A      
GCTCCTTCAGTTGACATTGGGACCGGCCGTGGTGGGAAGCTGAAATGCGCCAAATGGGCA 
  P    S    S    * 
CCCAGCTCCTGAGAATTCCCGGGTCGAC 
 
AvBD 9 C1A-C2A-C6A-C4G -C3G-C5G Six Cysteines to Alanine/Glycines (AvBD9 
6C A/G) 
TGAATTTTGATGCTGGCGACATCCTCCAAATCGGATCTGGAAGTTCTGTTCCAGGGGCCCCTGGGAT 
        A    D   T   L    A    A     R     Q    S    H    G    S    A     S   F    V    A     G    R    A   P  
CCGCTGACACCTTAGCAGCCAGGCAGAGCCACGGCTCCGCCTCTTTTGTTGCAGGCCGTGCTCCT 
  S    V    D     I     G    T    G     R    G    G     K    L     K    G     A      K   W    A    P    S       
TCAGTTGACATTGGGACCGGCCGTGGTGGGAAGCTGAAAGGCGCCAAATGGGCACCCAGC 
  S    * 
TCCTGAGAATTCCCGGGTCGACTCGAGC 
 
AvBD 9 W38G Tryptophan number 38 to Glycine (AvBD9 W38G) 
AGGGAATTTGTTTTGTGGGTGGCGACATCCTCCAAATCGGATCTGGAAGTTCTGTTCCAGGGGCCCC 
                    A    D    T    L    A   C     R     Q    S    H    G    S    C   S    F    V   A   C     R      
TGGGATCCGCTGACACCTTAGCATGCAGGCAGAGCCACGGCTCCTGCTCTTTTGTTGCATGCCGT 
  A    P    S    V    D    I     G    T   C     R    G    G    K    L     K      C    C    K    G    A    P     
GCTCCTTCAGTTGACATTGGGACCTGCCGTGGTGGGAAGCTGAAATGCTGCAAAGGGGCACCC 
  S   S   * 
AGCTCCTGAGAATTCCCGGGTCGACTCG 
E 
F 
G 
H 
Figure 4.14 A-H: DNA sequencing results of mutagenised plasmids. 
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Attempts to mutagenise the three cysteines, C3, C4 and C5 to alanines was unsuccessful. 
This was probably due to the GC rich mutagenesis primers (Table 4.1) either failing to 
anneal to the DNA sequences or mis-priming. To address this the three cysteines were 
mutated to glycines. 
Once the plasmids encoding the amino acid mutations were engineered they were 
transformed into BL21 (DE3) pLysS, the GST tagged proteins hyper-expressed and the 
peptides purified as described for mature AvBD9.  
The mutagenised variants were visualised using NUPAGE gels stained with Instant Blue.  
Figures 4.15 and 4.16 show purification of the AvBD9 3CA, and AvBD9 6CA/G and 
AvBD9 W38G peptides, respectively, and the yields are shown in Table 4.2.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primers Forward Reverse Change 
AvBD9 
C3A
GGCTCCTGCTCTTTTGTTGCA
GCCCGTGCTCCTT
AAGGAGCACGGGCTGCAACAA
AAGAGCAGGAGCC
TGC to
GCC
AvBD9 
C4A
GTTGACATTGGGACCGCCCG
TGGTGGGAAGCT
AGCTTCCCACCACGGGCGGTCC
CAATGTCAAC
TGC to
GCC
AvBD9 
C5A
GTGGTGGGAAGCTGAAAGCC
TGCAAATGGGCACC
GGTGCCCATTTGCAGGCTTTCA
GCTTCCCACCAC
TGC to
GCC
Table 4.1 Primers used to mutagenise cysteines, C3, C4 and C5 of AvBD9 to Alanines. 
15 
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Figure 4.15 NUPAGE gel stained with Instant Blue showing AvBD9 3CA purifications. CFE 
contains GST tagged AvBD9 (1). Cleaved GST tag from AvBD9 by 3C protease (2), eluted with 
cleaving buffer (3). Impure proteins trapped in the top of Vivaspin columns (4). Pellets (5). 
Desalted pure peptide (6). Freeze dried peptides reconstituted with water (7). Novex sharp 
prestained protein marker (M).    
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Figure 4.16 NUPAGE gel stained with Instant Blue showing AvBD9 6CA/G (Lanes 1-4) and 
AvBD9W38G (Lanes 5-8) purifications. CFE contains GST tagged AvBD9 (1 and 5). Cleaved 
GST tag from AvBD9 by 3C protease (3 and 7). Pure peptides (4 and 8).  Pellets (2 and 6). 
Novex sharp prestained protein marker (M).   
AvBDs Mean±SEM (mg/L) n
9 mature 0.33± 0.03 7
9 promature 0.64± 0.12 3
9 3C A 0.35± 0.05 8
9 6C AG 0.42± 0.06 8
9 W38G 0.30± 0.06 8
6 mature 0.16± 0.03 4
6 promature 0.15± 0.01 2
Table 4.2 Yields of AvBD9 recombinant peptides (mg/L bacterial growth culture). n is 
the number of purifications. Mean± SEM.   
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4.4.Antimicrobial activities of the AvBD peptides 
To test the antimicrobial activities of the wild-type AvBD6 and 9 peptides and mutated 
variants of AvBD9 two anti-microbial assay systems were used. Initially, a radial immuno-
diffusion assay (RIDA) was used, which allowed bacterial killing properties to be identified 
quickly but did not support reproducible and accurate quantification of the antimicrobial 
data. The use of time-kill colony counting assays (CCA) allowed the bacterial killing to be 
quantitated.   
4.4.1. Radial immuno-diffusion assay (RIDA) for AvBD6 and AvBD9 peptides against 
E. coli    
The radial immuno-diffusion assay used in the current study was adapted from the method 
described by Schroeder et al. (2011) and described in Section 2.22.1. These authors, 
investigating properties of human β-defensin-1, used concentrations of 0.5, 1 and 2 µg/ µl. 
A similar approach was adopted in this study using three peptide concentrations of 0.5, 1 
and 4 µg/ µl. To quantify the antimicrobial activity, the percentage of bacterial inhibition 
was determined by measuring the clear zone created by the AvBD peptide treatments 
relative to a positive control peptide. The diameters of the wells were considered as 
baselines and subtracted from the zone measurements. Two positive controls with known 
AMA, lysozyme (Schroder and Harder, 2006) and cecropin (Lu et al., 2012) were used 
routinely, but unless stated otherwise the positive control data relate to cecropin as its 
antimicrobial activity was more consistent in the RIDA than that of lysozyme. 
A typical example of the E. coli radial diffusion assay results for AvBD6 is shown in Figure 
4.17.  These data indicated that AvBD6, at 4 μg/μl, was antimicrobial causing an E. coli 
zone of inhibition comparable to that of the positive controls, cecropin (4 μg/μl) and 
lysozyme (10 μg/μl).  The antimicrobial data were less clear for AvBD6 at concentrations 
of 0.5 and 1 μg/μl.  
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A typical example of the E. coli  radial diffusion assay results following incubation of 
AvBD9 mature, promature and AvBD9 3CA peptides with E. coli  at concentrations of 0.5, 
1 and 3 μg/μl is shown in Figure 4.18. Clear halos or zones of inhibitions were observed at 
1 and 3 μg/μl, indicating that the peptides had antimicrobial properties against E. coli.  
Moreover the percentages of inhibition for 3 μg/μl AvBD9 mature, promature and AvBD9 
3CA peptides were comparable at 100, 90 and 110% (where AvBD9≡100%) 
Figure 4.19 shows the semi-quantitative analyses of the inhibition zones resulting from 
using 3 μg/μl AvBD9 mature, AvBD9 promature and AvBD9 3CA peptides. These data 
indicated no significant differences in the zones of inhibition and suggested comparable E. 
coli  killing between the variants (100±0 % (mean±SEM) killing for AvBD9 mature, 
83±8 % using AvBD9 promature and 88± 22 % using AvBD9 3CA).  
 
 
 
 
 
A 
B C D 
4 μg/μl 0.5 μg/μl 1 μg/μl 
Figure 4.17 Radial immuno-diffusion assay results following incubation of 0.5, 1 and 4 μg/μl 
recombinant AvBD6 mature peptide (A). PBS (B); 10 μg/μl Lysozyme (C) and 4 μg/μl 
Cecropin (D) with an E. coli  lawn. E. coli grown on TSB agar. 2.3 X magnification 
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Figure 4.19 Percentage inhibition zone created using 3 μg/μl of AvBD9 promature and 3CA 
peptides compared to AvBD9 mature. Mean ± SEM. Experiments =2. Replicates =4. AvBD9 
mature was used as a 100 % inhibition. 
B 
A 
D E 
C 
PBS (0 μg/μl)  
3 μg/μl 1 μg/μl 0.5 μg/μl 
90 % 
110 % 
40 % 
50 % 
100 % 
40 % 
0 % 
Figure 4.18 Radial immuno-diffusion assay of recombinant AvBD9 peptides using lawn of E. coli grown 
on TSB agar. AvBD9 mature (A); AvBD9 promature (B); AvBD9 3CA (C). The positive controls were 
Lysozyme 10 μg/μl (D) and Cecropin 4 μg/μl (E). PBS was used as the negative control. % represents 
percentage of inhibition zones compared to the AvBD9 mature as 100% inhibition. 2X magnification. 
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Zone of inhibition data relating to the variants containing either no cysteines AvBD9 
6CA/G or no C-terminal tryptophan AvBD9 W38G are shown in Figures 4.20 and 4.21. 
The 3 μg/μl data indicated that the AvBD9 6CA/G and AvBD9 W38G variants had 
bacterial killing properties with zones of inhibition comparable to that of the mature 
peptide. Minimal or no killing was observed at 1 μg/μl and 0.5 μg/μl. The quantification of 
inhibitory zones is shown in Figure 4.21 using AvBD9 data as 100% inhibition, 81±9 % 
inhibition was recorded for both AvBD9 6CA/G and AvBD9 W38G with no statistical 
differences. 
The inhibitory zone experiments were quick and the data useful in that they indicated 
whether or not the AvBD peptides were antimicrobial. However, the disadvantage of the 
methodology was that the inhibitory zone measurements were very subjective and 
essentially provided only qualitative data.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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1 μg/μl 3 μg/μl 0.5 μg/μl 
100 % 
72 % 
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0 % 
Figure 4.20 Radial immune-diffusion assay of rAvBD9 peptides in different concentrations against 
E. coli grown on TSB agar. AvBD9 mature (A). AvBD9 6CA/G (B). AvBD9 W38G (C). PBS as a 
negative control (D). Cecropin (E), 4 μg/μl.  % represents percentage of inhibition zones compared 
to the AvBD9 mature as 100% inhibition.  2.2 X magnification. 
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4.4.2. Time kill-colony counting assay 
To secure more quantitative data a time-kill colony counting assay was adopted.  
This method was adapted from that described by Townes et al. (2005), and explained in 
section 2.22.2. This assay is based on counting bacterial colonies following incubation with 
a peptide and hence the data are quantitative. 
4.4.2.1. rAvBD6 peptide AMA against E. coli   
The kill curves of the AvBD6 mature compared to the AvBD6 promature peptides are 
shown in Figure 4.22. These data revealed no statistically significant differences in the E. 
coli killing activities of the two peptides. For example, 15.9 % E. coli killing (84.1±10.8 % 
survival) was recorded using 2.5 μg/ml of mature AvBD6 compared to 13.2 % killing 
(86.8±12.8 % survival) using the promature peptide. Similarly 44.4 % (55.6±7.1 % 
survival) of E. coli colonies were killed using 25 μg/ml of mature AvBD6 compared to 
55.7 % (44.3±17.9 survival) using pro-mature AvBD6. These data suggested that the short 
pro-piece hexamer amino acid sequence had no effect, in vitro, on the E. coli AMA 
properties of AvBD6.   
 
 
 
Figure 4.21 Percentage inhibition zone created by 3 μg/μl of AvBD9 6CA/G and 
W38G peptides compared to AvBD9 mature against E. coli. Data presented as 
mean ± SEM. Experiments=2, Replicates=4. AvBD9 mature was used as a 100 % 
inhibition. 
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4.4.2.2.AvBD6 AMA against E. faecalis   
The time-kill assays were repeated using E. faecalis, a Gram positive bacterium, isolated 
from the gut of an Aviagen broiler chicken and these data are presented in Figure 4.23.  As 
the previous data indicated that the hexamer pro sequence had no effects on AvBD6 killing 
the assay was performed using only the mature AvBD6 peptide. E. faecalis killing was 
observed and the killing curve was comparable to that of E. coli. For example at 100 µg/ml, 
the peptide killed 84 % (16.0±6.5 % survival) of the Enterococci compared to 76.4% 
(23.6±2.3 % survival) of E. coli. However, at concentrations <5 μg/ml, the AvBD6 peptide 
was not anti-microbial and indeed bacterial survival values >100% were observed 
reproducibly, suggesting that at this concentration the bacteria were using the peptide as a 
nutrient source for growth. Complete killing of E. faecalis was observed at 250 µg/ml.   
 
 
 
 
 
 
Figure 4.22 Time–kill assay data comparing E. coli killing by rAvBD6 mature and promature 
peptides. Data presented as Mean±SEM.  Experiments=3, Replicates=9.  
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4.4.2.3.AvBD9 AMA against E. coli   
The curve showing the killing of E. coli by the AvBD9 mature peptide is presented in 
Figure 4.24A. As marked E. coli killing was observed at 25 μg/ml 29.4 % (70.6±2.3 % 
survival) this concentration, as well as 50, 100, 250 and 500 μg/ml, was chosen to compare 
the killing properties of the wild-type and mutated AvBD9 peptides. These data are shown 
in Figure 4.24B. E. coli killing did not differ significantly when equivalent concentrations 
of the mature, promature and AvBD9 3CA peptides were used (Figure 4.24B: blue, grey & 
red columns). These data suggested that, in vitro, the pro-piece of AvBD9 had no impact 
on the AMA of the peptide against E. coli and that AvBD9 3CA retained its AMA activity. 
However, mutation of the six AvBD9 cysteines to alanines and/or glycines (AvBD9 
6CA/G), and the C-terminal tryptophan to glycine (AvBD9 W38G), significantly reduced 
the killing capabilities of the resulting peptides against E. coli. For example incubating E. 
coli  with 50 μg/ml AvBD9 6CA/G and AvBD9 W38G resulted in ≥100% bacterial survival 
(112.3±5.8) and (154.8±15.1) while increasing the dose five-fold to 250 μg/ml resulted in 
only 35.3 % (64.7±15.4 % survival) and 25.9 % (74.1±13.7 % survival) killing (Figure 
4.24B: yellow and green columns). These data indicated that the presence of six cysteine 
amino acids and a C-terminal tryptophan residue are important in the AMA of AvBD9 
against E. coli. 
 
Figure 4.23 Time–kill assay data comparing E. faecalis killing by rAvBD6 mature peptides. 
Data presented as Mean±SEM.  Experiments=3, Replicates=9   
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Figure 4.24  A: Time–kill assay data comparing E. coli killing by rAvBD9 peptides.  
Experiments=2, Replicates=6.  Mean±SEM. Data were compared to the number of 
bacterial colonies observed using PBS. 
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Figure 4.24B:  Time–kill assay data comparing E. coli killing by rAvBD9 peptides. Data presented as Mean±SEM.  Experiments=2, Replicates=6.   * P<0.05. * * P<0.01. Data were 
analysed using one way ANOVA, followed by Dunnett’s multiple comparison test.  
** 
** 
** 
* 
* 
* 
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At concentrations of 25 and 50 μg/ml pro-microbial activity, >100% E. coli survival, was 
recorded when AvBD9 6CA/G and AvBD9 W38G peptides were used in the time-kill 
assay. To explore whether the bacteria were utilising the recombinant peptides as a nutrient 
source, two non-antimicrobial proteins, bovine serum albumin (BSA) and the recombinant 
GST tagged 3C enzyme (GST-3C), were used at 25 μg/ml along with AvBD9 and AvBD9 
W38G in the time-kill assay. The resultant data shown in Figure 4.25 showed that all three, 
AvBD9 W38G, BSA and GST-3C, enhanced the growth of E. coli with survival recorded 
as 140±26, 125 ±1.0 % and 119±1.0%. These data suggested that in the absence of 
antimicrobial peptide killing effects, the E. coli were able to exploit the recombinant 
peptides as a nutrient source, hence the >100% values.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.2.4.Dimerization of AvBD9 3CA 
Mutagenesis of cysteines C1, C2 and C6 to alanines did not affect the antimicrobial 
effectiveness of the AvBD9 peptide. Previous work (Campopiano et al., 2004) focussed on 
mouse defensin, Defr1, explained the antimicrobial activity of this five cysteine molecule 
through the formation of intermolecular disulphide bonds and a dimer tertiary structure. To 
explore the possibility of AvBD9 C3A dimer formation through intermolecular disulphide 
bond formation, the AvBD9 C3A peptide was analysed using NUPAGE following 
*** 
* 
Figure 4.25 Time–kill assay data comparing E. coli killing by rAvBD9 mature, rAvBD9 W38G; 
GST-3C and BSA. Experiments=2, Replicates=6.  Mean±SEM, P<0.05. *** P<0.001. Data 
were analysed using one way ANOVA, followed by Dunnett’s multiple comparison test.  
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incubation for 10 minutes in either reducing or non-reducing conditions. AvBD9 wild type 
was used as the control. The results, Figure 4.26, showed that AvBD9 wild type migrated 
as a single band in non-reducing conditions (Lane 1), compared to the AvBD9 3CA variant, 
which migrated as two bands (Lane 2). In reducing conditions (Lanes 3 and 4), both 
peptides migrated as single bands with molecular weights of approximately 4.5 kDa. The 
double bands of 4.5 and 9 kDa (Lane 2) suggested that the AvBD9 C3A peptides formed 
dimers, with inter molecular disulphide bond formation occurring between the free 
cysteines of the two peptide molecules.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, as AMAs were not performed under reducing conditions it was not possible to 
directly relate the AMA of AvBD9 3CA to the formation of the tertiary molecule.  
 
 
 
AvBD9 
3C/A 
AvBD9  
Mature 
AvBD9 
3C/A 
AvBD9  
Mature 
3 
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20 
30 
M 
4.5kDa 
9 kDa 10 
Non-reducing Reducing 
1 2 4 
3.5 
Figure 4.26 NUPAGE gel stained with Instant Blue and comparing AvBD9 mature 
and AvBD9 3CA in both reducing (1 and 2) and non-reducing (3 and 4) conditions. 
Novex sharp prestained protein marker (M).  
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4.4.2.5.AvBD9 AMA against E. faecalis  
The AMAs of the mature and mutated AvBD9 peptides were also tested against E. faecalis. 
As data indicated that the hexamer pro-piece sequence had no effects on killing the assays 
did not include the AvBD9 promature peptide. The results are shown in Figure 4.27.  
The pro-microbial activities recorded at 10 μg/ml suggested that, as observed with E. coli, 
the E. faecalis bacteria were using the recombinant peptides as a nutritional growth source.  
At 25 µg/ml the data were characterised by large error bars, but statistically the AvBD9 6C 
A/G and AvBD9 W38G peptides showed no antimicrobial activity. However, both the 
AvBD9 mature and AvBD9 3CA peptides were antimicrobial resulting in 20.8% 
(79.2±34.4% survival) and 69% (41.0±12.5% survival) E. faecalis killing. The significant 
reduction in AvBD9 6CA/G AMA compared to AvBD9 3CA further supported the 
significance of the dimer molecules, via intermolecular disulphide bonding, in E. faecalis 
killing. 
No statistical differences in AMA were observed between the AvBD9 variants at 50 µg/ml, 
although again these data were characterised by large error bars. Of note was the reduced 
AMA of the AvBD9 W38G peptide 15.1 % (84.9±20.5 % survival) compared to that of the 
mature AvBD9 53.3 % (46.7±20.1% survival). This difference in AMA was significant 
(P<0.05) at 100 μg/ml and supported the importance of the AvBD9 C-terminal tryptophan 
in bacterial killing. 
The antimicrobial activities of all the AvBD9 variants were similar at the highest 
concentration tested, 250 μg/ml. 
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Figure 4.27 Time–kill assay data comparing E. faecalis killing by rAvBD9 peptides. Data presented as Mean±SEM.  Experiments=3, Replicates=9. * 
P<0.05. Data were analysed using one way ANOVA, followed by Dunnett’s multiple comparison test. 
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4.4.3. Recombinant AvBD10 production and AMA  
The AMA data highlighted the potential importance of the C-terminal tryptophan in the 
AMA of AvBD9. AvBD10 has no tryptophan at its C-terminal or indeed within its primary 
sequence of 46 amino acids (Figure 4.12). Thus to further explore the importance of the C-
terminal tryptophan in bacterial killing the C-terminal alanine of AvBD10 was replaced by 
a tryptophan and the impact of the aromatic hydrophobic residue on AvBD10 A45W 
explored.  
4.4.3.1.AvBD10 site directed mutagenesis: 
The recombinant plasmid for mature AvBD10 was previously constructed by colleagues 
Kevin Caldwell and Vanessa Butler (PhDs, Newcastle University) and the DNA sequence 
is shown in Figure 4.28A. In this study, and using site-directed mutagenesis, a tryptophan 
was substituted for Alanine 45 in the AvBD10 primary sequence (Figure 4.28B). Both 
mutagenised and mature AvBD10 plasmids were transformed into BL21, the GST tagged 
proteins hyperexpressed and the peptides purified as described previously for AvBD9. 
Results of the purification are shown in Figure 4.29.  
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A 
B 
Figure 4.28 AvBD10 DNA sequences of the mature (A) and mutagenized plasmids (B). 
Restriction sites (BamH1) and (EcoR1) are highlighted in grey. The green sequence shows the 
mutated codon changed from Alanine (GCG) to Tryptophan (TGG).  
 
 
128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The average yields of AvBD10 and AvBD10 A45W were 0.13 and 0.09 mg/L (Table 4.3).  
 
 
 
 
4.4.3.2.AvBD10 AMA against E. coli   
Radial immuno-diffusion and time-kill colony counting assays were used to compare the 
AMAs of the mature AvBD10 and AvBD10 A45W recombinant peptides. The immuno-
diffusion assay was performed to quickly verify AMA and the data relating to E. coli is 
shown in Figure 4.30. 
1 M 3 2 4 
3.5 
15 
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40 
30 
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50 
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160 
260 
5 kDa 
26 kDa 
31 kDa 
46 kDa 
Figure 4.29 NUPAGE stained by Instant Blue showing purification of AvBD10 
recombinant peptides. CFE (1); GST tagged AvBD10 (2); AvBD10 (5 kDa) cleaved from 
GST tag (26 kDa) by 3 C enzyme (46 kDa) (3); Purified AvBD10 (4). Novox pre-stained 
marker (M).  
AvBDs Mean±SEM (mg/L) n
10 wild type 0.13± 0.04 3
10 A45W 0.09± 0.02 3
Table 4.3 Final yields of AvBD10 and AvBD10 A45W (mg/L bacterial growth media) 
purification. Mean±SEM.  n is number of purifications. 
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Both the mature and mutated AvBD10 peptides showed antimicrobial activity against E. 
coli and although the analyses was subjective no obvious differences were observed 
between the two peptides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The time-kill assay data relating to the AvBD10 peptides and E. coli survival is shown in 
Figure 4.31. The kill curves relating to AvBD10 and AvBD10 A45W were comparable and 
in fact almost super-imposed. However, these data indicated that the mature and A45W 
mutant peptides were poor antimicrobial agents. For example 50 μg/ml doses of mature and 
A45W mutant peptides killed <10% E. coli [4.3 % (95.7±34.1 % survival) and 6.9 % 
(93.1±38.9 % survival) respectively]. Moreover the AMAs of both peptides remained 
constant at 100, 250 and 500 μg/ml and did not even reach 75% killing; at the highest 
concentration tested, 500 μg/ml, AvBD10 and AvBD10 A45W achieved only 69.3% and 
74.1 % E. coli  killing (31.7±7.1 % and 25.9±8.1 % survival), which compared to >90% 
(92%) for AvBD9 (Figure 4.24B). These data indicated that AvBD10, characterised by 
reduced numbers of positively charged amino acids, is less active in killing gram negative 
bacteria.   
 
PBS 
25 % 
AvBD10 A45W 
3 µg/µl 
AvBD10 mature 
3 µg/µl 
A 
B C D 
Figure 4.30 Radial immuno-diffusion assay comparing the AMAs of AvBD10 mature and 
AvBD10 A45W (A) using E. coli grown on TSB (C). PBS negative control (B). Cecropin, 1 
μg/μl, positive control (D). 4 X magnifications. 
 
 
130 
 
No statistical differences were observed between the AMA of mature AvBD10, which has 
no tryptophan at its C terminus, and the mutant AvBD10 A45W in which the C-terminal 
alanine 45 was changed to a tryptophan. These data indicated that the tryptophan had not 
increased the AMA of AvBD10 against E. coli.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.3.3.AvBD10 AMA against E. faecalis   
Similar results were observed in relation to the effects of AvBD10 and AvBD10 A45W on 
the survival of the gram positive isolate E. faecalis (Figure 4.32), with the kill curves again 
comparable and in fact over-lapping. These data also suggested that a C-terminal 
tryptophan is not important for the killing of E. faecalis by AvBD10.  However, in contrast 
to the E. coli killing curves, these data showed increased bacterial killing at lower peptide 
concentrations. For example using 10 μg/ml AvBD10 and AvBD10A45W peptides, killing 
was recorded as 45.0 % and 61.9 % (55.0±5.1 % and 39.1±15 % survival) respectively, 
which compared to >100% survival with E. coli  (Figure 4.31).  
Using 50 μg/ml, 83.4 % and 84.1 % E. faecalis killing (17.6±4.0 % and 15.9±3.0 % 
survival) was recorded using the mature and mutant AvBD10 peptides. Following a five-
fold increase in the peptides to 250 μg/ml the killing values reached only 88 % (12.0±5.1 % 
survival) and 87.4 % (12.6±5.8 % survival), but again were greater than those observed for 
E. coli. Overall, these data suggested that the AvBD10 peptides had increased activity 
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Figure 4.31 Time–kill assay data comparing E. coli killing by rAvBD10 mature and AvBD10 
A45W peptides. Data presented as Mean±SEM.  Experiments=3, Replicates=9.     
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against gram positive organisms, but that the C-terminal tryptophan residue had no impact 
on AvBD10 AMA against E. faecalis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5.Time-kill assays using synthetic AvBD peptides 
In addition to using recombinant peptides in the time-kill antimicrobial assays three 
synthetic peptides were also used, but with the knowledge that these peptides were 
synthesised and supplied as linear molecules. The three linear synthetic AvBD peptides 
were sAvBD6 mature, sAvBD9 mature and sAvBD9 W38G; these peptides were HPLC 
purified and 95% pure. 
The HPLC data provided by Protein Peptide Research Ltd shows the purity of the sAvBD6, 
sAvBD9 and sAvBD9 W38G fractions and their collection times, 8.1, 9.5 and 7.3 minutes 
post injection (Figures 5.33-35).   
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Figure 4.32 Time–kill assay data comparing E. faecalis killing by AvBD10 mature and 
AvBD10 A45W peptides. Experiments=3, Replicates=9.  Mean±SEM. 
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Figure 4.34 HPLC analysis of mature sAvBD6 
Figure 4.33 HPLC analysis of mature sAvBD9 
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4.5.1. Comparison of synthetic and recombinant AvBD6 mature, AvBD9 mature and 
AvBD9 W38G peptide AMAs against E. coli   
The AMAs of the synthetic and recombinant peptides against E. coli were compared at 50 
and 100 μg/ml (Figure 4.36). Using 50 μg/ml (Figure 4.36 A), the recombinant AvBD6 and 
9 mature peptides killed 56% and 50% (44.0±2.6 and 51.3±12.4 % survival) of the E. coli, 
but surprisingly the synthetic peptides appeared inactive with E. coli survival reproducibly 
>100%.  
This result was also observed at 100 μg/ml, where the E. coli  survival rates following 
incubation with the recombinant AvBD mature peptides, AvBD6 and AvBD9 mature, were 
31.1±7.3 % (78.9 % killing) and 35.7±7.2 % (74.3 % killing), while the survival rates 
relating to the synthetic peptides, sAvBD6 and sAvBD9 were again >100% (Panels B and 
C). Bacterial survival >100% suggested degradation of the synthetic peptides and the 
bacterial usage of the amino acid/peptide fragments as growth nutrients. A similar pattern 
(Panel D) was observed using AvBD9 W38G with recombinant (r )AvBD9 W38G killing 
19.9 % E. coli  (80.1±11.6 % survival) while synthetic AvBD9 W38G actually supported 
bacterial growth (>100% survival).  
These data suggested that the synthetic linear AvBD peptides were inactive against E. coli.
Figure 4.35 HPLC analysis of AvBD9 W38G 
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Figure 4.36 Time–kill assay data comparing E. coli killing by synthetic and recombinant peptides. AvBDs 6 and 9 at 50 μg/ml (A); AvBD6 at 100 μg/ml (B); 
AvBD9 at 100 μg/ml (C); AvBD9 W38G at 100 μg/ml (D). Data presented as Mean±SEM.  Experiments=2, Replicates=6.  *P<0.05, ** P< 0.01 and *** 
P<0.001. 
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4.5.2. Comparison of synthetic and recombinant AvBD6 mature, AvBD9 mature and 
AvBD9 W38G peptide AMAs against E. faecalis  
In contrast to the E. coli data, there were no significant differences between the killing 
activities of the recombinant and synthetic peptides when E. faecalis was used in the time-
kill assays (Figure 4.37). For example using rAvBD6 and rAvBD9 mature peptides at 50 
µg/ml, 66.2% (33.8±1.6 % survival) and 53.3 % (46.7±20.1 % survival) E. faecalis killing 
was observed. At the same concentrations, the synthetic peptides, sAvBD6 and sAvBD9 
killed 47.5 % (52.5±11.4 % survival) and 19.2 % (80.8±13.9 % survival) E. faecalis. These 
data suggested that both recombinant and linear synthetic AvBDs were active against E. 
faecalis but that the recombinant peptides were the more potent killing agents. However, 
using synthetic AvBD9 W38G resulted in >100% E. faecalis survival. The data using the 
recombinant peptide supported only weak killing, 15.1 % (84.9±20.5 % survival), which 
again supported a role for the C-terminal tryptophan in E. faecalis killing. 
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Figure 4.37 Time–kill assay data comparing E. faecalis killing by synthetic and recombinant 
peptides. AvBDs 6 and 9 at 50 μg/ml (A); AvBD6 at 100 μg/ml (B); AvBD9 at 100 μg/ml (C); 
AvBD9 W38G at 100 μg/ml (D).  Experiments=2, Replicates=6.  Mean±SEM.  
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4.5.3. Effect of proteases and buffer ionic strength on sAvBD6/9 and rAvBD6/9 AMAs 
against E. coli  
Section, 4.5.1 showed that using the synthetic peptides in the time-kill assays involving E. 
coli, resulted in bacterial growth as opposed to killing and suggested that the linear 
synthetic peptides were easily degraded in the assay. It was hypothesised that this occurred 
due to production and activity of bacterial proteases with the amino acids, and peptide 
fragments, exploited nutritionally by the bacteria for growth. That the time-kill assay data 
supported E. faecalis killing by the synthetic peptides (section 4.5.2), suggested that the 
gram positive bacteria were unable to produce such proteases.  
To explore the protease idea further, the E. coli BL21 strain, which lacks the outer 
membrane proteases OmpT and lon was used in the AMA assays instead of the original E. 
coli clinical isolate. Additionally protease inhibitors were employed as well as sodium 
phosphate (NaP) buffer (10 mM), which contained no sodium chloride.  Sodium chloride 
has been proposed to reduce the AMA of defensins (Bals et al., 1998; Garcia et al., 2001).  
The data (Figure 4.38) showed that sAvBD6 (100µg/ml) was inactive (p<0.05) against the 
chicken E. coli clinical isolate compared to rAvBD6 (Panel A). Interestingly however, 
sAvBD6 was as active as rAvBD6 against E. coli BL21, which lacks the two major outer 
membrane proteases (Panel B). Furthermore, using protease inhibitors (Panels C and D) 
described in section 2.22, and sodium phosphate buffer (NaP) (Panels E and F) significantly 
increased the AMA of sAvBD6 and resulted in complete killing of both the clinical and 
BL21 E. coli  strains at 100 µg/ml. Less marked effects were observed with the rAvBD6 
peptide. 
These data suggested that both bacterial proteases and the ionic strength of the assay buffer 
had negative effects on the AMA of the synthetic but not the recombinant AvBD6 peptide. 
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Figure 4.38 Time-kill assay data using 100 μg/ml of synthetic and recombinant AvBD6 peptides against E. coli  clinical isolate (A, C and E) and BL21 (B, D and F) in PBS (A 
and B), protease inhibitors (C and D), and sodium phosphate (NaP) buffer 10 mM (E and F). Experiments= 2, Replicates=6 Mean±SEM. *P<0.05 and **P<0.01 
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Using rAvBD9 and AvBD9 W38G at 100 μg/ml against E. coli  (Figure 4.24B) detected 
64.3 % (35.7±7.2% survival) and 19.9 % (80.1±11.6 % survival) killing, compared to 0% 
killing using sAvBD9 and sAvBD9 W38G (Figure 4.39, Panel A). However, unlike 
sAvBD6, sAvBD9 and its variants still showed no AMA against the E. coli BL21 strain 
(Panel B). Moreover, replacing PBS buffer with sodium phosphate buffer (Panels E and F) 
did not alter the data.  This suggested that decreasing the buffer salt concentration had no 
impact on the AvBD9 killing mechanisms. Using a cocktail of protease inhibitors did not 
affect the activity of sAvBD9 against the E. coli  clinical isolate (Panel C), but it did rescue 
the AMA of the peptide against BL21 (Panel D), with 54.1% (45.9±1.2 % survival) killing 
recorded. Additionally 12.8 % killing (87.2±7.3 survival) was observed for sAvBD9 W38G 
respectively (Panel D). These data suggested that proteases, in addition to OmpT and lon, 
were involved in the degradation and thus inactivation of sAvBD9. Additionally, the 
significant difference (p<0.05) in the AMA of sAvBD9 and sAvBD9W38G against BL21 
in presence of protease inhibitors (Panel D), suggested that the C-terminal tryptophan does 
play a role in AvBD9 bacterial killing.  
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Figure 4.39 Time-kill assay comparing synthetic AvBD9 peptides against E. coli clinical isolate (A, C and E) and BL21 strain (B, D and F) in PBS (A 
and B), protease inhibitors (C and D), and sodium phosphate (NaP) buffer 10 mM (E and F). Experiments=2, Replicates=6 Mean±SEM *P<0.05 
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4.6.Discussion 
The previous chapter indicated that the gut expression of the AvBD6 and 9 genes by 
Aviagen broiler chickens was not affected by the rearing environment. These data 
suggested that the encoded defensin peptides were little importance in the host defences 
and in controlling the gut microbiota.  
The AvBD peptides, because of their primary amino acid sequences, which contain six 
cysteines as well as cationic and hydrophobic residues, are predicted to be antimicrobial 
agents, but their AMA has still to be proven. Thus the aim of this chapter was to synthesise 
recombinant AvBD6 and 9 peptides and explore their AMA against Gram negative and 
Gram positive bacteria, focussing particularly on bacteria isolated from the chicken gut.  
The procedure used to produce the recombinant (r) AvBD6/9 peptides involved a GST 
hyper-expression system and was relatively successful. The recombinant peptides were 
purified without their GST tags, which compared favourably to other studies in which the 
researchers utilized GST or His tagged peptides in their peptide functionality studies 
(Milona et al., 2007; van Dijk et al., 2007; Wang et al., 2010b). During the procedures, 
rAvBD6 was identified as less soluble than rAvBD9, which was probably due to protein 
misfolding or partial folding resulting in inclusion body formation (Villaverde and Carrio, 
2003), and this made AvBD6 purification challenging. In fact the inability to completely 
remove GST protein from the AvBD6 peptide preparations (Figure 4.10) was probably due 
to presence of a large number of both hydrophobic and cationic residues in the peptide 
affecting its solubility (Figure 4.40) and hence reducing the efficiency of GST cleavage. It 
was however interesting that the presence of a six hexamer pro-piece increased the yield of 
AvBD9 (AYSQED) but not AvBD6 (GQPYFS). This was probably due to the presence of 
aromatic hydrophobic residues (YF) in the latter and anionic residues (ED) in the pro-piece 
of the former peptide.  
To assess the bacterial killing functions of the recombinant peptides two antimicrobial 
assays were used. The first, a radial immuno-diffusion assay system used bacterial lawns, 
involved small amounts of peptide and killing was assessed by observing circles or zones 
of cleared bacteria (Figure 4.17). The technique involved measuring the diameter of the 
Figure 4.40: amino acid sequences of AvBD6 and 9. Yellow: cysteine, blue: cationic, red: 
anionic, green: aromatic hydrophobic, grey: glycine and underline: pro piece 
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zones, and equating each value to bacterial killing, but because of poor assay 
reproducibility, often due to the thickness of the bacterial lawn, it was difficult to quantitate 
the resultant data.  Thus this method was very subjective and qualitative. Therefore, a 
quantitative time-kill colony counting assay (Townes et al., 2004) was used to confirm all 
the data.  All peptide variants were successfully tested and their bacterial killing properties 
compared using this method. 
Previous work has suggested that the pro-piece of an AMP, which is generally anionic, 
reduces the AMA of the peptide, for example mouse α-defensin, cryptdin-4 (Figueredo et 
al., 2009). In fact in vivo, pro-pieces are generally cleaved to activate the peptide (Lynn et 
al. 2004, van Dijk et al. 2008). However, the predicted pro-pieces of the AvBDs are either 
absent or small (6 amino acids) and to date it is not known whether or not they are cleaved 
in vivo (Xiao et al. 2004, van Dijk et al. 2007). However, the fact that the AMAs of the 
promature and mature (no pro-piece) AvBD6 and 9 peptides were similar against E. coli 
(Figures 4.22 and 4.24) probably relates to the small sizes of each pro-piece and the rarity 
of negatively charged amino acids reducing the anionic charge. Moreover, these two pro-
pieces contain hydrophobic amino acids e.g., A, F, P and Y that may function in facilitating 
membrane perforation and disruption (Soman et al., 2010; Tai et al., 2014).  
AvBDs, like all β-defensins, have six conserved cysteines, which are reported as necessary 
for structural conformation (van Dijk et al., 2008). However, their contribution to peptide 
antimicrobial activity is still debatable (Maemoto et al., 2004; Chandrababu et al., 2009; 
Derache et al., 2012; Zhao et al., 2012). It was not known whether the rAvBD6 and AvBD9 
peptides synthesised in this study and containing 6 Cys (C) were correctly folded ie C1-C5, 
C2-C4 and C3-C6.  None-the-less, mutagenising three of the cysteines of AvBD9 ie C1, 
C2 and C6 to alanines did not affect its AMA profile (Figures 4.24 and 4.27). As the 
mutagenesis did not significantly affect the charge of the peptide (+3.8 to 4) (Innovagen 
peptide property calculator: http://pepcalc.com/), the data suggested that a correctly folded 
structure is not essential for AMA. Following mutagenesis, each AvBD9 3CA peptide had 
3C and based on the report of a mouse defensin, Defr1 with 5 cysteines it was predicted 
that two of these 3C could form, naturally an internal di-S bond leaving one free C 
(Campopiano et al., 2004). The free C of one AvBD9 3CA molecule could then form a 
disulphide bond with the free C of another AvBD9 3CA molecule, thus creating a dimer 
molecule (Figure 4.41).  Gel electrophoresis (Figure 4.26) confirmed this occurred in vitro 
and these data suggested the dimer molecules were contributing to the observed AMA. This 
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was further supported by the fact that removal of all cysteines resulted in reduced E.coli 
killing (Figure 4.24). Yet, the AvBD9 6CA/G peptide was still active against E. faecalis 
(Figure 4.27), which suggested that peptide folding was more important for AvBD9 AMA 
against gram negative than gram positive microbes. Interestingly, this result contrasted to 
that found for AvBD2, in which disulphide bonds were required for its AMA against gram 
positive compared to gram negative bacteria (Cuperus et al., 2013). Collectively, these data 
indicate that the impact of the C amino acids on the functionality of the AvBDs cannot be 
generalised. Folding however produces a globular molecule that is more protected than a 
linear one from proteolysis caused for example by bacterial proteases. Indeed data relating 
to the AMA of linear AMP peptides may reflect the ability of the bacteria studied to 
synthesise degradative proteases.    
 
 
 
 
 
 
 
 
 
 
 
 
 
The identification of evolutionarily conserved amino acids has been linked to the functional 
activity of the defensin peptides (Yeaman and Yount, 2003). Interestingly, the four amino 
acids, CCKW, located at the C-terminal end of AvBD9 (Figure 4.12) also appear conserved 
in the predicted AvBD9 peptide sequences of other avian species including pheasant and 
quail (Kannan et al., 2013). Moreover, ten out of the 14 AvBDs have a C-terminal 
tryptophan (Figure 4.12) suggesting a critical role for this amino acid in AMP function. 
Additionally as the C-terminal location of the tryptophan promotes its flexibility and the 
fact that tryptophans are known to help anchor peptides into membranes which facilitates 
membrane permeation (Kluver et al., 2005; Kim et al., 2013) argues strongly for a role of 
Figure 4.41: Predicted inter molecular disulphide bonds between two monomers of 
AvBD9 3CA leading to dimer formation 
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the C-terminal tryptophan (W38) in AvBD9 AMA. In fact the argument strengthens as 
mutagenising the C-terminal W in the mature peptide to a glycine resulted in the loss of 
AvBD9 AMA (Figures 4.24 and 4.27). Disappointingly, however, engineering AvBD10 to 
contain a C-terminal tryptophan did not enhance its AMA properties. Only AvBDs 8, 10, 
12 and 13 do not contain a C-terminal tryptophan and interestingly all have charge at pH7 
of ≤ 2. Previous studies have shown baseline AvBD10 expression to be significant in tissues 
such as the kidney and testes (Butler, 2010), that are not exposed continuously to microbes, 
thus it is feasible that an increased overall charge is just as important as a C-terminal 
tryptophan in AMA and both together are not required for AvBD AMA. 
The inability to completely purify AvBD6 prompted the use of custom synthesised 
peptides, the disadvantage being that the peptides were supplied as linear and not pre-folded 
molecules. Surprisingly, however, when the synthetic peptides were used against E. coli 
they appeared pro-microbial (Figure 4.36) ie supporting rather than decreasing bacterial 
growth, although antimicrobial activity was detected against E. faecalis (Figure 4.37).  
Previous studies have found that there are several mechanisms through which microbes, 
particularly human pathogens, can acquire resistance to AMPs and one such mechanism is 
the secretion of proteolytic enzymes that degrade linear peptides (Nizet, 2006). For 
example, the heat shock serine protease DegP increases the survival of E. coli and S. aureus 
against killing by Lactoferricin B (Ulvatne et al., 2002; Yeaman and Yount, 2003). 
Similarly, the outer membrane protease, OmpT, also plays an important role in the 
degradation of AMPs with an E. coli  OmpT mutant strain showing increased sensitivity to 
protamine (Yeaman and Yount, 2003). In this study, the promicrobial data suggested 
proteolytic degradation of the linear peptides by enzymes synthesised by the chicken gut 
E.coli isolate and the use of the resultant amino acids as a nutrient supply. This was 
supported by the sAvBD6 killing of protease (OmpT and lon) negative E.coli mutant strains 
and these data also highlighted potential pathogenicity factors ie proteases, synthesised by 
the chicken E.coli isolate.  
Two studies have examined the impact of high salt buffers on the antimicrobial properties 
of AvBDs. For example, a high salt concentration (150 mM NaCl) reduced the AMAs of 
duck AvBD1, 3, 5, 6, and 16 against Micrococcus tetragenus and Pasturella multocida, 
and geese AvBD1, 3 and 6 against S. aureus and P. mirabilis (Ma et al. 2012, Ma et al. 
2013). Similarly, synthetic linear ostrich AvBD2 and 7 showed decreased AMA at 100 
mM, and no AMA at 150 mM, salt concentration, against E. coli  and S. aureus, and to 
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explain this the authors suggested the ionic strength of the buffer was inhibiting peptide 
binding to the bacterial membrane (Lu et al., 2014). In this study, a similar effect was noted 
for AvBD6 as the linear synthetic AvBD6 exhibited reduced AMA in PBS compared to 
NaP buffer although this effect was not observed for sAvBD9. It is difficult to explain these 
data but may relate to the high charge (+7) of the AvBD6 peptides at pH 7.  Interestingly 
the AMA of folded AvBD9 against both Gram positive and negative bacteria has been 
reported to be inactivated in high salt (150 mM),  but rescued using sodium phosphate 
buffer (10 mM) or low salt buffer (20 mM) (van Dijk et al., 2007). However, the rAvBD9 
used in this study and presumably at least partially folded, was highly active against E. coli 
in PBS (Figure 4.24).  
4.7.Conclusions 
rAvBD6 and 9, both promature and mature peptides, were hyperexpressed and purified in 
vitro and shown to have AMA against two isolates, Gram negative E. coli  and Gram 
positive E. faecalis,  isolated from the chicken GI tract.  
The synthesis and purification of mutant peptides AvBD9 3CA, AvBD9 6CA/G, AvBD9 
W38G, indicated the functional importance of the cysteine and C-terminal tryptophan 
amino acids in AMA.  
rAvBDs 6 and 9 were shown to have AMA against bacteria isolated from the chicken 
gastrointestinal tract thus supporting their in vivo  roles as host defence molecules.  
The next chapter will investigate the secondary structure and membrane disruptive ability 
of the AvBD6 and 9 using CD spectra and calcein-entrapped liposomes.  
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Chapter 5  
5. AvBD structure-membrane interactions (Part I) 
5.1.Introduction 
In Chapter four, AvBDs 6 and 9 were shown to have antimicrobial activity against E. coli 
and E. faecalis.  Moreover, the data using recombinant and chemically synthesised peptides 
suggested the importance of the disulphide bonds, and the C-terminal tryptophan in AvBD 
killing.  
Cationic peptides have been reported as killing microbes through mechanisms involving 
membrane interactions that can be described by one or more of four models namely the 
aggregate, toroidal pore, barrel stave and carpet models (Jenssen et al., 2006). 
Fundamentally each model exploits the cationic and hydrophobic amino acid structure of 
the AvBDs; the cationic charge facilitates electrostatic interaction with negatively charged 
bacterial membranes and the hydrophobicity enables insertion of the defensin molecule into 
the membrane causing its disruption and bacterial cell death (Jenssen et al., 2006).  
To further explore the actual interactions of AvBD6 and 9 with bacterial cell membranes 
in vitro models were adopted. The first in vitro system utilised sodium dodecyl sulphate 
(SDS), which forms a negatively charged micelle that mimics the microbial membrane.  
The AvBD peptides were each mixed with the micelles and any structural changes 
occurring in the peptides following this interaction were determined using circular 
dichroism (CD).  
The second in vitro system, known as a calcein leakage assay, used calcein entrapped 
liposomes to explore the membrane destructive ability of the AvBD peptides. The 
liposomes used in this study represented a mixture of phospholipids including 
phosphatidylcholine, phosphatidylethanolamine and inositol phosphatides, a class of 
phosphatidylglycerol, with the latter two phospholipids being major components of the E. 
coli  lipid membrane (Ruiz et al., 2006). Calcein is a self-quenched fluorescent dye, which 
can be trapped inside the liposomes and its release, following peptide addition, is detected 
using fluorimetry.  
The aim of this chapter was to use the in vitro systems described to further explore the 
mechanisms underpinning the microbial killing properties of AvBD6 and 9. This work was 
performed in collaboration with Professor Jeremy Lakey (Newcastle University). 
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5.2.Secondary structure-membrane interaction activities of recombinant AvBD9 
peptides 
The reduced purity of rAvBD6, caused by GST contamination (Figure 4.10), meant that 
rAvBD6 could not be used in any of the following analyses. However, the 
structure/membrane interactions of rAvBD9, rAvBD9 3CA, rAvBD9 6CAG and rAvBD9 
W38G were investigated using (i) SDS micelles and CD analyses and (ii) leakage assays 
employing calcein entrapped liposomes.   
5.2.1. CD spectra of recombinant AvBD9 peptides 
The freeze dried rAvBD9 peptides were reconstituted in water to 500 μg/ml, mixed with 
either 50mM sodium phosphate buffer (NaP) or 1% SDS at a final peptide concentration 
of 250 μg/ml and the CD spectra measured using a Jasco-810 CD spectropolarimeter at a 
range (250-185nm). The CD measurements of the machine (θ) in millidegree were changed 
to delta epsilon (Δε), which is the per residue molar absorption unit (M -1cm-1) directed by 
the following equation: 
Δε=θX(0.1*MRW)  
      (P * CONC) * 3298 
Mean residue weight ((MRW) =protein mean weight (in atomic mass units/ daltons)/ number of 
residues) for the protein, path length (P) in cm and protein concentration (CONC) in mg/ml:  
(http://dichroweb.cryst.bbk.ac.uk/html/userguide.shtml). 
Typical peptide conformations are shown in Figure 5.1 (Woody, 2010). An α-helix displays 
as two negative absorption bands at 208 and 222 nm, and a positive absorption band below 
200 nm (Line A). A βeta-sheet structure displays as a negative absorption band at 217 nm 
and a positive absorption band below 200 nm (Line B). A β-turn structure displays a broad 
negative absorption band between 205-220 nm and a positive absorption band at 200 nm 
(Line C). Unordered peptides display as a positive absorption band at 212 nm and a 
negative band at 195 nm (Line D). 
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The CD spectrum of rAvBD9 mature peptide (blue) (250 μg/ml) in 50 mM NaP buffer is 
shown in Figure 5.2 A. The spectrum displays as a broad negative absorption band from 
195 to 215 nm with maximum absorption at 203 nm (-2.5 M-1cm-1). These data suggested 
that the peptide was folded and contained a mixture of β-sheet, α- helices, β-turns and 
unordered structures. The CD spectra also supported the rAvBD9 3CA peptide (red) being 
more folded than either the rAvBD9 W38G (purple) or rAvBD9 6CA/G (green) peptides. 
This was deduced because rAvBD9 3CA showed maximum absorption at 200 nm (-4.3 M-
1cm-1), while the latter peptides rAvBD9 W38G and rAvBD9 6CA/G both displayed 
maximal absorption at 199 nm (-5.2 M-1cm-1) and (-7.0 M-1cm-1) respectively.  
 
 
 
 
 
A 
B 
C 
D 
α-Helix 
β-sheet 
-turn 
Unordered 
Figure 5.1 CD spectra of standard peptide conformations Α-helix (A), β-sheet (B), type I β-turn 
(C), Unordered (D). (Woody, 2010). 
 
 
 
148 
 
 
 
 
 
 
 
 
 
 
To quantitate the secondary structures of the rAvBD9 peptides an online software 
programme, Dichroweb (http://dichroweb.cryst.bbk.ac.uk/html/process.shtml), was used 
(Whitmore and Wallace, 2004; Whitmore and Wallace, 2008) as described in Section 2.24. 
The results are shown in Table 5.1 and Figure 5.2 B. 
These data supported folding of the rAvBD9 mature peptide and predicted 52.4 % β-sheet, 
19.4 % α-helix, 20.2% β-turns and 7.9% unordered structure. In comparison rAvBD9 3CA, 
which contains only three cysteines was predicted to contain 29.6 % β-sheet and 31.7% 
unordered structure, which suggested only partial folding of the peptide. Interestingly, these 
data were comparable to that of rAvBD9 W38G, which contained all six cysteine amino 
acids. The CD spectra data indicated 40.1% unordered structure for the rAvBD9 6CAG 
variant. The lack of cysteines was therefore associated with a predominantly disordered 
structure.  
 
  
Figure 5.2 CD spectra of recombinant AvBD9 variants in 50 mM Na P buffer 
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Figure 5.2 B: Pie charts showing quantification of CD secondary structures (%) including α-helices (Blue), β-strands (Red), β-turns (Green) and 
unordered (Purple) following exposure of rAvBD9 variants to 50 mM NaP buffer. 
Table 5.1 Dichroweb quantification of CD secondary structures (%) including α-helices, β-
strands, β-turns and unordered structure following exposure of rAvBD9 variants to 50 mM 
NaP buffer. 
Peptides α-Helices % β-Strands % β-Turns % Unordered %
rAvBD9 19.4 52.4 20.2 7.9
rAvBD9 3CA 15.5 29.6 23.2 31.7
rAvBD9 6CAG 12.9 24.4 22.5 40.1
rAvBD9 W38G 12.1 27.7 24.7 35.4
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Sodium dodecyl sulphate (SDS) is an anionic detergent, which spontaneously forms 
micellar structures each with a hydrophobic core and hydrophilic exterior thereby 
mimicking the negatively charged  phospholipid bilayer of bacterial membranes (Lindberg 
and Graslund, 2001). Therefore, to investigate AvBD peptide interactions with bacterial 
membranes, the rAvBD peptides were exposed to 30 mM (1%) SDS micelles (section 2.24) 
as described previously (Hu et al., 2013; Bi et al., 2014).  
The resultant data are shown in Figure 5.3 A.  Qualitatively both rAvBD9 mature (Blue) 
and rAvBD9 3C A (Red) displayed disordered structures as evidenced by the absorption 
bands (-6.9 M-1cm-1) and (-10.1 M-1cm-1) detected at 197 nm. In contrast, rAvBD9 6CAG 
(Green) showed absorption bands at 201 nm (-11.7 M-1cm-1) and 222 nm (-3.6 M-1cm-1) 
respectively, indicating the ability of these peptides, lacking disulphide bonds, to adopt an 
α-helical conformation.  However, the secondary structure of rAvBD9 W38G (Purple) was 
comparable to previous observations (Figure 5.2) with its maximum absorption, -8.9 M-
1cm-1, recorded at 200 nm.  
 
 
 
 
 
 
 
 
Figure 5.3 A: CD spectra of recombinant AvBD9 variants in 1% SDS micelles 
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Quantification of the CD data is shown in Table 5.2 and Figure 5.3 B. These data showed 
that in the presence of the SDS micelles the β-strand component of rAvBD9 was reduced 
from 52.4 to 31.3 % while the unordered structure increased from 7.9 to 31.9 %. These 
values therefore indicated that exposure to the SDS micelles disrupted the disulphide bonds 
of the rAvBD9 molecule.  Interestingly, mixing rAvBD9 6CAG with the micelles resulted 
in β-strand component of 8.6%, which was three to four times less than the other AvBD9 
variants, but an α-helix structural component of 35.9%, which was three times higher. The 
secondary structures of rAvBD9 3CA and rAvBD9 W38G remained relatively unchanged 
in the presence of the SDS micelles.  
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Table 5.2 Quantification of CD secondary structures (%) including α-helices, β-strands, β-
turns and unordered structure following exposure of rAvBD9 variants to 1% SDS micelle 
solution. 
Peptides+SDS α-Helices % β-Strands % β-Turns % Unordered %
rAvBD9 13.6 31.3 23.2 31.9
rAvBD9 3CA 13.8 33.1 19.3 33.8
rAvBD9 6C AG 35.9 8.6 21.8 33.7
rAvBD9 W38G 11.8 25.1 23.8 39.5
Figure 5.3 B: Pie charts showing quantification of CD secondary structures (%) including α-helices (Blue), β-strands (Red), β-turns (Green) and 
unordered (Purple) following exposure of rAvBD9 variants to 1% SDS micelle solution. 
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5.2.2. Investigations of rAvBD9 peptide/ bacterial membrane interactions using 
calcein leakage assays  
Focussing specifically on the membrane destructive activities of the peptides, rAvBD9 and 
the variants rAvBD9 3CA, rAvBD9 6CA/G and rAvBD9 W38G (10 µg/ml), were exposed 
to calcein dye-entrapped liposomes prepared with phospholipids to resemble the E. coli 
lipid bilayer (Section 2.23). The liposomes were incubated with the rAvBD9 peptides and 
any calcein leakage monitored using a Varain fluorescent spectrophotometer set to 
excitation (493 nm) and emission (505-600nm). The positive control was Triton X-100 (1% 
final concentration).  
As shown in Figure 5.4A, there was no detectable calcein leakage from the liposomes 
during a 60 min incubation period in 50mM NaP at room temperature.  These data indicated 
that the calcein loaded liposomes were stable up to a minimum of one hour. Figure 5.4 
Panel B shows the results of adding Triton X to the liposomes to a final concentration of 
1%. Immediately on adding the detergent the calcein leakage changed from 42.5 AU, which 
was considered as 0 % leakage to 94.7 AU, which was stable up to 5 minutes and regarded 
as 100% leakage.  
The experiments were repeated using the rAvBD9 peptides and the following equation was 
used to calculate any leakage. 
Leakage %= (Fp-F0)/ (Ft-F0) *100% 
Where Fp is the measurement of fluorescent leakage after treating the calcein entrapped liposomes 
with the peptides, Ft is the complete leakage measurement by TritonX and F0 is intact vesicles 
before adding peptide or TritonX (Bi et al., 2013). 
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The results of the calcein leakage assays at 2 to 5 minutes following the addition of the 
rAvBD9 peptides (10 µg/ml final concentration) are shown in Figure 5.5. Calcein leakage 
(mean) within two minutes of peptide addition were: AvBD9 (4.7%), AvBD9 3CA (4.9%), 
AvBD9 6CAG (3.0%) and AvBD9 W38G (2.7). Within 5 minutes the leakage values were 
AvBD9 (14.4%), AvBD9 3CA (15.5%), AvBD9 6CAG (12.6%) and AvBD9 W38G 
(13.3%). These data were characterised by poor reproducibility and no differences between 
the peptides were detected.  
 
B 
A Liposome+ NaP 
Figure 5.4 Calcein leakage recorded using entrapped liposomes incubated for 60 
minutes at room temperature in 50 mM NaP buffer (A); following the addition of  10 % 
Triton X 100 (1% final concentration) (B). 
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5.3.Secondary structure-membrane interaction activity of synthetic AvBDs 
The CD spectra described in section 5.2.1 suggested that changes in rAvBD9 and rAvBD9 
6CAG peptide secondary structures were associated with the peptides interacting with 
target membranes. It was therefore disappointing that the leakage assay data did not 
differentiate between any of the rAvBD9 peptides. However, these assay data were 
compromised by large error bars that may have masked any significant differences. The 
reasons for the large error bars were not known, but the actual purity of the rAvBD9 
peptides, which were not HPLC purified, was a concern. It was also frustrating that due to 
purity issues rAvBD6 secondary structure and membrane interaction properties could not 
be analysed.  
It was therefore decided to use the AvBD6 and 9 synthetic peptides whose purity was 
guaranteed to further explore the potential activity of the AvBDs to cause membrane 
damage and hence cytoplasmic leakage.  
 
 
Mean (range). Experiments=2; replicates=2.  
Figure 5.5 Calcein leakage assay following addition of rAvBD9 and variants to dye-
entrapped liposomes. 
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5.3.1. Circular dichroism of the synthetic peptides 
Although it was acknowledged that the sAvBD6, sAvBD9, sAvBD9 W38G peptides were 
in a linear rather than folded form they were subjected to and analysed by CD as previously 
described for the recombinant peptides.   
5.3.1.1.CD spectra for synthetic AvBD6 peptide 
The CD spectrum for sAvBD6 (250 g/mL) in NaP buffer and shown in Figure 5.6 (blue 
line) revealed a disordered structure (38.4%) with a negative absorption band at 197.5 nm 
(-6.2 M-1cm-1) although β-sheet (25.9%) and β-turn secondary structures (25.1%) were also 
predicted. However, in the presence of SDS micelles mimicking the bacterial membrane 
(red line) the sAvBD6 structure was characterised by two negative absorption bands at 
204.5 nm (-4.6 M-1cm-1) and 220 nm-(2.6 M-1cm-1), and a single positive band at 191 nm 
(+1.4 M-1cm-1), which predicted a mix of α-helix (25.6%), disordered (33.9%) and β-turn 
(23.6%) secondary structure conformations.   
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B: Table and Pie charts show quantification of CD secondary structures (%) including α-helices 
(Blue), β-strands (Red), β-turns (Green) and unordered (Purple) following exposure of sAvBD6 
to NaP and 1% SDS micelle solution. 
  
Peptides Helices% β-Strands % β-Turns % Unordered %
sAvBD6 10.8 25.9 25.1 38.4
sAvBD6 SDS 25.6 17.0 23.6 33.9
A 
B 
Figure 5.6: A: CD spectra of sAvBD6 in NaP buffer (Blue) and 1% SDS micelle solution (Red). 
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5.3.1.2.CD spectra for synthetic AvBD9 variants 
The CD spectra for sAvBD9 (250 g/mL) in NaP buffer and SDS are shown in Figure 5.7. 
In NaP buffer (blue line) the spectrum, characterised by a negative absorption band at 197.5 
nm (-6.5 M-1cm-1), supported a disordered structure (42.4%), but as observed with sAvBD6, 
β-sheet (22.2%) and β-turn secondary structures (24.8%) were present. In the presence of 
SDS (red line), the spectrum was characterised by two negative absorption bands at 202 
nm (-5.4 M-1cm-1) and 220 nm (-2.2 M-1cm-1) and a weak single positive band at 192 nm 
(+0.8 M-1cm-1). As observed for AvBD6 disordered structure again predominated (31.9%), 
but the secondary structure also changed in SDS towards an α-helical conformation (10.5% 
to 25.1%).   
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Figure 5.8 shows the CD spectra for sAvBD9 W38G in NaP buffer (blue line) and 1% SDS 
(red line). The peptide also formed a disordered structure (44.9%) in NaP buffer with single 
negative band at 198.5 nm (-5.8 M-1cm-1). As observed previously β-sheet (19.1%) and β-
turn secondary structures (24.2%) were also present. Following exposure to 1% SDS two 
B: Table and Pie charts show quantification of CD secondary structures (%) including α-
helices (Blue), β-strands (Red), β-turns (Green) and unordered (Purple) following exposure 
of sAvBD9 to NaP and 1% SDS micelle solution. 
 
Peptides Helices% β-Strands % β-Turns % Unordered %
sAvBD9 10.5 22.2 24.8 42.4
sAvBD9 SDS 25.1 18.3 24.7 31.9
B 
A 
Figure 5.7 A: CD spectra of sAvBD9 in NaP buffer (Blue) and 1% SDS micelle solution (Red). 
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negative bands at 203 nm (-5.3 M-1cm-1) and 220 nm (-2.2 M-1cm-1) and a weak single 
positive band at 190 nm (+0.7 M-1cm-1) were observed. This was linked to a reduction in 
disordered structure (44.9% v 32.5%) and increase in α-helix (11.7% to 24.0%). Again no 
changes in either β-sheet (19.1% v 18.9%) or β-turn (24.2% v 24.5%) components were 
predicted from the CD data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
B: Table and Pie charts show quantification of CD secondary structures (%) including α-
helices (Blue), β-strands (Red), β-turns (Green) and unordered (Purple) following exposure of 
sAvBD9 to NaP and 1% SDS micelle solution.  
Peptides Helices% β-Strands % β-Turns % Unordered %
sAvBD9 W38G 11.7 19.1 24.2 44.9
sAvBD9 W38G SDS 24.0 18.9 24.5 32.5
A 
B 
Figure 5.8 A: CD spectra of sAvBD9 W38G in NaP buffer (Blue) and 1% SDS micelle solution (Red). 
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In summary, the secondary structures of the synthetic linear AvBDs were essentially 
unordered, but they did respond to the presence of SDS micelles, mimicking bacterial 
membranes, by an increase in the α-helix content.  
5.3.2. Calcein leakage assay: sAvBD6 and sAvBD9 
As reported in section 4.5.1, the synthetic sAvBD6 and 9 peptides (100g/ml) were not 
active against the E. coli chicken gut isolate when the time-kill assays were performed in 
PBS. However, complete killing was observed with sAvBD6 when the buffer was replaced 
with NaP (Figure 4.38 E). In contrast neither sAvBD9 nor sAvBD9 W38G were active 
against the E.coli strain in NaP buffer (Figure 4.39 E). These data suggested different 
mechanism actions for each of the two peptides that potentially related to their membrane 
interactive abilities. 
Thus to assess the membrane destructive activities of the linear peptides calcein leakage 
assays were performed. A range of synthetic peptide concentrations, 1 to 10 μg/ml, were 
used and the pore forming AMP, melittin specific to the honey bee, was used as the positive 
control at a final concentration of 1.5 μg/ ml.  As previously sodium phosphate buffer (50 
mM) and 10 % Triton X100 (final concentration 1%) were used to define 0 and 100% 
leakage.  
5.3.2.1.Leakage assay and AvBD6  
The results of the leakage assays performed using sAvBD6 (1.5 µg/ml) and melittin are 
shown in Figure 5.9 A&B. The positive control, melittin (blue line), induced 92.9±4.4% 
leakage within 6 seconds of its application, which remained constant (94.3±3.4 %) for up 
to two minutes (Figure 5.9B). In contrast sAvBD6 caused 47.2±6.4% leakage of calcein-
entrapped liposome within 6 seconds of its application (Figure 5.9A), but leakage increased 
to a peak of 60.3±6.3 % at two minutes (Figure 5.9B). These data strongly indicated that 
AvBD6 was able to cause membrane damage.  
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A 
B 
Figure 5.9 Calcein leakage recorded using entrapped liposomes incubated for up to 1 minute (A) 
and 4 minutes (B) at room temperature in 50 mM NaP buffer and either 1.5 μg/ml sAvBD6 (red 
line) or melittin (blue line). Experiments = 4; Replicates =4.  Mean±SEM. 
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5.3.2.2.Leakage assay and AvBD9 peptides 
Calcein leakage relating to the membrane disruptive capacities of the sAvBD9 peptides at 
concentrations of 1.5, 3 and 10 μg/ml are shown in Figures 5.10 & 5.11. It is acknowledged 
that these three sets of data each relate to only one experiment. However, six seconds 
following the addition of either 1.5 μg/ml sAvBD9 (blue line) or AvBD938G (green line) 
calcein leakage was detected (Figure 5.10A), but at 3.0 % it was reduced markedly 
compared to the levels observed using AvBD6 (47.2%). While the fluorescence levels 
increased with time (Figure 5.10B) the maximum leakage detected for the AvBD9 
treatment was only 11.5% (compared to 60.3% for AvBD6). In contrast, calcein leakage in 
response to sAvBD9 W38G treatment did not increase above 4%, which suggested either 
the inability of sAvBD938G to penetrate the liposomes fully to cause leakage or the 
immediate reorganisation of the liposomes following damage. To explore this further the 
concentrations of the peptides were increased to 3 and 10 µg/ml and the experiments 
repeated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 5.10 Calcein leakage recorded using entrapped liposomes incubated for up to 1 
minute (A) and 4 minutes (B) at room temperature in 50 mM NaP buffer and either 1.5 
μg/ml sAvBD9 (blue) or sAvBD9 W38G (green). n=1  
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At 3 μg/ml the data (Figure 5.11A) were similar to previous as sAvBD9 (blue) and sAvBD9 
W38G (green) peptides were associated with 4.3 % and 1.3 % calcein leakage at six 
seconds, and 14.5 % and 4.7 % within one minute. At 4 minutes the leakage relating to 
sAvBD9 was 17.9% compared to that for sAvBD9 W38G which remained <5% (Figure 
5.11B). Increasing the peptide concentrations to 10 μg/ml (Figure 5.11C) resulted in 
AvBD9 being associated with 12.6 % leakage (6 seconds), but again sAvBD9 W38G had 
little effect with <5% leakage detected. Similar to previous leakage data activity associated 
with sAvBD9 increased gradually, in this case to a maximum of 22.3 % at four minutes 
(Figure 5.11D), but leakage associated with sAvBD9 W38G still remained at <5%. These 
data indicated that overall the ability of sAvBD9 to penetrate the liposomes was poor, and 
that the C-terminal tryptophan was important for the leakage activity of sAvBD9. Using 
these liposomes 2.5 μg/ml melittin (positive control) resulted in 94.4±2.9% (n=3) calcein 
leakage while BSA (negative control) resulted in 0 leakage.  
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D 
C A 
B 
Figure 5.11 Calcein leakage recorded using entrapped liposomes incubated for up to 1 minute (A & C) and 4 minutes (B & D) at room temperature in 50 mM NaP 
buffer and either 3 (A & B) or 10 μg/ml (C & D) sAvBD9 (blue) or sAvBD9 W38G (green). N=1 for each.  
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The AvBD6 and 9 data shown in Figures 5.9 to 5.11 support the activity of sAvBD6, but 
not sAvBD9 as an acute acting membrane permeabilising agent. To investigate this further 
calcein leakage data were recorded for up to one hour following the addition of the sAvBD9 
and sAvBD9 W38G peptides to the calcein loaded liposomes and these data are 
summarised in Figure 5.12. Essentially sAvBD9 [2.5, 5 and 10 μg/ml] induced 8.5±3.5 %, 
12.2±3.0 % and 10.2 ±5.2 % leakage, while sAvBD9 W38G induced 1.8±1.8%, 4.3±4.3% 
and 2.4±1.3 % leakage.  Mellitin (2.5 μg/ml) and BSA (2.5 μg/ml) were used as the positive 
and negative controls, and at 60 minutes leakage was measured at 97.8±5.5 and 0 % 
respectively.   
These 60 min leakage data were consistent with the values recorded at 4 min indicating that 
the sAvBD9 and sAvBD9 W38G peptides were unable to penetrate and/or disrupt the 
liposome membranes. Although not statistically significant the mean leakage data of the 
sAvBD9 W38G peptide was lower (6 - 8%) than that of sAvBD9, which hinted that the 
AvBD9 C terminal located tryptophan plays a role in membrane disruption.  
 
 
 
  
 
 
 
 
 
 
In summary these data support different mechanisms of action of the synthetic AvBD6 and 
AvBD9 peptides in disrupting bacterial membranes with sAvBD6 causing immediate and 
major membrane disruption compared to sAvBD9. Furthermore, these data also suggested 
that the AvBD9 C-terminal located tryptophan plays a role in the membrane disruption 
process. 
Figure 5.12 Calcein leakage assay of sAvBD9 and sAvBD9 W38G at 2.5, 5 and 10 
µg/ml incubated with the vesicles for 1 hour. n=3. Mean±SE.  
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5.4.AvBD6 and 9 structure modelling  
To try and further understand the mechanisms of action of the AvBD6 and 9 peptides their 
structures were modelled using Raptor X online software (http://raptorx.uchicago.edu/) 
(Peng and Xu, 2011). The three dimensional structure prediction used the Penguin AvBD 
103b (Spheniscin-2) structure as its template, which had been solved by two dimensional 
NMR (Landon et al., 2004). Using this tool the structures of AvBD6 and 9 were predicted 
to include three β-strands connected by three disulphide bonds and N-terminal α-helices 
(Figures 5.13 and 5.14).  
 
 
 
Figure 5.13 Predicted structure of AvBD6. Disulphide bonds (orange). C-terminal 
and middle tryptophan (green) (http://raptorx.uchicago.edu/) 
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B A 
Figure 5.14 Predicted structures of AvBD9 (A) and AvBD9 W38G (B). (http://raptorx.uchicago.edu/) Disulphide bonds (orange). C-terminal tryptophan 
and glycine (green). 
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The three dimensional configurations of AvBD6 and 9 were also simulated using the Raptor 
X online service and these data are presented in Figures 5.15-16. In the AvBD6 model 
(Figure 5.15) specific clustering of positively charged amino acids was predicted. For 
example, arginine residues R10, R38 and R40 formed a cluster with the C-terminal 
tryptophan 41 (W41), while K33, R24 and R19 formed a contiguous bunch with tryptophan 
20 (W20). Connecting the clusters were the aromatic residues, Y22 and Y23, with this 
connection creating a foramen hook-like structure. Interestingly in this model the arginine 
R7 side chain is buried with the cysteines toward the centre of the molecule.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15 Simulated 3D structure of AvBD6. Aromatic amino acids including tryptophan (W) 
and Tyrosine (Y) are highlighted in green; cationic residues such as arginine (R), lysine (K) and 
histidine (H) in red; cysteines in yellow and disulphide bonds in orange 
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Figures 5.16A and B, show the predicted three dimensional conformations of AvBD9 and 
AvBD9 W38G peptides, respectively. The tertiary structures of both peptides appeared 
similar with the positively charged (red) R7, R19, R29, H10 and K32 residues and 
negatively charged (purple) D2 residue surface exposed. The two hydrophobic aromatic 
residues, W38 and F15 (green) were also exposed on the AvBD9 surface (Figure 5.16A). 
Interestingly, the model predicted the lysines, K34 and K37, (yellow) to be embedded in 
the molecule. Unlike AvBD6 however, no hook-like foramen structure was predicted. 
Substitution of the C-terminal tryptophan (W38) with glycine (G38) reduced the 
hydrophobicity of the molecule, but also appeared to impact on the orientation of the 
arginine 19 (R19) side chain (Figure 5.16B).  
In summary, the AvBD6, AvBD9 and AvBD9 W38G 3D models indicated that both 
aromatic and cationic residues were exposed to the peptide exteriors and the cysteines were 
located to the centre of the peptides, forming three intra molecular disulphide bonds. These 
models although basic were consistent with other β-defensins, including the mammalian 
defensins.  
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B A 
AvBD9 W38G peptide 
Figure 5.16 Simulated 3D structures of AvBD9 (A) and AvBD9 W38G (B). Aromatic amino acids including tryptophan (W) and phenylalanine (F) 
are highlighted in green; cationic residues including arginine (R), lysine (K) and histidine (H) in red; anionic residue aspartic acid (D) in purple; 
cysteines in yellow and disulphide bonds in orange. In (B) tryptophan W38 was replaced by glycine (G38) which is also highlighted in green. 
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5.5.Discussion 
The defensin killing mechanism of action is predicted to involve the interaction of the 
cationic peptide with a negatively charged bacterial membrane and insertion of the peptide, 
facilitated by its hydrophobic structure, into the membrane resulting in bacterial membrane 
depolarisation and death (Ganz, 2003). The aim of this chapter was to explore the 
mechanisms of action of AvBD6 and 9 by investigating their secondary structure 
conformations and membrane interactive properties. 
The lack of purity for rAvBD6, due to contamination with the 26 kDa GST protein, meant 
that clear reproducible CD spectra could not be obtained. However, the CD spectral 
analyses of rAvBD9 was successful and predicted β-sheet structure (52%) consistent with 
disulphide bond formation (three anti-parallel β-sheets characterise the β-defensins (van 
Dijk et al., 2008)); α-helix presumably linked to amino acids at the N-terminus as modelled 
in Figures 5.13 and 5.14; β-turns presumably linking areas of secondary structure to 
produce a compact and globular protein, and unordered structure. The fact that the rAvBD9 
3CA and 6CAG peptides showed reduced β-sheet structure, 29.6% and 24.4% respectively, 
also supported disulphide bond formation in the mature 6 C rAvBD9. The peptide folding 
was native and not chemically produced via oxidation thus the experimental data did not 
allow confirmation of the expected C1-C5, C2-C4 and C3-C6 bonding pattern. To verify 
this, NMR spectral analyses similar to that used to investigate AvBD2 is required (Derache 
et al., 2012). The secondary structure data relating to rAvBD9 W38G was more difficult to 
explain as the only amino acid mutated was the C-terminal tryptophan and thus the 
percentage of β-sheet structure calculated from the spectral data (27%) was unexpected. In 
fact although the encoded peptide contained six C the β-sheet content was more equivalent 
to that of rAvBD9 3CA. This reduced β-sheet content was also not supported by the 
modelling data (Figures 5.14 & 5.16), but changing the tryptophan for a glycine appeared 
in vitro to affect the folding of the AvBD9 molecule and moreover the CD spectral data 
indicated a major negative impact on disulphide bond formation.   
To model the interactions of the rAvBD9 peptides with bacterial membranes a SDS micelle 
model system, which consists of a negatively charged outer surface and a hydrophobic 
inner core was adopted. A comparable system used to investigate Alyteserin-1c, a 23 amino 
acid AMP secreted by toad skin indicated that the peptide, in the membrane mimicking 
environment, assumed an α-helical structure (Subasinghage et al., 2011). The exposure of 
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the rAvBD9 mature peptide to a 1% SDS micelle solution resulted in a reduction in β-strand 
structure and an increase α-helix, which predicted that the AvBD9 peptide adopted an α-
helical conformation in the presence of bacterial membranes. α-helicity is proposed to be 
important for defensin/membrane interactions, with the α-helix structure facilitating the 
embedding of hydrophobic residues into the membrane (Yeaman and Yount, 2003). α-
helicity is also associated with the bacterial killing activity of an antimicrobial peptide 
(Sudheendra et al., 2015), and this was supported by the data reported in Chapter 4, where 
rAvBD9 was shown to have potent antimicrobial activity against E.coli.  
Exposing the rAvBD9 peptides to SDS, also increased the percentage of disordered 
structure (Figure 5.3 and Table 5.2), indicative of the reduction and hence loss of the 
disulphide bonds. In fact the unordered structure observed following SDS exposure was 
comparable to that calculated for the rAvBD9 6CA/G peptides, lacking cysteines and hence 
disulphide bonds, in NaP buffer. In addition, the spectral characteristics of rAvBD9 W38G, 
which lacks its C-terminal tryptophan, were relatively unchanged following SDS micelle 
exposure, which highlighted a strategic role of the bulky aromatic residue in the folding of 
the AvBD9 peptide.  
The increase in α-helicity following exposure of the peptide to SDS micelles is also an 
indicator of a pore forming mechanism. Models predict that binding of the peptide initially 
involves the helical axis lining up parallel to the membrane surface, followed by insertion 
into the bilayer and disruption of membrane permeability (Jenssen et al., 2006). However, 
the majority of studies exploring and modelling AMP/membrane interactions have actually 
focussed on small linear α-helical peptides and not complex peptides such as the defensins. 
Pistolesi et al (2007), using spin labelling EPR spectroscopy determined the interaction of 
a 15 amino acid linear hybrid cecropin-melittin molecule with a membrane bilayer. The 
authors found no evidence of peptide-peptide interactions <20 Å eliminating a barrel-stave 
mechanism and proposed a toroidal pore mechanism in which the peptides were separated 
by intervening phospholipids (Pistolesi et al., 2007). Investigations reporting defensin-lipid 
interactions are less common, but indicate that the mechanisms reported often reflect the 
peptide concentrations employed. For example, work with the HBD3 and helical peptides 
suggests that at low peptide concentrations a thinning or destabilisation of the membrane 
occurs, explained by the ‘sand in a gear-box theory’ (Derache et al., 2012), but with higher 
concentrations pore formation is the more probable mechanism of action (Bonucci et al., 
2013). The actual mechanisms by which AvBD9 interacts with bacterial membranes are 
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not known, but probably involves an initial binding step in which the N-terminal α-helix of 
the molecule lines up parallel to the membrane surface, followed by insertion of the peptide 
into the bi-layer and disruption of membrane permeability through pore formation.     
Data from Chapter 4 indicated that the AvBD6 and 9 peptides caused bacterial killing and 
to further explore the potential membrane destructive capacity of the peptides, calcein 
entrapped artificial vesicles mimicking the bacterial lipid bilayer were exploited. The initial 
data using rAvBD9 was disappointing as it lacked reproducibility (Figure 5.5), which was 
attributed to purity issues caused by pooling several different recombinant peptide 
preparations. This and the fact that rAvBD6 could not be used underpinned the use of 
synthetic peptides. The disadvantage was that the synthetic peptides were linear, ie 
oxidative folding was not performed, but the CD spectral data analyses supported an 
increase in α-helicity was observed in the presence of SDS micelles, which mimicked the 
patterns observed with the recombinant peptides.   
The use of sAvBD6 resulted in 47% calcein leakage within six seconds compared to 3% 
for sAvBD9, which suggested that the mechanisms by which the peptides interacted with 
the lipid membrane were different. Interestingly despite the original concerns the sAvBD9 
data were comparable to that using rAvBD9. However, a mechanism of AvBD9 action 
where it has little membrane damaging activity does not fit with the AMA data and suggests 
a model in which the AvBD9 peptide has additional killing properties, for example a DNA 
inhibitory function once inside the bacterial cell (Wilmes, 2012). In support previous 
electron microscopic studies have shown that AvBD9 peptides lead to granulation of 
intracellular materials, irregular septum formation in dividing cells, cytoplasmic retraction 
and cell lysis at the cell septa (van Dijk et al., 2007). This appears a novel property of the 
AvBDs as others such as ostrich AvBD1 and AvBD2 have also been reported to cause little 
membrane leakage, but to have high DNA binding ability (Sugiarto and Yu, 2007b), and 
penguin AvBD103b has both membrane disruption and nucleic acid binding abilities that 
appear to be involved in its mechanism against Salmonella enteritidis (Teng et al., 2014). 
These data indicate that bacterial killing by the AvBD family is complex.  
The leakage data showed that the absence of the AvBD9 C-terminal tryptophan was linked 
to minimal or no calcein release. Furthermore, the negative data relating to AvBD9 W38G 
(Figure 5.10 B) may have been due to the inability of the peptide to insert into the vesicles. 
Interestingly, the C-terminal tryptophan of human α-defensin HNP-1 has been shown to be 
involved in the penetration of the peptide through a membrane bilayer (Bonucci et al., 
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2013), which lends further support to a critical role for this amino acid in bacterial killing. 
The 3D modelling of the two structures did not help explain why the tryptophan was as 
important as the tertiary structures of both AvBD9 and AvBD9 W38G appeared similar 
although the large aromatic tryptophan made the surface of the wild type more 
hydrophobic.  
Modelling did reveal potential differences in AvBD6 and 9 structures which may help 
explain their different membrane disruption properties and AMAs.  Most marked was the 
clustering of positively charged amino acids and presence of a ‘claw-like’ structure in 
AvBD6 (Figure 5.15), the latter involving the large bulky side chains of two tryptophan 
amino acids. This structure has also been observed in Apl_AvBD2 and suggested to 
function as a ‘prehensile grasp’ mechanism presumably functioning in attaching the peptide 
to lipid bilayers (Soman et al., 2010). It is feasible that this structure enhanced the 
membrane permeating abilities of AvBD6 compared to AvBD9 although such analyses 
requires further experimentation.  
5.6.Conclusions 
CD spectra showed that rAvBD9 was folded and exhibited β-sheet structure consistent with 
di-sulphide bond formation.  
Membrane leakage experiments suggested sAvBD6 > sAvBD9, which indicated that 
AvBD9 may have other properties related to bacterial killing. 
Synthetic sAvBD6, rAvBD9 and sAvBD9 variants responded to a SDS environment 
mimicking a bacterial membrane via increased α-helical structure, indicative of a pore-
forming mechanism of action.  
The C-terminal tryptophan appears critical for AvBD9 folding, membrane permeation and 
antimicrobial function.  
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Chapter 5 (Part II) 
AvBD1 structure-membrane interactions 
5.7.Introduction 
In addition to ABDs 6 and 9, AvBD1 belongs to the AvBD family. The AvBD1 peptide is 
predicted to be highly hydrophobic (52.5%) and cationic, with a net positive charge of 8 at 
pH 7, which compares to 7 for AvBD6 and 4 for AvBD9. AvBD1 is of particular interest 
as analyses of Aviagen birds identified SNPs within the AvBD1 coding regions of two 
different commercial broiler chicken lines resulting in the synthesis of three AvBD1 
variants, NYH, NYY and SSY (Figure 5.17) ( Butler 2010, PhD thesis), with the NYH 
variant acknowledged as the ‘wild-type’ peptide. SNPs resulting in non-synonymous amino 
acid changes are relatively rare in host defence peptides as they can impact on the function 
of that encoded peptide and expose the host to microbial assault and infection. Overall 
however, the amino acid changes underpinning the NYY and SSY variants did not appear 
to significantly affect either the overall charge of the variants (+8) or their hydrophobicity 
(50%).   
These observations suggested that the amino acid changes would not affect the 
functionality of the peptides, but to verify this time-kill anti-microbial assays were 
performed. Initially, in house hyperexpression and purification of the AvBD1 peptides was 
attempted, but this proved difficult technically due to their hydrophobicity and charge, thus 
linear peptides (Figure 5.17) were custom synthesised and utilised in determining and 
comparing the antimicrobial properties against E. coli  (Cadwell, 2014, PhD thesis).  
 
 
 
 
 
Figure 5.17 Amino acid sequences of synthetic AvBD1 SNP peptides. Pink: amino acids 
encoded by SNPs. Green: C- terminal tryptophan. Yellow: cysteine residues.  
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Interestingly, the data (Figure 5.18 A & B; Cadwell, 2014, PhD thesis) indicated that the 
AvBD1 NYH peptide was more potent than AvBD1 SSY, which in turn was more active 
than AvBD1 NYY. Thus to further investigate the peptides and their interactions with 
bacterial membranes the synthetic AvBD1 variants were analysed by CD spectra and using 
the calcein leakage assay.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
A 
B 
NYH 
SSY 
NYY 
4 µg 2 µg 1 µg 
Figure 5.18 A: Radial diffusion assay showing the inhibitory effect of AvBD1 variants 
‘NYH’, ‘SSY’ and ‘NYY’ at 4, 2 and 1μg. B: Time-kill assay showing percentage 
bacterial (E. coli) growth following 2 h incubation of E.coli (1/1000 dilution) with NYH, 
SSY and NYY AvBD1 peptides.  
All percentage growth is shown relative to PBS (dotted line). Percentage values < 0% indicate 
fewer colonies after 2 h than at 0 h and hence, indicate bacterial killing. Mean ± SEM from three 
experiments. (Cadwell, 2014, PhD thesis). 
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5.8.CD analyses of synthetic AvBD1 Peptides  
The three synthetic AvBD1 peptides were each available as 1 mg/ml solutions reconstituted 
in PBS (kind gift by Kevin Cadwell, PhD Newcastle University). The peptides were further 
diluted either in NaP (50 mM) or 1% SDS to final concentrations of 250 µg/ml.  
The results of the CD analyses performed in NaP buffer and 1% SDS, the latter to mimic 
the bacterial membrane, are shown in Figures 5.19 and 5.20. In NaP buffer (Figure 5.19 A) 
both AvBD1 NYH and AvBD1 SSY formed disordered structures as evidenced by the 
single absorption bands (-5.5 M-1cm-1) and (-3.3 M-1cm-1) observed at 200.5 nm. In contrast 
AvBD1 NYY displayed negative absorption bands (-2.2 M-1cm-1 and -2.7 M-1cm-1) at 207 
and 216 nm respectively, and a positive absorption band (+1.5 M-1cm-1) at 193 nm, which 
supported a mixture of α-helix and β-sheet conformations.  
The sAvBD1 peptides were originally reconstituted in PBS solution, which meant the 
preparations contained chloride ions. Chloride ions absorb strongly below 200nm (Kelly et 
al., 2005). Despite using NaP for the subsequent dilutions the lowest wavelength relating 
to the CD spectral analyses was 193nm. Because of this quantification of the data was 
performed using K2D as opposed to Selcon3 software. 
The quantitative results are shown in Figure 5.19 B. As expected these data indicated that 
the peptides contained significant unordered structure (48 to 63%). β-sheet and α-helical 
conformations were also predicted with NYY containing  15 % α-helix compared to 9 % 
and 8% for NYH and SSY.  
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Peptides α-helix % β-sheet % Unordered %
AvBD1 NYH 9 28 63
AvBD1 NYY 15 30 55
AvBD1 SSY 8 44 48
B 
A 
Figure 5.19 A: CD spectra of sAvBD1, NYH (Blue), NYY (Red) and SSY (Green).  
B: Table and Pie charts show quantification of CD secondary structures (%) including α-
helices (Blue), β-sheet (Red), and unordered (Green) following exposure of sAvBD1 to 
NaP (50 mM). 
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In 1% SDS (Figure 5.20 A) the NYH (blue) and SSY (green) sAvBD1 peptides formed α-
helix conformations, as characterised by two negative absorption bands at 208 nm and 222 
nm, and a positive band at 193 nm.  
Values for the two negative absorption bands of the NYH variant were  -1.5 M-1cm-1, while 
the two bands relating to SSY were recorded as -1.7 and -1.6 M-1cm-1; the positive 
absorption bands observed for NYH and SSY were +2 and +2.5  M-1 cm-1. The two negative 
absorption bands for NYY were at 211 nm (-1.3 M-1cm-1) and 220 nm (-1.5 M-1cm-1), the 
positive absorption band was at 195 nm (+1.1 M-1cm-1).  
The quantitative data (Figure 5.20 B), predicted that following exposure to 1% SDS the 
NYH, NYY and SYY peptides contained similar amounts of α-helix (22%, 20% and 23%) 
with the increases offset by a reduction in the β-sheet component.  
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The paired CD spectra of each of the sAvBD1 peptides in NaP buffer and 1% SDS are 
shown in Figures 5.21-5.23. Figures 5.21 and 5.22 show the clear changes in the CD spectra 
of the NYH and SYY peptides following their exposure to 1% SDS with the α-helices 
characterised by negative bands at 208 and 220nm, and a positive band at around 193nm. 
A 
B 
Figure 5.20 A: CD spectra of sAvBD1, NYH (Blue), NYY (Red) and SSY (Green). 
 B: Table and Pie charts show quantification of CD secondary structures (%) 
including α-helices (Blue), β-sheet (Red), and unordered (Green) following exposure 
of sAvBD1 to 1% SDS. 
Peptides+SDS α-helix % β-sheet % Unordered %
AvBD1 NYH 22 24 54
AvBD1 NYY 22 26 53
AvBD1 SSY 23 22 55
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The NYY spectra were shallower and less supportive of a change in secondary structure in 
the 1% SDS environment, with a mixture of β-sheet and α-helix structure predicted (Figure 
5.23A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptides α-helix % β-sheet % Unordered %
AvBD1 NYH 9 28 63
AvBD1 NYH SDS 22 24 54
A 
B 
Figure 5.21 A: CD spectra of sAvBD1 NYH in NaP buffer (Blue) and 1% SDS micelle 
solution (Red). 
 B: Table and Pie charts show quantification of CD secondary structures (%) including α-
helices (Blue), β-sheets (Red) and unordered (Green) following exposure of sAvBD1 
NYH to NaP and 1% SDS micelle solution. 
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Peptides α-helix % β-sheet % Unordered %
AvBD1 SSY 8 44 48
AvBD1 SSY SDS 23 22 55
B 
A 
Figure 5.22 A: CD spectra of sAvBD1 SSY in NaP buffer (Blue) and 1% SDS micelle 
solution (Red).  
B: Table and Pie charts show quantification of CD secondary structures (%) including α-
helices (Blue), β-sheets (Red) and unordered (Green) following exposure of sAvBD1 SSY 
to NaP and 1% SDS micelle solution. 
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Peptides α-helix % β-sheet % Unordered %
AvBD1 NYY 15 30 55
AvBD1 NYY SDS 22 26 53
A 
B 
Figure 5.23 A: CD spectra of sAvBD1 NYY in NaP buffer (Blue) and 1% SDS micelle 
solution (Red).  
B: Table and Pie charts show quantification of CD secondary structures (%) including 
α-helices (Blue), β-sheets (Red) and unordered (Green) following exposure of sAvBD1 
NYY to NaP and 1% SDS micelle solution. 
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5.9. Leakage assay and sAvBD1 Peptides  
The calcein entrapped liposome assay described previously was used to investigate and 
compare the abilities of the AvBD1 variants to disrupt bacterial membranes.  The leakage 
assay data (Figure 5.24 A and B) showed that sAvBD1 NYH (blue line), SSY (green) and 
NYY (red) at concentrations of 1.5ug/ml induced 47.9±2.9%, 26.5±1.4% and 21.7±0.3% 
calcein leakage, within 6 seconds of addition (Panel A). The control peptide was melittin 
(purple), which caused 46.4±0.5% leakage. In each case leakage plateaued within three 
minutes at 58.9±1.6 %, 38.6±1.9 % and 32.7±2.5 % (Panel B), which compared to 
70.5±1.9 % for melittin.  
These data suggested that the sAvBD1 NYH peptide was significantly more potent 
(P<0.0001) in permeabilising membranes compared to the NYY and SSY peptides. In 
addition the sAvBD1 SSY variant was significantly more potent (P<0.05) than the NYY 
variant.  
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**** 
**** 
* 
* 
**** 
**** 
A 
B 
Figure 5.24 Calcein leakage recorded using entrapped liposomes incubated for up to 1 minute 
(A) and 3 minutes (B) at room temperature in 50 mM NaP buffer and 1.5 μg/ml sAvBD1 NYH 
(blue), SSY (green), NYY (red) and melittin (purple). Experiments=3. Mean ± SEM. *P<0.05 
and **** P<0.0001. Data were analysed using one way ANOVA, followed by Dunnett’s 
multiple comparison test. 
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Increasing the peptide concentrations to 2.5 µg/ml caused increased leakage as shown in 
Figure 5.25 A and B. Although this experiment was performed only once due to limited 
peptide stocks, the AvBD1 peptide potency patterns were comparable to previous. Indeed, 
sAvBD1 NYH (blue), SSY (green) and NYY (red) induced 78.0%, 61.4% and 47.5% 
leakage within 6 seconds, (Panel A), which compared to 72.7% for melittin. Leakage was 
stable at 3 minutes (Panel B) and recorded as 89.8 % (melittin), 100% (NYH), 88.0 % 
(SSY) and 74.6 % (NYY) respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 5.25 Calcein leakage recorded using entrapped liposomes incubated for up to 
1 minute (A) and 3 minutes (B) at room temperature in 50 mM NaP buffer and 2.5 
μg/ml sAvBD1 NYH (blue) SSY (green) NYY (red) and melittin (purple). n=1.  
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5.10. AvBD1 modelling 
The primary amino acid sequences of the AvBD1 variants differ in amino acids 10, 20 and 
32, with NYH, SSY and NYY composed of asparagine (N)10, tyrosine (Y)20 and 
histidine(H)32; S10, S20 and Y32 and N10, Y20 and Y32, respectively.  
Modelling the AvBD1 variant sequences using Raptor X on line software resulted in 
comparable backbone structures displaying β-sheet structures corresponding to the three 
disulphide bonds and a N-terminal α-helix (Figure 5.26 A-C). The predicted 3D structures 
all three variants were, as expected, also similar, with areas of positive charge and 
hydrophobicity, but the three amino acid ‘substitutions’ did appear to impact on the model 
structures (Figure 5.27 A-C).  
Most marked was that the 3D model of AvBD1 NYH (Panel A) predicted that the W39 and 
K9 side chains, and R30 and R2 side chains formed ‘claw-like’ structures. The NYH model 
predicted externalisation and clustering of the positively charged side chains relating to 
K36, K9, R8, R37 and potentially K17, and K27, H32 and K3. Clustering and 
externalisation of the hydrophobic amino acids Y20 and W39, and four phenylalanine side 
chains F7, F12, F15 and F31 were also predicted.  
Although the SSY model predicted a similar configuration to NYH, subtle changes were 
evident. For example the hydrophobicity of the Y20/W39 cluster was disrupted to the 
replacement of Y20 with a negatively charged serine residue; Only the R30 and R2 ‘claw’ 
structure was modelled in the SSY model but the claw-like structure modelled around W39 
and K9 was lost presumably due to the impact of substituting the serine (S) for N10 and 
the presence of Y32 (replacing H32) disrupted the positively charged K27, H32 and K3 
cluster.   
The model relating to the NYY variant, the least antimicrobial of the three peptides, was 
particularly characterised by the loss of the two claw-like structures presumably related to 
the N10 and Y32 substitutions.  
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Figure 5.26 Predicted secondary structures (β-sheet and α-helix) of AvBD1 variants NYH (A), SSY (B) and NYY (C). 
 Disulphide bonds (orange). C-terminal tryptophan (green). Blue boxes show different amino acid side chains.  
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A B C 
Figure 5.27 Simulated 3D structures of AvBD1 NYH (A), SSY (B) and NYY (C) variants.  
Aromatic amino acids including tryptophan (W); phenylalanine (F) and tyrosine are highlighted in green; cationic residues including arginine (R), lysine (K) and 
histidine (H) in red; anionic residue aspartic acid (D) in purple; cysteines in yellow and disulphide bonds in orange.  
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5.11. Discussion 
The earliest response to a microbial attack is determined by innate immune factors and 
genetic variants of these can increase or decrease susceptibility to infection and disease. 
The defensins are key innate elements in controlling microbial numbers thus SNPs resulting 
in non-synonymous amino acid changes are rare. Genome analyses of commercial chicken 
broiler lines linked to Aviagen Ltd identified SNP variants of the AvBD1 gene that encoded 
amino acid changes at positions 10, 20 and 32 of the AvBD1 mature peptide. The resulting 
peptides were identified as NYH, SSY and NYY AvBD1 variants.  Bacterial killing data 
using synthetic linear peptides (Cadwell 2014, PhD), indicated that NYH >SSY> NYY 
(Figure 5.18). The aim of this chapter was to further understand this hierarchy by 
comparing the membrane interactive and disruptive activities of these three AvBD1 
variants. To achieve this CD spectra and calcein leakage assays were performed.  
The CD spectral data showed that all three peptides assumed an α-helix conformation when 
exposed to SDS (Figure 5.20). These data suggested that all the AvBD1 variants bound to 
anionic lipid membranes via similar mechanisms. It was acknowledged however that this 
α-helix mechanism was also consistent with the data recorded for the defensins AvBD6 
and 9, and thus may have reflected the use of synthetic linear AvBD peptides generally. 
However, the leakage data supported NYH>SSY>NYY, which was consistent with the 
AMA data and indicated that the NYH variant was the most efficient permeabilising agent.  
Previous studies focussed on ostrich defensins have linked membrane leakage to the overall 
net charge of the peptides (Sugiarto and Yu, 2007b). However, in this scenario overall 
charge appears less important as the net charge of the NYH peptide was calculated as +7.8 
at pH 7 compared to net charges of +7.7 for SSY and NYY.  Still it is tempting to speculate 
that the increased leakage capacity of the NYH variant was influenced locally by the 
histidine residue at position 32, which modelling indicated created a very cationic cluster 
comprising R30, K27, H32, R2 and K3 (Figure 5.27A).  The calcein leakage data supported 
the NYH peptide to be the most potent permeabilising agent thus the importance of the 
hydrophobic residues cannot be ignored since they are thought to have a significant impact 
on membrane insertion (Cuperus et al., 2013). None-the-less, the low AMA and reduced 
leakage ability of the NYY variant with its two tyrosine bulky side chains did not support 
a role for these particular hydrophobic amino acids in membrane permeabilisation. 
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The modelling data showed that the basic structures of AvBD1 NYH, AvBD1 SSY and 
AvBD1 NYY, for example disulphide bond arrangement, β-sheet structures and N-terminal 
α-helix were similar (Figure 5.26). The differences, according to the proposed models, were 
in the distribution of the ‘substituted’ amino acids over the surface of the peptides. 
Interestingly, the AvBD1 NYH model predicted the side chain of K9 to protrude and form 
a ‘claw-like appearance’ with W39 (Figure 5.27 A). In the predicted SSY (Figure 5.27 B) 
and NYY (Figure 5.27 C) models this claw appeared to be ‘lost’ due to the impacts of the 
S10 and N10 side chains.  Similar claw-like structures were shaped between R2 and R30 
in the NYH and SSY models, but not in the NYY model. As the antimicrobial potency of 
the three peptides is NYH >SSY> NYY, these data predict a key role for the claw-like 
structures in AvBD antimicrobial activity. It has been suggested that the claw-like region 
plays a role in microbial membrane attachment (Soman et al., 2010) and as described 
previously, was also predicted as part of the AvBD6, a potent antimicrobial agent, structure.  
The AvBD1 variants were characterised by four phenylalanine amino acids F7, F12, F15 
and F31. It is worthy to note that the phenylalanine residues of the cathelicidin LL-37 
molecule have been shown by NMR to play key roles in the binding of the peptide to 
anionic membranes (Wang, 2008). Although LL-37 is a linear peptide this information 
indicates the importance of the phenylalanine side-chains in attaching to bacterial 
membranes. The AvBD1 NYH, SSY and NYY models predict the four phenylalanine 
residues to be located on the exterior surface of the peptides, which strengthens their 
putative roles in microbial binding. However, the siting of H32 and K27 in the NYH (the 
most antimicrobial) model compared to Y32/K27 in SSY and NYY again provide support 
for localised charge effects in determining the activities and potencies of the peptides.  
The prevalence of these non-synonymous SNPs in different bird lines could impact on gut 
health status since AvBD1 NYH peptides were synthesised by Line X (birds with less 
optimal gut performance), and SSY and NYY peptides by Lines Y and Z (birds with 
optimal gut performance), respectively (Butler, 2010). It is therefore easy to speculate that 
the AM potency of the NYH variant was linked to disruption of the gut microbiota of the 
Line X birds, for example through killing of Lactobacillus sp, leading to dysbacteriosis and 
reduced gut health (Cadwell 2014). 
In vitro analyses indicated that the identified AvBD1 peptide non-synonymous amino acid 
changes did impact on the antimicrobial activity of the resultant peptides, and the data 
indicated that this occurred in part through effects on [bacterial] membrane 
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permeabilisation. In silico models suggested that this involved localised charge effects and 
the formation of claw-like structures.  
5.12. Conclusions 
The CD spectra indicated that the AvBD1 NYH, SSY and NYY peptide variants formed α-
helix conformations in the presence of lipid micelles, modelling bacterial membranes, 
although it is acknowledged that linear peptides were used in all the experiments.   
In the calcein leakage experiments AvBD1 NYH induced more leakage than SSY, which 
in turn was more potent than NYY.  
Modelling simulations indicated that AvBD1 NYH contained two claw-like structures, 
SSY one claw-like structure and NYY no claw-like structures (NYY) suggesting roles for 
claw-like structures in the AvBD mechanism of action.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
194 
 
Chapter 6 
Final Discussion 
The European Union regulation 1831/2003/EC banning the use of antibiotic growth 
promoters in animal feed since 2006 was introduced to address problems of antimicrobial 
resistance. Its introduction has forced commercial livestock breeding companies to focus 
their research on the immune systems of animals with the objectives of selecting for and 
breeding disease resistant animals. In particular the innate system has been targeted as it is 
important in the early days of life with the premise being that a ‘robust’ innate immune 
system helps to protect young animals against infectious diseases. One facet of the innate 
immune system is the epithelial synthesis of host defence proteins, particularly 
antimicrobial peptides, which are <5kDa in size, show broad antimicrobial activity and are 
constitutively synthesised or induced in response to bacterial challenges. The focus of this 
thesis was avian β-defensins (AvBDs), particularly the expression, anti-microbial activities 
and mechanisms of action of AvBDs 6 and 9.  
Birds raised in commercial poultry farm environments are continually exposed through 
bedding, feed and faeces to numerous microbes. Thus robust birds, ie those resisting disease 
and showing optimal feed to weight gain ratio, are particularly desired by the breeders. As 
the defensins are predicted to play a role in shaping the resistance of such birds to microbial 
diseases, analyses of their gene expression profiles and peptide anti-microbial activities are 
essential. However, for the data to be valuable such studies need to be performed using 
birds from commercial breeding lines and the rearing environments need to mimic 
commercial establishments rather than those of the laboratory. The resultant data will then 
inform breeders which, if any, of the defensin genes are the most desirable to select for. 
To date the majority of chicken in vivo  microbial challenge studies have focussed on the 
expression of AvBDs and pro-inflammatory cytokines in ‘laboratory raised’ birds 
following inoculation with a single bacterial or parasitic species (Zhao et al., 2001; Hong 
et al., 2012). In vitro experiments have similarly used specific cell lines and single bacterial 
challenges (Derache et al., 2009a; Abdelsalam et al., 2012). These approaches have 
produced informative data about disease pathology and mechanisms, from both the 
perspective of the microbe and the avian tissue examined. However, these data do not 
directly reflect what actually happens in the bird tissues in vivo during exposure of either 
newly hatched, young or adult chickens, raised in commercial environments, to multiple 
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microbial challenges. Chapter three addressed this by focussing on a line of Aviagen Ltd 
(Line X) birds raised in two different farm environments, low hygiene and high hygiene, 
and exploring AvBD6 and 9 as well as cytokine gene expression in an array of bird tissues.   
Despite the supposed genetic identity of the Line X birds the quantitative PCR data showed 
the AvBD6 and 9 expression were highly variable among individual birds. AvBD6 and 9 
were selected for study due to SNPs within introns and non-coding regions, so the variation 
was perhaps not particularly surprising. For example, the AvBD9 gene contains a SNP in 
its 3’UTR (Table 3.1), which potentially can affect expression through mRNA stability, as 
shown for sheep β-defensin 1 (Monteleone et al., 2011). Both genes also carry intronic 
SNPs (Table 3.1) and such SNPs can also affect expression. Indeed, a recent study reported 
the impact of intronic SNPs on human β-defensin 1 gene expression with individuals with 
a 5’UTR homozygous polymorphism showing increased salivary peptide concentrations 
(Polesello et al., 2015). However, as the corresponding genomic DNA sequences of the 
birds were not available it was only possible to report trends and not link the expression 
data to actual SNPs.  As a result it was also not possible to link the expression data to either 
environmental and/or genomic effects. It was also acknowledged that the numbers of birds 
used in the AvBD gene expression studies were low, thus reducing the statistical power of 
the analyses. Future studies involving SNP analyses will require significantly greater 
numbers of birds.   
None-the-less, interesting trends in AvBD expression were observed. Increased baseline 
expression of AvBD6 in the lung and AvBD9 in both kidney and liver may relate to 
functions other than antimicrobial activity including wound healing, and 
immunomodulation. Indeed, such functions have been reported for mammalian defensins 
(Steinstraesser et al., 2011; Semple and Dorin, 2012), and for duck Apl_AvBD2 (Soman 
et al., 2009). Additionally, AvBD6 expression in the caecal tonsils compared to the caecum 
indicated a potential role for this secondary lymphoid tissue in the innate defences of the 
chicken gut and this requires further investigation. In support, AvBD6 expression was also 
increased in the caecal tonsils of chicks infected with Salmonella enterica serovar 
Typhimurium (Akbari et al., 2008).  
The line of birds examined in the study was characterised by its increased susceptibility to 
gut inflammation.  However, overall the pro-inflammatory and anti-inflammatory cytokine 
gene responses in the different environments, although limited to IL-6 and TGFβ4, were 
supportive of physiological rather than pathological inflammatory responses. While it 
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cannot be excluded that other pro-inflammatory cytokines, e.g ILβ1 were involved in the 
responses, the fact that the guts of the birds were not scored for inflammation and hence 
damage when the tissues were collected makes it difficult to reach any definitive 
conclusions.  Future studies focussed on Line X birds will also need to concentrate on the 
gut pathology and cytokine responses of individual birds.  
It was noteworthy that chicken galectin-3 (CG3) expression was elevated in the gut 
compared to other tissues. Galectin-3 functions as an opsonin, facilitating microbial 
destruction through attachment to the lipopolysaccharide (LPS) of the bacteria cell 
membrane and phagocyte surface glycoproteins (Almkvist and Karlsson, 2004). It also has 
chemo-attractive properties, attracting macrophages and stimulating monocyte migration 
(Sano et al., 2000). The levels of expression support potential roles for CG3 in the innate 
defences of the gut and warrant further investigations, including IHC to confirm protein 
synthesis and gut localisation. Such studies in birds with healthy versus inflamed guts will 
be particularly interesting. 
The data revealed individual birds with ‘high’ levels of AvBD expression (Figure 3.16 A). 
Although it is tempting for breeders to select birds showing such high expression in the gut 
tissues and hence increased AMA, it could be argued that this may not always be beneficial. 
For example in the caecum, high AvBD peptide concentrations may actually cause 
disruption of the enteric commensal community leading to dysbacteriosis and gut problems 
including inflammation. As discussed earlier future studies, to be informative for breeders, 
will need to increase the bird numbers, and explore the gut pathology, defensin and 
cytokine responses of individual birds as well as the groups per se.  
Mammalian defensins are secreted in the intestinal crypts at concentrations of up to 10 
mg/ml and in epithelial cells at concentrations of 10-100 µg/ml (Ganz, 2003). Measurement 
of the actual AvBD peptide concentrations in the tissues and blood were absent in this study 
due to the lack of appropriate samples, antibodies and synthetic peptides for ELISA 
development. It is acknowledged that future studies need to address this as mRNA levels 
can indicate, but do not always reflect, peptide concentrations.  
It is assumed from their primary structures that the AvBD6 and 9 peptides are antimicrobial 
agents. To actually confirm this the peptides encoded by the Line X AvBD6 and 9 bird 
genes were synthesised in vitro using a BL21 hyper-expression system, and the AMAs of 
the recombinant peptides tested using radial immuno-diffusion and time kill colony 
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counting assays. The data reported in Chapter four indicated that both rAvBD6 and 9 have 
killing properties against both Gram positive and negative bacteria. The bacteria used in 
these studies were isolated from chickens raised on Aviagen farms, which strengthened the 
antimicrobial data as many clinical strains often show increased resistance to AMPs 
compared to laboratory passaged microbial strains (Derache et al., 2009b). The assays 
showed that recombinant (r) AvBD6 was a more potent antimicrobial agent than rAvBD9, 
which probably related to charge, with AvBD6 being more cationic (+6.8) than AvBD9 
(+3.8), and hydrophobicity. It was interesting that the presence of a pro-piece did not appear 
to affect the antimicrobial activity of rAvBD6 or 9 especially as the pro-piece of a mouse 
α-defensin, cryptdin-4, although 36 amino acids in size and anionic, has been reported to 
reduce the killing properties of the peptide (Figueredo et al., 2009). Interestingly, the in 
vivo  cleavage of the AvBD hexapeptide pro-piece has not been confirmed (Xiao et al., 
2004; van Dijk et al., 2007), but if it is retained in vivo  then its size and hydrophobicity 
could be argued as aiding killing by facilitating membrane perforation and disruption 
(Soman et al., 2010; Tai et al., 2014). 
A previous study had suggested the importance of the 6C in AvBD2 activity (Derache et 
al., 2012), thus Chapter four also explored the roles of the six conserved cysteines (6C) and 
the C-terminal tryptophan in AvBD9 antimicrobial activity. The AvBD9 6CA/G variant 
with no cysteines showed antimicrobial activity and in fact was more antimicrobial against 
E. faecalis than E. coli although this may have reflected its stability in the presence of 
proteases synthesised by the different bacteria. However, the AMA data relating to both 
AvBD9 analogues, 3CA and AvBD9 6CA/G, strongly supported the roles of the di-
sulphide bonds in protecting against the proteolytic activities of enzymes secreted by 
bacteria and presumably those synthesised by eukaryote tissues. Essentially the folding 
produces a globular AvBD structure that is more resistant to proteolysis than is a linear one.  
Interestingly, some mammalian defensins have been reported to work efficiently both in 
the linear and folded forms. For example, HBD1and HD6 are secreted into the gut lumen 
as folded peptides, but following linearisation in the reducing environment of the gut still 
retain their AMA killing properties (Schroeder et al., 2011; Schroeder et al., 2015). It is 
probable that the AvBDs show similar properties although further experiments are needed 
to explore this.  
While the AvBD structures and mechanisms of action are not wholly relevant to poultry 
breeders, they are of scientific interest and may help explain the evolution of an array of 
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AvBD peptides in the avian tissues. Through work using mammalian peptides it is 
generally accepted that the defensin killing mechanism is via microbial membrane 
interaction and disruption (Ganz, 2003). To investigate this further in relation to the AvBDs 
6 and 9, CD spectra and calcein leakage assays were adopted. These data, reported in 
Chapter five, predicted a predominantly β-sheet structure for rAvBD9 and this was 
supported by the reduced β-sheet structures of rAvBD9 3CA and 6CAG peptides. These 
data also suggested spontaneous folding of the 6C recombinant peptide; in support a recent 
study has shown that the mouse α-defensin cryptidin-4 expressed in BL21 (DE3) pLysS 
folds spontaneously and correctly (Tomisawa et al., 2015). Interestingly, the β-sheet 
content of rAvBD9 W38G, which contained 6C, but lacked the C-terminally located 
tryptophan conserved in 10/14 AvBDs (Figure 4.12), was reduced and suggested a major 
impact of tryptophan on the in vitro folding of the peptide.   
The actual mechanisms by which AvBD causes microbial killing are not known. The CD 
spectra and calcein leakage data described in Chapter five suggested it involves an initial 
binding step in which the N-terminal α-helix of the molecule lines up parallel to the 
membrane surface, followed by insertion of the peptide into the bi-layer and disruption of 
membrane permeability through pore formation.  The calcein data relating to the linear 
sAvBD1 and sAvBD6 peptides were particularly supportive of membrane disruption.  
Modelling data also predicted the structure of AvBD6 to contain a hook-like foramen 
structure containing two tryptophans, which presumably facilitates peptide attachment to a 
target microbial membrane. A similar claw-like structure was predicted for AvBD1 NYH, 
which had potent AMA, suggesting important roles for such structures in microbial killing.  
Interestingly the linear sAvBD1 peptides were reported to be highly antimicrobial against 
E. coli (Kevin Cadwell, 2014, PhD thesis), suggesting they function as anti-microbial 
agents even in reducing conditions. These data were comparable to that of the mammalian 
HBD1 and HD6 peptides, following reduction by thioredoxin in the gut epithelium 
(Schroeder et al., 2011; Schroeder et al., 2015), and suggests key roles for the AvBD1 
peptides in the innate defences of the gut.  
In contrast AvBD9 was associated with AMA, but minor calcein leakage, suggesting its 
action was not directly through membrane destruction. Alternative killing mechanisms 
include inhibition of nucleic acid synthesis and/or cell division (Sugiarto and Yu, 2007b; 
Teng et al., 2014). In relation to AvBD9 these require further investigation through the use 
of fluorescent and electron microscopy studies of dividing bacteria in the presence and 
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absence of peptide (Peng et al., 2013; Teng et al., 2014). It was interesting that the C-
terminal tryptophan of AvBD9 was also important for its AMA. As tryptophans are known 
to facilitate peptide insertion into membranes (Wei et al., 2010) it would be interesting, 
scientifically, to explore this idea further. 
In selecting for chicken genes that focus on innate immunity care must be taken to fully 
investigate the targeted genes in all rearing conditions and to ensure that the genes selected 
encode peptides/proteins that enhance protection, and do not cause, for example, gut 
dysbacteriosis. Work presented in this thesis has shown the expression of two AvBD genes 
in a line of commercial birds raised in different rearing environments. Despite the genetic 
identity of the birds the AvBD expression patterns were very variable between individual 
birds. However, the small bird numbers and lack of individual bird genomic DNA 
sequences did not allow these data to be related specifically to either the external 
environment and/or specific SNPS. Future studies will address these parameters. It was 
demonstrated in vitro that the AvBDs 6 and 9 genes expressed by the Line X birds encode 
potent antimicrobial killing agents that presumably function in defending the epithelia 
through microbial killing. Their synthesis as globular structures helps reduce potential 
degradation by proteases although the in vitro AMA data did support the linear peptides as 
having killing properties. This may have immunological significance in vivo especially in 
relation to the reductive environment of the gut where it may permit fine control of the 
microbial numbers and communities. Gut microbiota studies will allow this to be explored 
further.  Interestingly, the in vitro studies supported different mechanisms of action of the 
two defensins studied with AvBD6 causing membrane damage compared to AvBD9, which 
probably functions through disrupting intracellular systems. These data suggest that the 
AvBD peptides work in synergy in defending the epithelia and perhaps caution against 
poultry geneticists just selecting individual AvBD genes for breeding purposes.    
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